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Cellular Mechanisms of Luteal Regression in the Bovine 




The corpus luteum (CL) is a transient endocrine gland that produces progesterone (P4) 
for the establishment and maintenance of pregnancy. In absence of pregnancy, timely 
regression of the CL is essential for normal ovarian cyclicity. Several factors are known 
to participate in luteal regression. In this study, two factors, PGF2 alpha and endothelin 
(ET-1) are being studied. Protein kinase C (PKC) and calcium are the two main 
intracellular mediators of PGF2 alpha. The role of ET-1 in the regulation of luteal 
regression is unclear. The early CL is insensitive to the luteolytic actions of PGF2 alpha 
and the cellular mechanism(s) involved in this process are poorly understood. This study 
investigates: (1) the array of PKC isozyme expression as a function of development in the 
bovine CL and the ability of PGF2 alpha and ET-1 to activate the PKC isozymes in the 
early (day-4) and late (day-10) luteal phase, (2) the physiological role of the luteal PKC 
isozymes on PGF2 alpha -induced rise in intracellular calcium concentration and 
luteinizing hormone (LH) stimulated P4 accumulation at the mid lueal phase and (3) the 
cellular source of the luteal PKC isozymes. PKC alpha, beta I, beta II, epsilon and meu 
were observed to be expressed in the bovine CL with beta II and epsilon being 
differentially expressed as a function of development. In day-10 CL PGF2 alpha and ET-
1 were able to activate PKC alpha, beta I and epsilon. More importantly, PKC epsilon 
was found to be involved in the regulation of PGF2 alpha induced rise in intracellular 
calcium concentration and antagonized the inhibitory effect of PGF2 alpha and ET-1 on 
LH-stimulated P4 accumulation in cultures of day-10 luteal steroidogenic cells (SC). 
PKC epsilon was found exclusively expressed in SC. In contrast, PKC alpha, beta I and 
beta II were expressed in both SC and endothelial cells (EC), with SC expressing higher 
amounts than EC. In this study we have proposed that the differential expression and 
activation of PKC epsilon as a function of development may be one of several factors 
responsible for the insensitivity of the early CL. Expression of PKC epsilon in the mid 
luteal phase shifts the PGF2 alpha induced rise in intracellular calcium concentration 
from a P4 favorable to a P4 inhibitory condition. Based on these observations it is 
hypothesized that the insensitivity of the early CL towards the luteolytic actions of PGF2 
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Chapter I: Literature Review 
I.  History: 
In 1642 Regnier de Graaf reported the appearance of “globules” after coitus in the 
ovary of rabbits [Corner GW, 1943]. It was Marcello Malphighi who in 1681 [Malphighi 
M, 1689] termed these “globular bodies” as Corpora (bodies) lutea (yellow) or Corpus 
Luteum (CL). In 1897, Beard [Beard J, 1897] first suggested the involvement of the CL 
in the suppression of ovulation and estrus during pregnancy. The very next year, Prenant 
[Prenant LA, 1898] proposed that the CL might be a gland involved in secretion that is 
associated with pregnancy. 
Nearly two centuries after the introduction of the term “Corpus Luteum”, in 
1901 two students of Gustav Born, Ludwig Fraenkel in Germany [Fraenkel L, 1901] and 
Vilhelm Magnus in Norway [Magnus V,1901] reported the precise physiological function 
of the CL. These two researchers independently demonstrated the importance of the CL 
in implantation and in the subsequent maintenance of pregnancy in rabbits. Thereafter, 
Corner and Allen [Corner GW et al, 1929] using relatively pure alcoholic extract of the 
CL prepared from sows demonstrated that this extract was able to maintain pregnancy in 
ovariectomized rabbits. In 1934, four independent laboratories, Wintersteiner and Allen 
[Wintersteiner O and Allen WN, 1934], Slotta et al [Slotta KH et al, 1934], Butenandt 
and Westphal [Butenandt A, Westphal U, 1934] and Hartmen and Wettstein [Hartmen H, 
Wettstein A, 1934], claimed to isolate the pure crystalline hormone secreted by the CL 
and named it Progesterone (P4). 
 
II. Development of the CL  
During ovulation, the preovulatory surge of Luteinizing hormone (LH) from the 
anterior pituitary results in the rupture of the mature follicle and expulsion of the ovum. 
The residual follicular cells, (theca and granulosa cells) in the ovary, under the influence 
of LH and various mitogenic factors undergo hypertrophy and hyperplasia. The wall of 
the follicle collapses into folds along with invasion of capillaries, while various 
angiogenic factors result in neovascularization. These events lead to the formation of a 
transient endocrine gland called the Corpus Luteum. The major function of the CL is to 
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produce P4 that is essential for the maintenance of pregnancy. However, if pregnancy 
does not occur, timely regression of the CL is necessary for normal ovarian cyclicity. 
 
1. Cellular Composition, Cell morphology, Cell division and Differentiation: 
  The CL is comprised of theca (TC) and granulosa (GC) derived luteal 
steroidogenic cells as well as endothelial cells (EC), fibroblasts, pericytes and cells from 
blood [Channing CP, 1969a; Channing CP, 1969b]. In domestic animals, the cells derived 
from the GC are called large luteal cells (LLC) while those derived from the TC are 
known as small luteal cells (SLC) [Niswender GD and Nett TM, 1994]. These luteal 
steroidogenic cells differ not only in origin but also in morphology and physiology. The 
LLC are greater than 20 μm in size with spherical nuclei and high amounts of rough 
endoplasmic reticulum (ER). These cells are responsible for basal P4 synthesis, have less 
LH receptor (LHR) and are less sensitive to LH stimulation (require high LH 
concentration). These cells also have higher amounts of estrogen (E2) receptors and 
prostaglandin F2α (PGF2α) receptors [Farin CE et al, 1986]. In contrast, SLC are smaller 
than 20 μm with irregular nuclei and are devoid of rough ER [Fitz A et al, 1982; 
Wiltbank M C, 1994]. These cells are responsible for LH-stimulated P4 synthesis [Koos 
RD et al, 1981]. There is also evidence that some SLC may transform into LLC with the 
development of the CL [Alila HW and Hansel W, 1984]. 
Although the CL is a transient endocrine gland, it is one of the most highly 
vascularized tissues in the body [Reynolds LP et al, 1998; Redmer DA et al, 1996] with 
the EC constituting about 50% of the total luteal cell population. In the CL, the EC are 
involved in neovascularization [Spanel-Borowski K and Fenyves A, 1994a], inter-cellular 
communication and steroidogenesis [Girsh E et al, 1995]. Proliferation and 
morphological changes of EC are important regulatory factors for luteal development. 
Over the past few years, microvascular EC have been isolated and cultured from the CL 
of different species: rabbit [Bagavandoss P et al, 1991], pig [Plendl J et al, 1996b], sheep 
[Rodgers RJ et al, 1982], cow [Spanel-Borowski K and Fenyves A, 1994a; Spanel-
Borowski K and van der Bosch J, 1990, Girsh E et al, 1995], rhesus monkey [Christenson 
LK et al, 1996] and humans [Ratcliffe KE et al, 1999]. These studies have led to the 
identification of 5 distinct sub-types of EC, namely Types 1,2,3,4 and 5 [Spanel-
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Borowski K and Fenyves A, 1994a; Spanel-Borowski K and van der Bosch J, 1990]. 
These sub-types of EC have been characterized by differences in morphology, surface 
molecule expression and function [Spanel-Borowski K, 1991]. In the bovine CL, the 
microvascular EC have been classified based on the presence or absence of cytokeratin 
filaments [Spanel-Borowski K and Fenyves A, 1994a; Spanel-Borowski K et al, 1994b; 
Spanel-Borowski K et al, 1990]. These two different EC types differ in their expression 
and function during luteal development. The cytokeratin positive EC are expressed 
predominantly in the early CL and their expression decreases during the mid-late stage 
[Ricken AM et al, 1995]. These EC are involved in the sprouting of capillaries and in the 
formation of branching points during neovasculariztion at the early developmental stage 
of the CL. Moreover, the CL of pregnancy is completely devoid of the cytokeratin 
positive EC [Ricken AM et al, 1995]. Plendl et al [Plendel J et al, 1996a] proposed that 
the EC isolated from the bovine CL during pregnancy produce specific angiogenic factors 
that are absent or present in limited amounts in EC isolated from the CL of the estrous 
cycle. Less is known about the expression and function of the cytokeratin negative EC. 
However, the selective presence of different EC types during luteal development may be 
involved in the regulation of luteal physiology. For example, there is a controversy in the 
literature about the expression of PGF2α receptor (FPr) in the EC. It is possible that these 
EC types may differ in their expression of FPr [Aust BEG et al, 1999; Lehmann I et al, 
2000] and presence / absence of these EC types during luteal development may be one of 
the factors regulating the life span of the CL. Thus, further studies are needed to 
investigate the physiological functions of these different types of EC. 
 A characteristic of early CL development is rapid tissue growth and cellular 
proliferation. The growth of the CL in many cases has been compared to that of rapidly 
growing tumors [Jablonka-Shariff A et al, 1993]. For example, the weight of a day 3 
bovine CL is about 640 mg, while on day 14, the average weight will be 5.1g [Fields MJ 
et al, 1996]. Most of this increase in tissue mass has been attributed to hypertrophy and 
mitotic division of LLC, SLC, EC and fibroblasts. The LLC do not increase in number 
but in size. In contrast SLC and endothelial cells undergo rapid increase in number 
[Reynolds LP et al, 1994]. The factors responsible for the regulation of cell proliferation 
are basic fibroblast growth factor (bFGF) [Neufeld G et al, 1987], platelet derived growth 
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factor (PDGF) [Khachigian LM et al, 1996], insulin-like factor I (IGF-I) [Juengel JL et 
al, 1997], heparin binding growth factor [Grazul-Bilska AT et al, 1992] and vascular 
endothelial growth factor (VEGF) [Redmer DA et al, 1996]. Little is known about the 
specificity of these factors with respect to proliferation of specific luteal cell types. VEGF 
is considered as the main mitogenic regulator of EC during luteal neovascularization. 
Capillary network accounts for 22% of the total CL volume [Dharmarajan AM et al, 
1985] and the CL has greater blood flow rate per unit tissue than any organ [Reynolds LP 
et al, 1998; Redmer DA et al, 1996]. 
 
2. Angiogenesis 
Angiogenesis is a critical aspect of growth and function of the CL [Reynolds LP 
et al, 1992]. During luteal development, VEGF and bFGF [Reynolds LP et al, 1998] are 
two main angiogenic factors responsible for neovascularization [Gospodaorwicz D et al, 
1985]. VEGF is involved in vascular permeability, EC protease production, migration 
and proliferation, all of which are integral parts of angiogenesis [Ferra N et al, 1997]. 
Also, in the bovine CL, VEGF receptors are localized exclusively in EC [Berisha B et al, 
2000]. It is well established that VEGF acts via fms-like tyrosine kinase-1 receptor (Flt-1) 
and fms-like kinase insert domain-containing receptor (Flk-1) [Fong GH et al, 1995]. In 
the early bovine CL, VEGF and its receptors are highly expressed [Redmer DA et al, 
1988; Redmer DA et al, 1996]. Based on in situ hybridization and immunohistological 
studies on the bovine CL, it is known that VEGF is mainly present in steroidogenic cells 
while Flt-1 and Flk-1 are present only in EC [Berisha B et al, 2000]. VEGF expression 
can be stimulated by bFGF, hormones and cytokines involved in angiogenesis [Ferra N et 
al, 1997]. Ablation of VEGF and VEGF receptor gene expression by knock out strategies 
[Shalaby F et al, 1995] and disrupting VEGF function with neutralizing monoclonal 
antibodies [Kim KJ et al, 1993]  have shown that VEGF plays a role in the organization 
and maintenance of the microvasculature [Carmeliet P et al, 1996]. Reynolds and Redmer 
[Reynolds LP et al, 1998; Reynolds LP et al, 1999] have proposed a model of 
vascularization of the CL that is different from the vascularization in the growing 
follicles. The follicles are supplied by one artery which forms 3 4 arterioles in the theca 
externa. Entering the theca interna, the arterioles break up into a rich network of 
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capillaries that build a basket-like network around the avascular stratum granulosum 
[Plendl J, 2000]. The basement membrane, forms a barrier within the follicular wall and 
prevents the thecal vasculature from invading the stratum granulosum. After ovulation, 
the breakdown of the basement membrane results in the invasion of the theca-derived 
pericytes, into the granulosal region. According to the model proposed by Reynolds and 
Redmer, pericytes of the thecal capillaries are the initial vascular cells that produce 
VEGF.  The proliferation and migration of these pericytes are stimulated by GF, FGF-2 
and PDGF produced by the GC. The pericytes then produce VEGF, which in turn 
stimulates the migration of the theca-derived EC into the granulosal-derived region. 
Subsequent interaction between pericytes and EC leads to the formation of a mature 
capillary bed of the luteal parenchymal lobule [Reynolds LP et al, 1998; Reynolds LP et 
al, 1999]. 
Additional angiogenic factors like angiopoietins [Tsigkos S et al, 2003] play an 
important role in the regulation of vascular development during early stages of the CL. 
Angiopoietin-1 and 2 (ANPT-1, ANPT-2) act via Tie 2 receptor (tyrosin kinase with 
immunoglobulin and EGF homology domains) [Goede V et al, 1998]. ANPT-1 is 
necessary to maintain and stabilize blood vessels, while ANPT-2 destabilizes vascular 
structures. Since both ANPT-1 and ANPT-2 bind to same Tie 2 receptor, the ratio of 
ANPT-2/ANPT-1 plays a critical role in maintaining vascular stability. VEGF and 
ANPT-1 act synergistically in maintaining vascular networks and can reverse the 
destabilizing effects of ANPT-2 [Yancopoulos GD et al, 2000].  In vitro studies have 
demonstrated that angiopoietin-1 stimulates sprouting and maturation of blood vessels 
[Tsigkos S et al, 2003; Goede V et al, 1998]. In the bovine CL, high amounts of 
angipoietin-1 mRNA were found to be present in developing and fully functional CL of 
the estrous cycle [Goede V et al, 1998].  
In the bovine [Schams D et al, 1994; Zheng J et al, 1993; Berisha et al, 2002] and 
ovine CL [Grazul-Bilska AT et al, 1992; Jablonka-Shariff A et al, 1997], other factors 
like bFGF (FGF-1 and FGF-2) and angiotensin II are involved in luteal development, 
vascularization and steroidogenesis. In this section, only luteal development and 
vascularization will be discussed. Primarily, in the early luteal phase, FGF-2 stimulates 
EC proliferation [Gospodarowicz D et al, 1986]. Neutralization of FGF-2 action greatly 
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decreases mitogenic activities of EC in bovine, porcine and ovine CL [Redmer DA et al, 
1996; Reynolds LP et al, 1998]. In luteal parenchymal cells, FGF-1 and FGF-2 acts via 
FGF receptor. It has been suggested that binding of FGF-2 with FGFR in luteal 
microvessels is important for protection of luteal tissue against regression [Reynolds LP 
et al, 1998]. Expression of FGF-1 significantly increases in the mid-late CL with higher 
localization to larger microvessels [Reynolds LP et al, 1998]. The exact role of FGF-1 in 
luteal development is unclear. 
A potential role of angiotensin-II in early CL development has been suggested in 
many studies. In the bovine luteal EC, angiotensin-I is converted into angiotensin II by 
angiotensin converting enzyme (ACE) [Schauser KH et al, 2000]. In primary cell culture 
of bovine luteal cells, angiotensin II has been shown to stimulate mRNA of bFGF in 
bovine luteal cells [Stirling D et al, 1990]. In vivo studies with bovine CL have 
demonstrated that angiotensin II stimulates expression of VEGF and FGF-2 [Berisha B et 
al, 2002]. These actions of angiotensin in the CL occur via angiotensin II type 1 (AT1R) 
and type 2 (AT2R) receptors that are expressed in steroidogenic cells and EC [Hayashi K 
et al, 2000]. Another vasoactive peptide, atrial natriuretic peptide (ANP) enhances release 
of angiotensin II, thereby suggesting its involvement in the angiogenic process during 
luteal development [Acosta TJ et al, 2000].  
 
III. Luteal Steroidogenic Pathway 
 Progesterone (P4) is the major steroid of the CL that plays a central role in 
reproduction, being involved in implantation, pregnancy and in many other physiological 
functions. Before ovulation, estrogen (E2) is the primary steroid secreted by the ovary. A 
major alteration of steroidogenic pathway occurs following luteinization of GC and TC 
that makes P4 the steroid of the CL. In the cells undergoing differentiation during 
luteinization, enzymes necessary for P4 synthesis are upregulated. For example, in the 
bovine system, expression of P450 side chain cleavage enzyme (P450 scc) and 3-beta 
hydroxysteroid dehydrogenase (3β-HSD) involved in conversion of cholesterol to P4 are 
upregulated while enzymes like 17α-hydroxylase, cytochrome P-450 and aromatase 
cytochrome P-450 involved in the conversion of P4 to E2 are downregulated [Bao B et al, 
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1998]. Cholesterol is the substrate for P4 synthesis. The CL is capable of de novo 
cholesterol synthesis. However this method plays a minor role in steroidogenesis in the 
CL due to low expression of HMG-CoA reductase and other key enzymes of cholesterol 
biosynthetic pathway [Gwynne JT et al, 1982]. Majority of the cholesterol for P4 
synthesis in the CL is obtained from low density lipoprotein (LDL) and high density 
lipoprotein (HDL). Also, cholesterol esterase has been shown to hydrolyze stored 
cholesterol ester for P4 synthesis in the CL [Johnson WJ et al, 1997]. 
   
1. Cholesterol transport into and within cells: 
Transport of cholesterol into the cells is the first challenge for P4 synthesis by luteal 
cells. Whether LDL or HDL serves as the cholesterol source for luteal steroidogenesis is 
species dependent. Transport of LDL across the cell membrane occurs via receptor- 
mediated endocytosis resulting in formation of LDL-receptor-clathrin coated pit complex 
[Brown MS et al, 1986]. In contrast, extracellular HDL enters the cell by binding to 
plasma membrane bound HDL binding protein. In mice, cloning of scavenger receptor BI 
(SR-BI) identified this receptor as the HDL receptor [Acton S et al, 1996]. Targeted 
deletion of this gene resulted in infertility in female mice and reduced lipid levels in the 
CL.  However, this decline in fertility could not be attributed to reduced steroid output, as 
endocrine profiles were normal. This observation led to the suggestion that de novo 
synthesis of cholesterol may have compensated for the absence of HDL delivery [Acton 
S et al, 1996]. The mechanisms of uptake of lipoproteins by cells are poorly understood. 
Cholesterol esters, stotage sites for P4 synthesis are formed by microsomal acyl 
coenzyme A: cholesterol acyltransferase (ACAT). The cholesterol esters accumulate in 
the rough ER and with increased concentration bud off into cytoplasm as lipid droplets. 
Inside the cell, receptor-mediated endocytosis of lipoprotein particles result in the 
formation of endosomes. Endosomal lysosomes recycle the lipoprotein receptors to the 
plasma membrane, while lysosomal degradation of LDL/HDL releases cholesterol into 
cholesteryl ester droplets. These cholesteryl ester droplets are transported to the 
mitochondria. The droplets are hydrolyzed by the extralysosomal enzyme, neutral 
cholesterol ester hydrolase (NCEH) into free cholesterol [Christenson LK et al, 2003] and 
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transported across the mitochondrial membrane [Voet D and Voet J, 1995] with the help 
of various proteins. 
         The cholesteryl ester droplets are transported to the mitochondria with the 
involvement of the cytoskeleton. In rat adrenal cells, inhibitors of microtubules and 
microfilaments assembly prevent accumulation of cholesterol [Crivello JF et al, 1978] 
while phosphorylation status of cytoskeletal proteins plays an important role in steroid 
transport [Ikonen E et al. 1997]. Sterol binding proteins also are suggested to play a role 
in the transport of cholesterol to the mitochondria [Scallen TJ et al, 1985; Jefcoate CR et 
al, 1992]. The exact mechanism of cholesterol transport from the plasma membrane to 
the mitochondria involving cytoskeletal proteins is poorly understood. 
 
2. Cholesterol transport across mitochondrial membranes: 
 Cholesterol transport from outer to inner mitochondrial membrane involves different 
proteins, namely steroidogenic acute regulator protein (StAR), sterol carrier protein 
(SCP-1) and peripheral-type benzodiazepine receptor (PBR). This process has been 
suggested to be the key regulatory step in P4 synthesis [Stevens VL et al, 1993]. The 
StAR protein is thought to play a major role in this process. It consists of a 37kDa 
precursor and a 30kDa mature form that was first observed in ACTH-stimulated 
adrenocortical cells [Krueger RJ et al, 1983]. Full length StAR protein was first cloned 
from MA-10 mouse Leydig cells [Clark BJ et al, 1994]. Transfection of MA-10 cells and 
COS-1 cells with StAR resulted in increased conversion of cholesterol to pregnenolone 
and steroid production [Lin D et al, 1995]. These experiments directly demonstrated the 
role of StAR in the steroid production pathway [Stocco DM et al, 1996]. 
The expression of StAR in the luteal steroidogenic cells is an indication of 
luteinization. Before ovulation, StAR is practically absent in GC as a result of which GC 
are unable to metabolize and synthesize P4 from cholesterol precursors. In contrast, StAR 
expression is found in TC that are involved in conversion of cholesterol to androgens 
[Pescador N et al, 1996]. Expression of StAR mRNA and protein is highest in early and 
mid-luteal phase of ovine CL, while it declines in the late luteal phase [Juengel JL et al, 
1995a]. Based on this observation, it has been proposed that regulation of StAR gene 
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expression and activity might be an essential component of luteal regression [Niswender 
GD, 2002]. 
In domestic animals, LH induces the expression of StAR in the early luteal stage 
[Juengel JL et al, 1999]. Binding of LH to its G-protein coupled receptor activates the 
cAMP - protein kinase A (PKA) pathway that results in the expression of StAR [Juengel 
JL et al, 1999]. In contrast, during luteal regression it is believed that PGF2α interferes 
with StAR expression, thereby disrupting P4 synthesis [Niswender GD, 2002]. The 
mechanism by which PGF2α inhibits StAR expression is poorly understood.  Thus, the 
transcriptional regulation of StAR has been an area of active research. Steroidogenic 
factor-1 (SF-1/AdBP/NR5A-1), a member of the nuclear receptor family, is activated by 
PKA and plays a central role in StAR gene expression [Parker KL et al, 1997]. Several 
SF-1 binding sites are present in the StAR promoter region that are essential for both 
basal and cAMP dependent regulation [Sandoff TW et al, 1998; Wooton-Kee CR et al, 
2000; Rust W et al, 1998]. The method by which SF-1 binding sites confers cAMP-
responsiveness and the regulatory factors involved in SF-1 function (i.e., ligands, 
phosphorylation, and coactivators) are not completely understood [Christenson LK et al, 
1998; Hammer GD et al, 1999; Ito M et al, 1998]. Also found in the StAR promoter 
region are cis elements responsive to CCAAT/enhancer-binding proteins (CEBP). These 
CEBP response elements that are needed for cAMP-stimulated transcription have been 
identified in murine [Wooton-Kee CR et al, 2000; Silverman E et al, 1999], bovine [Rust 
W et al, 1998] and human [Christenson LK et al, 2001] StAR promoters. CEBP and SF-1 
exert a synergistic effect on cAMP dependent StAR activity [Reinhart AJ et al, 1999]. 
Electrophorectic mobility shift assays and promoter analysis studies have shown a role of 
GATA-4 and a cooperative mediation of CEBP and GATA-4 in stimulation of basal and 
cAMP dependent StAR gene expression [Tremblay JJ et al, 2002; Tremblay JJ et al, 
2003]. Another, transcription factor, DAX-1 (dosage sensitive sex reversal; adrenal 
hypoplasia congenita; X chromosome; gene 1), a member of the nuclear hormone 
receptor family, inhibits StAR gene expression by binding to a hairpin structure in a 
region of single stranded DNA found in the promoter region of the StAR gene 
[Zazopoulos E et al, 1997]. It has been proposed that PGF2α activates DAX-1 and inhibits 
StAR expression [Diaz FJ et al, 2002]. Recently P4 has been reported to stimulate StAR 
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expression in MA-10 cells, the mechanism of which is still unknown [Schwarzenbach H 
et al, 2003]. However, classical P4 receptors are thought not to be involved in this 
process as MA-10 cells are devoid of these receptors.  
In addition to transcriptional control, StAR protein is regulated directly [Bose H et al, 
2002]. Truncation studies have demonstrated that the c-terminal end of StAR play an 
important role in cholesterol transport [Arakane F et al, 1996]. Steroid stimulating 
properties of MLN 64 protein, known to have significant homology with the C-terminal 
region of StAR further demonstrated the importance of this region in StAR activity 
[Watari H et al, 1997].  In ovine CL it is proposed that StAR has a mitochondrial 
targeting site (MTS) and a cholesterol binding site (CBS) [Niswender GD et al, 2000]. 
Six potential phosphorylation sites, 3 in MTS and 3 in CBS have been proposed in ovine 
StAR. Sequence analysis studies have reported the presence of PKA/CAM kinase II and 
PKC phosphorylation sites in StAR protein [Niswender GD et al, 2000]. In ovine luteal 
cells, phosphorylation of esterase and StAR by PKA increases the level of free 
cholesterol available for P4 synthesis [Caffrey JL et al, 1979]. In mouse, mutational 
studies of phosphorylation sites revealed that phosphorylation of StAR by PKA/CAM 
kinase II at positions 194/195 significantly increases its biological activity [Arakane F et 
al, 1997]. Thus, it is likely that in the early luteal stage LH, via cAMP-PKA pathway, 
induces StAR expression and activity, thereby stimulating P4 synthesis. In contrast, 
during luteal regression, PGF2α inhibits StAR expression and activity, thereby disrupting 
P4 synthesis. 
The interaction of StAR with other proteins, mainly PBR and endozepine is unclear. 
[Hauet T et al, 2002; Miller WL et al, 1999]. Targeted deletion of PBR resulted in loss of 
steroidogenic capacity in leydig cells, which was restored on supplying the cells with 
membrane-permeable cholesterol analogues [Papadopoulos V et al, 1997b]. Also 
mutations in PBR at Y153 and R156 caused significant reduction in the interaction 
between PBR and cholesterol. [Li H et al, 1998].  PBR appears to be associated with 
voltage dependent anion channel (VDAC) and molecular modeling indicates that PBR-
VDAC complex forms a pore permeable to cholesterol that spans the mitochondrial 
membrane [Papadopoulos V et al, 1997a]. The expression of PBR in steroidogenic cells 
was found to be independent of hormonal regulation, but the affinity of the receptor 
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greatly increased after hormone treatment [Papadopoulos V et al, 1995]. Endozepine, the 
natural ligand of PBR is thought to play a critical role in cholesterol transport. Targeted 
deletion of this molecule in MA-10 and R2C cells resulted in inhibition of trophic 
hormone stimulation and reduction of basal steroidogenesis [Boujard N et al, 1993]. 
Understanding the interaction of these three proteins, PBR, StAR and endozepine in the 
CL needs further investigation. 
 
3. Regulation of P4 synthesis by Luteotropic Factors: 
 Effects of LH  
In domestic animals and primates, LH is the major luteotropic hormone. A luteotropin 
is defined to be a substance that promotes the growth and development of the CL and 
stimulates P4 synthesis. The requirement for pulsatile release of LH from the pituitary for 
the development and maintenance of the CL varies from spieces to spieces. In the sheep 
[McNeilly AS et al, 1992] P4 synthesis is independent of LH pulses and can be 
maintained with basal LH secretion. In bovine CL [Peters KE et al, 1994], pulsatile LH 
secretion is a critical factor during luteal development. However, once the CL has 
developed, basal LH production is sufficient for P4 synthesis. In contrast, primates 
[Fraser HM et al, 1986] need pulsatile LH release throughout the luteal phase in order to 
maintain the CL [Zeleznik AJ et al, 1994]. Hypophysectomy in ewes [Farin CE et al, 
1990] decreased P4 synthesis [Juengel JL et al, 1995b] with reduced amounts of mRNA 
encoding StAR, P450scc and 3β-HSD [Juengel JL et al, 1995a]. Hypophysectomy did 
not have any affect on cholesterol intake or on HDL/LDL receptor expression [Tandeski 
TR et al, 1996]. This led to the idea that the expression of StAR, P450scc and 3β-HSD is 
LH dependent. In luteal cells, LH acts via a G-protein coupled receptor that activates the 
cAMP-PKA pathway. 
In vitro studies have demonstrated that LH receptor is also linked to the PLC-
PKC-Calcium pathway in luteal [Alila HW et al, 1989; Davis JS et al, 1996] and 
granulosal cells [Flores JA et al, 1998]. In ruminants, 80% or more of the circulating P4 
is derived from basal/constitutive P4 synthesis in LLC. A hypothesis has been proposed 
[Diaz FJ et al, 2002], that LLC contain an extra PKA catalytic subunit in relation to its 
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regulatory subunit. This extra subunit remains constitutively active and causes tonic PKA 
phosphorylation in LLC [Diaz FJ et al, 2002]. Also, it has been proposed that the 
presence of high a concentration of endozepine in LLC may play a role in increased basal 
P4 production in these cells [Niswender GD, 2002].  In LLC, both basal and LH-
stimulated P4 production is dependent on calcium. In contrast, in SLC, LH-stimulated but 
not basal, P4 synthesis is calcium dependent [Alila HW et al, 1989; Alila HW et al, 
1988b]. 
 
Effects of oxytocin (OT) and prostaglandins (PGE2, PGI2 and PGF2α) 
 Expression of OT receptors [Schams D, 1992; Evans JJ, 1996] and their 
localization in LLC and SLC of bovine CL are well established [Kruip TA et al, 1985]. 
Luteinization triggers production of ovarian OT that influences steroidogenesis [Schams 
D, 1987]. In vitro studies [Miyamoto A et al, 1991] have shown that OT is a potent 
luteotropin in the early developmental stage of the CL [Schams D et al, 1995a; Schams 
D, 1996]. This notion is further supported by other studies that have shown that cell-to-
cell contact plays an important role for the stimulation of P4 by OT [Okuda K et al, 1998; 
Sakumoto R et al, 1996]. 
 It is well established that prostaglandins, especially PGE2 and PGI2, play 
important roles in luteal protection [Hansel W et al, 1991; Milvae RA et al, 1980]. These 
prostaglandins are present in higher amounts in the early CL and are proposed to be 
involved in luteal development [Milvae RA et al, 1983]. In cows, indomethacin (PGH 
synthase I inhibitor) treatment in the early luteal phase significantly lowered P4 synthesis 
throughout the life span of the CL [Milvae RA et al, 1985]. Moreover, prostacyclin 
injection directly into the CL dramatically increased P4 production [Milvae RA et al, 
1980]. 
Both PGE2 [Fitz TA et al, 1984a] and PGI2 [Fitz TA et al, 1984b] have been 
shown to increase P4 synthesis in many species via an increase in cAMP [Alila HW et al, 
1988a]. PGI2 receptors are present in both LLC and SLC [Chegini NZ et al, 1990; 
Chegini NZ et al, 1991]. However, the exact mechanism by which PGI2 is luteotropic is 
poorly understood.  
 13
  There are four PGE2 receptor sub-types EP1, EP2, EP3 and EP4 [Narymiya S et 
al, 1999]. EP2 and EP4 receptors are coupled to the adenylate cyclase-cAMP-PKA 
signaling pathway. EP1 receptors are coupled to PLC-PKC-calcium pathway. EP3 
receptors exist in 4 isoforms designated A to D. These EP3 receptors are involved in a 
wide range of actions from inhibition of cAMP synthesis to increase of intracellular 
calcium [Arosh J et al, 2004a]. EP2 and EP3 are expressed in bovine CL [Arosh JA et al, 
2004b] while EP1 and EP4 are expressed in bovine endometrium [Arosh JA et al, 2003]. 
Expression of EP2 is highest in the early CL while that of EP3 is higher in late CL [Arosh 
JA et al, 2004b]. Also EP2 is more expressed more in LLC than SLC. In contrast, EP3 is 
not expressed in LLC of ovine CL [Fitz TA et al, 1982]. Recent studies have identified 
EP2 as the major cAMP generating receptor expressed in the CL [Arosh JA et al, 2003]. 
Intrauterine administration of PGE2 has been shown to have protective effect from 
spontaneous and/or induced luteolysis in ruminant CL [Pratt BR et al, 1977; Magness RR 
et al, 1981; Henderson KM et al, 1977; Reynolds LP et al, 1981]. When indomethacin 
was used to inhibit luteal prostaglandin production, there was a reduced P4 synthesis in 
the ovine CL [Kim L et al, 2001]. Moreover, a positive association between PGE2 and P4 
has been demonstrated during the estrous cycle in cows [Kotwica J et al, 2003]. 
 In ruminants, in contrast to the luteolytic actions of endometrial-derived PGF2α 
during luteolysis, in vitro microdialysis studies have provided evidence of a luteotropic 
action of PGF2α at the early developmental stage of the CL [Miyamoto A et al, 1993]. 
Results from other in vitro studies with total dispersed luteal cells as well as with pure 
populations of LLC and SLC have shown that PGF2α and several other prostanoids have 
luteotropic actions in these cells [Hansel W et al, 1991; Choudhary et al, 2005]. PGF2α 
via PLC-calcium-PKC intracellular mediators, stimulated P4 synthesis in bovine luteal 
cells [Hansel W et al, 1987]. There is a close relationship between intracellular calcium 
and steroidogenesis. It has been suggested that there exists a threshold of intracellular 
calcium for steroidogenesis [Wegner JA et al, 1991].  
 
 Effects of P4 
 In vitro studies provided evidence that P4 might have an effect on the 
functionality of the bovine CL [Skarzynski DJ et al, 2001]. In the bovine CL, P4 
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regulates the production of P4 [Skarzynski DJ et al, 1997], OT [Lioustas CH, 1997] and 
PGs [Pate JL 1996, Pate JL 1988]. It appears that the secretion of PGF2α and P4 is 
interrelated. In mid-late bovine CL, treatment with PGF2α inhibits P4 secretion [Pate JL 
1988; Choudhary et al, 2005]. In contrast, P4 treatment decreases PGF2α production in a 
dose dependent manner [Pate JL 1988]. It may be that the effects of P4 are dependent on 
the developmental stage of the CL. Findings with P4 antagonist, onapristone, have 
demonstrated that P4 appears to act in the early CL by stimulating P4, OT, PGE2 and 
PGF2α secretion but inhibits PGF2α secretion in the mid-cycle CL [Skarzynski DJ et al, 
1999].  Therefore, P4, OT and PGF2α are components of a feedback loop that may have 
both stimulatory and inhibitory roles depending on the stage of luteal development.  
 P4 has an anti-apoptotic action that protects the CL from premature luteolysis. 
Rueda [Rueda BR et al, 2000] showed that inhibition of P4 production by 
aminoglutethimide (P450scc inhibitor) caused apoptosis in cultured bovine luteal cells 
and this effect was abolished by P4 supplementation. Also, the effects of P4 on apoptosis 
in the cultured bovine luteal cells appeared to be mediated by P4 receptor, as RU-486 or 
onapristone caused luteal cell apoptosis without any effect on luteal P4 secretion [Rueda 
BR et al, 2000]. In cultured bovine luteal cells, P4 plays a luteotropic role by stimulating 
the synthesis of LH receptors [Jones LS et al, 1992]. In bovine luteal cells, the anti-
apoptotc action of P4 is believed to be via inhibition of expression of Fas and caspase-3 
mRNA expression [Okuda K et al, 2004]. 
 Rothchild postulated that progesterone stimulates its own secretion, thereby 
providing positive feedback for a free-running CL [Rothchild I, 1981]. In fact, discovery 
of P4 receptor in primate luteal tissue [Hild-Petito S et al, 1988] as well as membrane P4 
receptor in mouse luteal cells [Peluso JJ et al, 2005] further strengthen this idea. 
Progesterone receptor expression is induced in rat granulosal cells by the LH surge 
[Natraj U et al, 1993] and is dependent on cAMP and granulosal cell differentiation 
[Clemens JW et al, 1998]. Blockade of the conversion of pregnenolone to progesterone 
reduces CL mass in monkeys [Duffy DM et al, 1997]. Progesterone receptor antagonists 
inhibit luteinization in bovine granulosal cells, as indicated by loss of oxytocin gene 
upregulation [Lioutas C et al, 1997]. In immortalized porcine granulosal cells, synthetic 
progestins act in synergy with cAMP to increase progesterone synthesis, while 
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progesterone and other progestins upregulate P450scc [Rodway MR et al, 1999]. 
Progesterone further promotes differentiation and inhibits proliferation of human 
granulosa-luteal cells in vitro [Chaffkin LM et al, 1993]. 
 
IV. Prostaglandin (PG) Metabolic Pathway 
 Prostaglandins (PG) are all derivatives of a C20 fatty acid in which carbon atoms 8 
to 12 comprise the cyclopentane ring. Arachidonate is the substrate for series 2 PG 
biosynthesis. Arachidonate is stored in cell membranes esterified to glycerol at C2 of 
phosphatidylinositol, plasmenylcholine, phosphatidylcholine and other phospholipids. 
The production of arachidonate metabolites is controlled by the rate of arachidonate 
release from these phospholipids through three alternative pathways.  
1. Phospholipase A2 (PLA2) hydrolyzes acyl groups at C2 of phospholipids. 
2. Phospholipase C (PLC) specifically hydrolyzes the phosphatidylinositol head group to 
yield 1, 2-diacylglycerol (DAG), which is phosphorylated by diglycerol kinase to 
phosphatidic acid, a PLA2 substrate [Flint APF et al, 1986; Burns PD et al, 1997]. 
3.  DAG also may be hydrolyzed directly by diacylglycerol lipase. 
There are two pathways of arachidonate metabolism, one that involves the formation 
of PGs and the other in the formation of Leukotrienes and Hydroperoxyeicosatetraenoic 
acids (HPETE). The first step of PG biosynthesis is catalyzed by PGH2 synthase (PGH2 
synthase; PG endoperoxide synthase). This heme-containing enzyme has two catalytic 
activities; (1) a cyclooxygenase activity, that catalyzes the addition of two molecules of 
oxygen to arachidonic acid to form PGG2 and (2) a peroxidase activity that converts 
PGG2 to PGH2 by adding an OH group. PGH2 is the immediate precursor of all series 2 
prostaglandins, prostacyclins and thromboxanes. The fate of PGH2 depends on the 
relative activities of enzymes catalyzing specific interconversion of PGH2 to different 
PGs (PGE2, PGF2α, PGD2, PGI2 and thromboxanes). The presence and activity of these 
enzymes are dependent on tissue type and the physiological state of that tissue [Gibson 





1. Phospholipase A2 (PLA2) 
There are two families of PLA2, a calcium dependent cytosolic PLA2 (cPLA2), which 
is produced in an inactive precursor form and a calcium independent membrane bound 
PLA2 (iPLA2). Each family of PLA2 exists in a number of isoforms transcribed from 
separate genes located on the same chromosome [Murakami M et al, 1998]. In mammals, 
there are at least four cPLA2 isoforms: α, β, γ and δ (Six DA et al, 2000; Hirabayashi T et 
al, 2004].   Activation of cPLA2 requires calcium binding at the N-terminal C2 domain 
and phosphorylation on serine residues. Calcium binding causes redistribution of cPLA2, 
particularly to the nuclear envelope and ER, where cPLA2 hydrolyzes arachidonic acid 
from membrane phospholipids [Gijon MA et al, 1999]. Serine phosphorylation is 
mediated by mitogen-activated protein kinases (MAPKs) [Lin LL et al, 1993], calcium / 
calmodulin dependent protein kinase II (CAMK II) [Mubarack M. Muthalif et al, 2001] 
and MAPK interacting kinase Mnk 1 [Ying Hefner et al, 2000].  In some cell types, PKC 
activation and/or inhibition of certain phosphatases with okadaic acid contributes to 
cPLA2 activation [Gijon MA et al, 1999].  
 
 
2.   Conversion of Arachidonic acid to PGH2
Conversion of arachidonic acid to PGH2 is catalyzed by PG endoperoxidase G/H 
synthase (PGHS or Cox) and this step commits arachidonic acid to the PG biosynthesis. 
This process involves two enzymatic steps; first, conversion of arachidonic acid to PGG2 
involving cyclooxygenase (Cox) and second, a peroxidase step that reduces PGG2 to 
PGH2. In non-inflammatory PG production, Cox is the rate limiting enzyme of PG 
synthesis. There are two isoforms of Cox; Cox-1 and Cox-2 [Lysz TW et al, 1988]. Cox-
1 and Cox-2 utilize different pools of arachidonic acid [Wiltbank MC et al, 2003].  Cox-1 
is constitutively expressed in many tissues and is involved in homeostatic regulation of 
arterial blood pressure [Jun SS et al, 1999] and gastric epithelial function [Cohn SM et al, 
1997]. In contrast, Cox-2 is inducible and is expressed in many tissues during acute 
responses such as inflammation [Simon LS et al, 1999]. Moreover, these isoforms differ 
in their sub-cellular localization. Immunohistological studies [Morita I et al, 1995] have 
revealed that Cox-2 is present mainly in the nuclear membrane while Cox-1 is localized 
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equally to the ER and nuclear membrane. In vivo and in vitro treatment of the CL with 
PGF 2α results in increased Cox-2 expression during luteal regression [Tsai SJ et al, 1997; 
Diaz FJ et al, 2000]. Recently a third isoform of Cox, Cox-3, has been isolated and 
characterized [Willoughby DA et al, 2000]. Cox-3 is derived from the Cox-1 gene, but 
retains intron 1 in the mRNA. The exact physiological function of Cox-3 is yet to be 
determined but it is postulated to be the target of acetaminophen action [Chandrasekharan 
NV et al, 2002]. 
 
3. Conversion of PGH2 to PGE2
In cattle, conversion of PGH2 to PGE2 occurs via PGE synthases (PGES). Currently 
three forms of PGES [Parent J et al, 2005] have been identified. Microsomal PGES 
1(MPGES1) [Jakobsson PJ et al, 1999], also known as Prostaglandin E Synthase 
(PGTES) [Filion F et al, 2001], is membrane bound [Murakami M et al, 2000], inducible 
and associated with Cox-2 induction [Arosh JA et al, 2002]. Cytosolic PGES (CPGES), 
known as cytosolic PGTES (PGTES3) is coupled to Cox-1 [Tanioka T et al, 2000]. The 
third form of PGES is microsomal PGES2 (MPGES2), also known as prostaglandin E 
synthase 2 (PGTES2), which has been recently purified from the bovine heart [Watanabe 
K et al, 1999]. This PGES is associated with both forms of Cox, with slight preference 
for Cox-2 [Murakami M et al, 2003]. Immunohistological studies reveal that MPGES1, 
MPGES2 and CPGES are expressed in high amounts in the luminal and glandular 
epithelial cells of the bovine endometrium, as compared to the stromal cells. These 
isoforms are expressed in many other bovine tissues such as ovary, kidney and lung 
[Parent J et al, 2005]. Moreover, in the bovine endometrium, high expression of Cox-2 
[Arosh JA et al, 2002], MPGES1 [Parent J et al, 2005] and EP2 [Arosh JA et al, 2003] on 
days 10-18 of the estrous cycle closely follows production of PGE2 [Miyamoto Y et al, 
2000]. Authors of recent in vitro studies have suggested that CPGES and MPGES2 are 
involved in basal PGE2 production while MPGES1 in association with Cox-2 is the main 





4. Formation of PGF2α 
Synthesis of PGF2α can take place from PGE2, PGH2 and PGD2. Prostaglandin E2-9-
ketoreductase is NADPH –dependent enzyme that reduces the ketone on the 9th carbon of 
PGE2, thus converting PGE2 to PGF2α. Prostaglandin E2-9-ketoreductase is present in the 
CL [Albarracin CT et al, 1994; Beaver CJ et al, 1992; Wintergalen N et al, 1995] and 
uterus [Asselin E et al, 2000] of a number of species. Prostaglandin E2-9-ketoreductase is 
a member of aldoketo reductase superfamily. In rabbit CL, a pure preparation of 20α-
hydeoxysteroid dehydrogenase enzyme was found to contain prostaglandin E2-9-
ketoreductase activity [Wintergalen N et al, 1995]. Moreover the mRNA sequences of 
these two enzymes are identical, so it has been suggested that the enzyme that inactivates 
P4 also may inter-convert PGs within the CL [Asselin E et al, 2000]. In in vitro studies, 
addition of PGE2 to luteal tissue resulted in the formation of PGF2α, but the amount of 
conversion depended on the species. For example, the human CL converted a large 
amount of PGE2 to PGF2α, while the conversion is low in the porcine CL [Watson J et al, 
1979]. 
The conversion of PGH2 to PGF2α is catalyzed by PGF synthase (PGFS). There are a 
number of PGFS isoforms that may vary among species and tissues. The first three 
isoforms of PGFS isolated in the cow are: lung type prostaglandin F synthase (PGFS1) 
[Watanabe K et al, 1985], lung type PGFS found in liver (PGFS2) [Kuchinke W et al, 
1992], and liver type PGFS, also called dihydrodiol dehydrogenase 3 (DDBX) [Suzuki T 
et al, 1999; Chen LY et al, 1992]. DDBX exists in 4 isoforms in human beings and 3 
isoforms in the cow and has 3α-HSD activity. Only the DDBX3 isoform found in the 
liver has been characterized in the cow [Suzuki T et al, 1999]. The PGFS1 and PGFS2 
enzymes are 99% identical, whereas DDBX is 86% identical to each of them. Three other 
PGFS have been isolated and characterized from human tissue [Suzuki-Yamamoto T et 
al, 1999], sheep tissue [Wu WX et al, 2001] and Trypanosoma brucei [Kubata BK et al, 
2000].  All of these enzymes belong to the aldoketoreductase family [Jez JM et al, 1997]. 
The enzyme from Trypanosoma belongs to the AKR5A subfamily, whereas the others 
belong to the AKR1C family, which also is associated with hydroxysteroid 
dehydrogenases. Except for the Trypanosoma enzyme, all the other forms of PGFS 
possess PGD2 11-ketoreductase activity, thus giving them the ability to convert PGD2 
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into 9,11 PGF2α, an isomer of PGF2α [Watanabe K et al, 1986]. Recently it has been 
reported that bovine endometrium does not express any members of the AKR1C family 
(to which most of the PGFS belongs). Instead, aldoketoreduactase 1B5 (AKR1B5), which 
possesses 20α-HSD activity, is the main PGFS responsible for the production of PGF2α in 
the bovine endometrium [Madore E et al, 2003].  Studying pregnant and non-pregnant 
ewes, Costine [Costine B, 2004] has proposed that the regulation of PG synthesis likely 
occurs via transcriptional control of PGE and PGF synthase rather than that of COX-2. 
The same author has demonstrated apparent species differences with respect to the type 
of PGF synthase present in the CL. In the bovine CL, AKR1B5 and not PGF synthase 1 
is the main PGF synthase. In contrast, in the ovine CL, both PGF synthase 1 and 
AKR1B5 were present. 
 
5. Catabolism of PGs 
Catabolism of PG occurs in blood and is removed into the blood plasma filtrate in the 
kidney followed by excretion through the urine. Prostaglandin dehydrogenase (PGDH), 
an oxidoreductase enzyme, catalyses the oxidation of the OH group on carbon 15 of 
PGF2α and PGE2 to yield 15-keto PGF2α and 15-keto PGE2. There are two types of 
PGDH, one that transfers hydrogen to NADP+ and another that transfers hydrogen to 
NAD+ [Lee SC et al, 1975]. There are greater amounts of NADP+ than NAD+-dependent 
PGDH in the lung of ruminants and placenta of many species [Challis JR et al, 2002]. 
Recently NAD+-dependent PDGH has been identified in the ovine CL and it has been 
hypothesized that this is the rate limiting enzyme in PG catabolism [Silva PJ et al, 2000]. 
 A second step in PG catabolism involves the conversion of 15-keto PGs to 13,14-
dihydro-15-keto PGs (PGFM and PGEM). Fifteen-oxoPG 13- reductase (OXO-PGR) 
catalyzes this reaction by reducing the 13,14 double bond (by Δ13 reductase) resulting in 
the formation of PGFM or PGEM [Hansen HS, 1982]. The hydrolysis of other PGs to 





V. Regulation of PGF2α production 
1. Uterine PGF2α synthesis 
In many species, the endometrium is the site for uterine PGF2α synthesis. In 
ruminants, OT, P4 and E2 regulate uterine secretion of PGF2α. Estrogen increases uterine 
PGF2α production by stimulating the activity of metabolic enzymes involved in PG 
biosynthesis [Bonney RC et al, 1987; Dey SK et al, 1982; Ham EA et al, 1975; 
Wlodawer O et al, 1976]. Furthermore, in several species, prior exposure to P4 enhances 
E2-stimulated production of PGF2α [Barcikowski B et al, 1974; Castracane VD et al, 
1975; Ford SP et al, 1975; Lewis PE et al, 1977]. Several researchers have concluded that 
P4 action is required to prime the endometrium for subsequent PGF2α production [Garrett 
JE et al, 1988; Morgan GL et al, 1993; Vallet JL et al, 1990]. P4 enhances PGF2α 
synthesis by increasing the concentration and activity of endometrial PG synthases 
[Eggleston DL et al, 1990; Raw RE et al, 1988]. Also, the timely down regulation of P4 
receptors by P4 is an important component in timing the onset of luteolysis [Ottobre JS et 
al, 1980; Woody CO et al, 1967]. 
From in vivo and in vitro studies, it has become apparent that E2 and P4 control 
endometrial PGF2α production by regulating the concentration of endometrial OT 
receptors [Armstrong DT et al, 1959; McCracken JA, 1972; McCracken JA, 1980; 
Sharma RC et al, 1974; Soloff MS, 1975].  During the luteal phase, E2 enhances the 
formation of endometrial OT receptors. In contrast, P4 reduces the concentration of 
endometrial OT receptors by blocking the action of E2 [Grazzini E et al, 1998]. In vitro 
studies demonstrate that P4 also has a direct non-genomic inhibitory effect on uterine OT 
receptors [Rueda BR et al, 2000; MT Rae et al, 1998]. Thus, the uterus becomes 
refractory to OT during the luteal phase in terms of PGF2α secretion [McCracken JA et al, 
1999]. However, P4 eventually down regulates its own receptor towards the end of the 
luteal phase [Milligrom E et al, 1973; Vu Hai MT et al, 1977; Clarke CL, 1990]. This 
restores the action of E2 that stimulates the hypothalamus [McCracken JA et al, 1995] to 
secrete high frequency bursts of low levels of OT. At the same time upregulating 
endometrial OT receptors in the uterus are upregulated [McCracken JA et al, 1999]. 
McCracken [McCracken JA et al, 1999] proposed a double positive feedback loop 
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between the uterus and the CL as a possible mechanism of luteal regression. Low levels 
of PGF2α (subluteolytic) get released from the uterus due to the interaction of posterior 
pituitary OT and endometrium OT receptors [McCracken JA et al, 1995; McCracken JA 
et al, 1999]. In the CL, the uterine subluteolytic PGF2α initiates luteal OT release via high 
sensitivity PGF2α receptors (HFPR) [Wiltbank C et al, 1995]. Studies with PG treatment 
and injection of the PGF2α analog-cloprostenol in cow and sheep showed elevated levels 
of OT release from the CL [Flint APF et al, 1982]. In sheep and cow [Ivell R, 1985; Ivell 
R et al, 1984; Ivell R et al, 1990], OT is expressed fully in the developing CL shortly 
after ovulation. The site of OT synthesis in the CL was shown to be the LLC in cows 
[Fehr S et al, 1987; Fields MJ et al, 1986; Fields PA et al, 1983]. Moreover, OT and 
neurophysin have been identified in small electron-dense granules present in the LLC 
[Rice GE, 1988; Theodosis DT et al, 1986]. These oxytocin-containing granules are 
believed to be released by exocytosis. Luteal OT amplifies the release of endometrial 
PGF2α secretion. The latter then stimulates the low sensitivity PGF2α receptors (LFPR) 
resulting in the release of additional luteal OT thereby initiating luteal PGF2α production 
[McCracken JA et al, 1999]. Thus, the uterus appears to act as a transducer that converts 
neural signals (OT pulse generator) into uterine PGF2α pulses that are required for 
luteolysis. In cow and other ruminants, luteal OT appears to act as a supplemental source 
of OT that amplifies these neural signals and hence increases the magnitude of the 
luteolytic signal via intraluteal PGF2α synthesis [McCracken JA et al, 1999].The interval 
between subsequent uterine PGF2α pulses depends on two factors: 1) the high frequency 
burst of OT from the posterior pituitary that is regulated by the hypothalamus and 2) 
recovery of the endometrial OT receptors that may be down regulated atleast at the early 
stages of luteal regression.  
 OT is a nanopeptide hormone synthesized as part of a high-molecular weight 
precursor in the hypothalamic magnocellular neurons and is packaged into secretory 
granules. These OT secretory granules reach the neurohypophysis via axonal transport. In 
the neurohypophysis, OT precursor is cleaved into mature OT and released into the blood 
stream [Lincoln DW, 1984]. It has been proposed that E2 and P4 regulate the pulsatile 
release of OT. Both E2 and P4 receptors are present in the hypothalamus in many species 
[Blaustein JD et al, 1995; Lehman MN et al, 1993] and in rats P4 has been demonstrated 
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to down regulate its own receptor in the hypothalamus [Moguilewsky M et al, 1979]. In 
rat, co-localization of the beta-form of E2 receptor with the OT neurons significantly 
increased the chance of direct action of E2 on OT in the hypothalamus [Hrabovszky E et 
al, 1998]. Gonadal steroids have also been shown to upregulate OT and vasopressin gene 
expression in the hypothalamus, thus potentially amplifying steroid regulatory effects on 
the OT pulses [Akaishi T et al, 1985; Amico JA et al 1995; Cadwell JD et al, 1989].  
However, the exact mechanism by which these steroids alter the frequency of the central 
OT pulses is presently unknown. 
 Presently there is a controversy on whether luteal OT is actually necessary for 
regression. In both cows and ewes, the concentration of OT is lower in the late than in the 
mid luteal stage. Lowering OT concentration in the late luteal phase has no effect on the 
duration of the estrous cycle [Kotwica J et al, 1993]. Furthermore, in cows, in vivo 
microdialysis study demonstrated lack of detectable OT secretion during spontaneous 
luteolysis [Blair RM et al, 1997; Shaw DW et al, 2000]. Based on these observations, it is 
hypothesized that luteal OT may not be essential for luteal regression. In fact, Bacon and 
McCracken proposed that in sheep, luteal OT might play an advantageous role for the 
establishment of pregnancy [Bacon C et al, 2004]. 
 
2. Intraluteal PGF2α Production 
In luteal cells, an autoamplification loop exists involving PGF2α-induced 
intraluteal PGF2α production. Intraluteal PGF2α production involves interaction between 
multiple signaling pathways.  Treatment of luteal cells by PGF2α increases [Ca2+]i that 
results in cPLA2 activation [Wiltbank MC et al, 1989a]. In addition, PGF2α treatment 
activates MAP kinase [Chen DB et al, 1998] and PKC [Wiltbank MC et al, 1989b], both 
of which activate cPLA2, contributing to intraluteal PGF2α production [Wu XM et al, 
1990]. Studies conducted with in vivo administration of PGF2α demonstrate that luteal 
changes in cPLA2 may be mediated by protein activation rather than transcriptional 
regulation [Tsai SJ et al, 2001; Wiltbank MC et al, 2003].  Therefore, treatment of CL 
with PGF2α is likely to cause cPLA2 activation through a number of pathways allowing 
arachadonic acid release. Furthermore, in the CL, in vivo treatment with PGF2α greatly 
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increases expression of Cox-2 mRNA and protein [Tsai SJ et al, 1997; Diaz FJ et al, 
2000]. Thus, PGF2α induces both the key rate limiting steps of PG biosynthesis. 
In bovine and ovine CL, the molecular mechanisms involved in PGF2α induction 
of Cox-2 have been analyzed. In bovine CL, single in vivo treatment with PGF2α induces 
Cox-2 expression only in the mid-late luteal stage (days 10-12). In the early CL, even 
though PGF2α activates FP receptors, it fails to induce Cox-2 gene expression [Tsai SJ et 
al, 1998; Tsa SJ et al, 2001a]. Treatment of in vitro luteinized bovine granulosal cells 
with PGF2α induced Cox-2 expression only after 7 days of luteinization, similar to the 
timing observed in the in vivo experiment [Tsai SJ et al, 2001b]. Using the same model 
system, the authors demonstrated that in early stages of luteinization Cox-2 expression is 
induced by cAMP-PKA, while at the latter luteal stage (similar to the timing observed in 
the in vivo experiment) PKC induces Cox-2 expression [Wu YL et al, 2002]. The authors 
identified an E-box element in the Cox-2 promoter region that was a critical regulatory 
element for Cox-2 gene induction. Furthermore, both PKA and PKC act on the same E 
box element in a luteal stage dependent manner to induce Cox-2 gene expression [Wu YL 
et al, 2002]. Similar results were also obtained from ovine CL. Moreover, in the ovine 
CL, PGF2α acts via PKC α and β on the E-box DNA element to induce Cox-2 gene 
transcription [Wu YL et al, 2001]. 
The physiological role of intraluteal PGF2α production has not yet been clearly 
defined. However, in species with uterine dependent regression of the CL, it is clear that 
the luteolytic factor secreted by the uterus is PGF2α. It is believed that the small amounts 
of uterine PGF2α dramatically amplify intraluteal PGF2α production leading to luteal 
regression. It has been proposed that uterine PGF2α may initiate the inhibition of P4 
production that accompanies luteal regression, while the increase in intraluteal PGF2α 
production may be critical for the structural demise of the CL [Griffeth RJ et al, 2002]. 
 
3.   Prostaglandin Transport  
In most mammalian species, transport of endometrial PGs from the uterine to the 
ovarian compartment occurs via the vascular pathway [McCracken JA et al, 1999]. In 
ruminants, the ovarian artery is close to the surface of the utero-ovarian vein and 
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traverses the vein in an extremely tortuous manner to form an unique structure called the 
utero-ovarian plexus (UOP) before entering the hilus of the ovary [McCracken JA et al, 
1999]. The UOP has long been identified as the primary site of PG transfer and its 
anatomical and physiological significance has been well established [Ginther OJ, 1981]. 
Prostaglandins diffuse from the utero-ovarian vein to the ovarian artery and reach the 
ovary directly without passing through the systemic circulation. Infusion experiments 
with radiolabeled PGF2α confirmed the existence of the countercurrent transfer process in 
the utero-ovarian vascular pedicle [McCracken JA et al, 1999]. Bonnin et al [Bonnin P, 
1989] demonstrated that PGF2α is transported to the ovaries by a rapid systemic route and 
a slower buffer mechanism involving local diffusing in contrast to the counter current 
system. Moreover, absorption of PGF2α from uterine lumen to venous blood is low on the 
side of uterine horn with active CL [Koziorowski M et al, 1989]. Koziorowski et al 
[Koziorowski M et al, 1989] proposed that this effect was due to E2:P4 ratio on vascular 
constriction in area of uterine vasculature.  
Earlier the mechanism of PG transport across the cell membrane has been proposed to 
range from simple diffusion to passive transport, active transport and counter current 
exchange [McCracken JA et al, 1999; Schuster VL, 2002; Schuster VL, 1998]. However, 
PGs predominate as charged anions and diffuse poorly across cell membranes despite 
their lipid nature [Schuster VL, 2002; Schuster VL, 1998]. Even though anions (PGs) 
cross the plasma membrane by simple diffusion, it has been demonstrated that the 
estimated flow rate is too low to maintain a biological function [Lehninger AL, 2000]. 
Recently, PG transporter (PGT) has been identified in rat kidney [Kanai N et al, 1995], 
human liver [Lu R et al, 1996], mouse lung [Pucci ML et al, 1999] as well as in bovine 
uterus [Banu SK et al, 2003; Banu SK et al, 2005] and ovary [Arosh JA et al, 2004b]. 
Prostaglandin transporter belongs to the superfamily of 12 transmembrane organic anion-
transporting polypeptides (OATPs) [Schuster VL, 2002; Schuster VL, 1998]. Bovine 
PGT (bPGT) exhibits a high percentage of homology with its human, mouse and rat 
counterparts [Banu SK et al, 2003]. The bPGT has 12 hydrophobic transmembrane 
domains characteristic of OATP and PGT molecules in other species.  
In the bovine endometrium, bPGT facilitates efflux and influx of PGE2 and PGF2α 
with equal affinities in a competitive manner. Furthermore, PGT is highly expressed 
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when PG production and action is high. PGT expression closely matches the pattern of 
expression of PG biosynthetic enzymes and receptors [Banu SK et al, 2003]. In the CL, 
PGT expression is lower at the early developmental stage of the CL (days 1-6) than in the 
late, mature and regressing stages [Arosh JA et al, 2004b]. In the bovine CL, PGT is 
expressed exclusively in LLC [Arosh JA et al, 2004b]. Moreover, throughout bovine 
pregnancy, PGT gene and protein is expressed in the caruncular, intracaruncular, fetal 
membranes and the utero-ovarian plexus [Banu SK et al, 2005]. It has been suggested 
that regulation of bPGT expression and its activity may be one of the many factors 
causing a shift from luteotropic to luteolytic environment in the mid-late CL [Arosh JA et 
al, 2004b]. 
 
6. PGF2α Receptor 
Prostaglandin F2α acts primarily via transmembrane receptor known as FP 
receptor (FP) that belongs to the seven-transmembrane-domain receptor superfamily. FP 
gene has been cloned in many species [Sugimoto Y et al, 1994; Graves PE et al, 199] 
including the cow [Sakamoto K et al, 1994] and the exon / intron organization is 
conserved across species [Hasumoto K et al, 1997; Ezashi T et al, 1996]. The FP gene 
consists of three exons and two introns with translated regions located in exons 2 and 3 
[Ezashi T et al, 1996]. Deletion experiments in mice indicated that the promoter region of 
FP gene may differ for different tissues [Hasumoto K et al, 1997]. Two potential 
promoter regions have been identified in the bovine FP gene [Ezashi T et al, 1996]. One 
of these is a 1.6 kb region upstream of exon 1 and contains consensus sequences for 
transcription factors (TF): TRE/AP-1 (TPA-responsive element/activator protein-1), NF-
IL6 (nuclear factor interleukin 6), Sp1 and GCF (GC binding factor). The second 
potential promoter is located in intron 1 and contains binding motifs for Sp1, TRE/AP-1, 
CRE, NF-IL6 and AP-2 (activator protein –2) as well as CAAT and TATA boxes.  
There are two isoforms of FP – FPA and FPB [Sakamoto K et al, 2002]. These FP 
isoforms are formed by alternate splicing from a single FP mRNA [Anderson LE et al, 
2001]. The FPB isoform is produced by splicing a putative intron sequence of 3.2 kb in 
length that is retained in the FPA isoform [Pierce KL et al, 1997]. Thus, the FPB protein 
is 45 amino acid shorter in the C-terminal end than the FPA isoform [Pierce KL et al, 
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1997]. Wiltbank et al [Wiltbank MC et al, 1995] were unable to detect differences 
between the developing (days 2-4) and active bovine CL (days 10-12) in either affinity or 
concentration for FP. However, the localization of FP is controversial. It has been 
reported that LLC appear to have more FP than SLC [Sakamoto K et al, 1995], while 
others have reported the presence of FP in both cell types [Chegini N et al, 1991]. 
Mamluk et al [Mamluk R et al, 1998] identified the presence of FP mRNA in long term 
cultured granulosa and theca cells as well as in LLC, SLC and EC, while Cavicchio et al 
[Cavicchio VA et al, 2002] failed to detect it. Mamluk et al [Mamluk R et al, 1998] 
demonstrated that cAMP and PGF2α itself are major regulators of FP. There is a 
controversy about the expression of FP in EC. Mamluk et al [Mamluk R et al, 1998] 
reported the expression of FP mRNA in EC. In contrast, Cavicchio et al [Cavicchio VA 
et al, 2002] failed to detect FP mRNA. Moreover, these authors reported that the EC were 
unresponsive to PGF2α. Even though specific binding of PGF2α to EC has not been 
demonstrated, direct effects of PGF2α on EC have been reported [Girsh E et al, 1996b; 
Choudhary E et al, 2005]. Binding of PGF2α to its receptor activates multiple intracellular 
signaling cascades, details of which are explained in the next section. 
 
VI. PGF2α induced Intracellular Signaling 
1a. PLC-Ca2+-PKC Pathway 
In bovine luteal cells PGF2α on binding to its cognate G-protein coupled receptor, 
activates the membrane-bound phosphoinositide specific PLC [Wiltbank MC et al, 1991]. 
Phospholipase C hydrolyses phosphatydylinositol 4,5-bisphosphate, thereby yielding 
1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). Binding of IP3 to its specific receptor 
on the endoplasmic reticulum (ER) results in the mobilization of intracellular Ca2+. DAG 
and Ca2+ together activate a family of serine-threonine kinases called Protein Kinase C or 
PKC [Davis JS et al, 1987]. Protein Kinase C is a family of protein kinases that is present 
in all mammalian species and is involved in a vast array of cellular and physiological 
functions. Most members of this family depend for their activation on phosphatidylserine 
(PS), DAG and to different extents on calcium and other lipid secondary messengers. 
Upon activation by hormones, neurotransmitters, phorbol ester or GFs, PKC undergoes 
translocation from one intracellular compartment to another. The PKC family contains 11 
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isoforms that not only differ in their structures and co-activator requirements, but also in 
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Fig 1. PGF2α - induced PLC- Ca2+-PKC Pathway. 
 
The function of PGF2α-induced calcium signals and PKC isozymes in the luteal 
physiology is discussed in details in chapters 2, 3, 4, 5 and 6. Therefore this section 
reviews the structural and regulatory aspects of different PKC isozymes, an 
understanding of which is necessary for investigating the role of PKCs in luteal 
regression. 
 
1b. ERK-MAPK Pathway 
In bovine luteal cell primary cultures, it has been reported that PGF2α activates the 
Raf-1/MEK/ERK signaling cascade, resulting in expression of c-jun and c-fos mRNA 
[Chen DB et al, 1998; Chen D et al, 2001]. Furthermore, using a PKC inhibitor and PKC- 
deficient luteal cell model, the investigators demonstrated that the activation of the MAP 
kinase pathway occurs via PKC phosphorylation of ERK [Chen D et al, 2001].  In other 
tissues, PGF2α can activate ERK-MAP kinase pathway through different mechanisms 
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[Ohmichi M et al, 1997]. Thus it is believed that PGF2α may use cell-type-specific 
signaling pathways to activate ERKs in various tissue and cells. However, which PKC 
isozyme is involved in ERK activation or which genes are expressed via this pathway is 
still unknown. 
 
 2.   Protein Kinase C  
The discovery of PKC in 1977 by Nishizuka and co-workers was one of the major 
breakthroughs in the signal transduction field. Protein kinase C was first defined as a 
histone kinase from rat brain that could be activated by limited proteolysis. This was 
followed by the discovery that this new kinase could be activated by phosphotidylserine 
(PS) and DAG in a calcium-dependent manner as well as by phorbol esters. After 27 
years, exhaustive genetic screening has defined a super family of mammalian PKC 
isozymes that currently is comprised of 11 distinct isozymes. The number of PKC 
isozymes represents the greatest challenge to the understanding of PKC function. Protein 
Kinase C have a multitude of cellular substrates and are involved in a bewildering array 
of biological processes [Ron D et al, 1999]. 
The primary structure of PKC consists of a regulatory and a catalytic unit. The 
regulatory unit is present in the N-terminal end and contains a pseudosubstrate, a C1 
domain (C1A and C1B) and a C2 domain [Parker PJ et al, 1986]. The C1A and C1B 
domains bind to DAG or phorbol ester, the C2 binds anionic lipids and calcium while the 
pseudosubstrate is involved in the autoinhibitory regulation of PKC. The C-terminal half 
contains the catalytic portion involving C3 (ATP binding) and C4 (substrate binding / 
kinase) domains. The PKC family can be divided broadly into 4 subclasses based on their 
homology and co-activator requirements [Ron D et al, 1999]. Members of the 
conventional or cPKC subclass are α, βI, βII and γ and contain four homologous domains 
(C1A and B, C2, C3 and C4) interspersed with isozyme unique variable (V) domains. 
These isozymes require calcium, phosphotidyl serine, DAG or phorbol ester for 
activation. Members of the novel or nPKC subclass are δ, ε,η and θ. This subclass lacks 
the C2 domain and is calcium independent for activation. The third PKC subclass is the 
atypical or aPKC consisting of ζ, ι and λ that lacks C2 and one half of the C1 domain and 
is insensitive to DAG, phorbol ester and calcium. A related enzyme PKCμ or PKC D, 
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displays multiple unique features that make it a distant relative of the PKC family and it 
has been placed in a separate subclass. This isozyme is phopholipid dependent, calcium 
insensitive and activated by phorbol ester. It contains 2 hydrophobic domains in place of 
the C1 domains, and lacks the C2 domain, but has a putative pleckstrin domain and 
distinct C3 and C4 domains. Recently a large number of proteins have been characterized 
that have close association with the PKC family and these proteins have been termed as 
PKC-related kinases [Mellor H et al, 1998]. 
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Fig 2.  Primary structure of members of the conventional and novel PKC subclasses 
[Adapted from, Principles of molecular regulation. Edited by Conn MP, Means AR. 
Humana Press, NJ]. 
 
Protein kinase C after synthesis is associated with particulate fractions of the 
cytoskeletal and plasma membrane components via anchoring proteins. Proteolytic 
sensitivity experiments have indicated that after synthesis, the C-terminus of PKC 
occupies the active site. This immature PKC undergoes post-translational modification 
involving two phosphorylation switches, one at the activation loop and one at the C-
terminus [Keranen LM et al, 1995]. The former is phosphorylated by PDK-1 or related 
kinases. This phosphorylation is required to process catalytically competent PKC; its role 
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appears to be correctly aligning residues for catalysis to promote the phosphorylation of 
the two C-terminal sites. Once the C-terminal ends are phosphorylated, phosphate on the 
activation loop is no longer required for the catalytic action of the enzyme. At least for 
cPKC, the C-terminal sites are modified by autophosphorylation. Phosphorylation at 
these latter two positions locks the enzyme in a catalytically competent conformation and 
releases the enzyme into the cytosol in a mature but inactive form. In this inactive 
conformation, the pseudosubstrate binds the active / substrate binding cavity of the kinase 
domain, thus sterically blocking substrate binding [Newton AC, 1997]. Activation of 
PKC involves generation of DAG or PMA that binds with the C1 domain and recruits 
PKC to the membrane. The translocation of PKC involves the interaction of PKC with 
isozyme specific anchoring proteins. Protein kinase C also can be recruited to the 
membrane by the C2 domain alone; this interaction requires anionic lipids and for cPKC, 
calcium. Membrane binding by either domain alone does not provide sufficient energy to 
release the pseudosubstrate from the active site. This requires the interaction of both C1 
and C2 domains with the membranes. Once C1 is bound to the membrane, the enzyme 
displays a 10-fold increase in affinity for phosphotidylserine (PS) and other relative 
anionic lipids. The energy supplied by binding of DAG, PS and calcium (for cPKC) helps 
break electrostatic interactions between the basic pseudosubstrate and acidic substrate 
binding cavity, resulting in the release of the pseudosubstrate and activation of PKC. 
Membrane binding with C2, but not C1, results in conformational change that exposes 
the hinge region between the regulatory and catalytic subunits thereby making the 
catalytic site available for substrate phosphorylation [Newton AC, 1997]. 
PKC is a serine / threonine kinase and phosphorylates a number of proteins, 
including receptors, ion channels, cytoskeletal proteins as well as cell cycle regulatory 
proteins. One of the best characterized PKC substrates is MARCKS (Myristoylated 
Alanine Rich C Kinase Substrate) [Newton AC, 1997]. Presence of MARCKS in bovine 
LLC has been reported and its involvement in exocytosis after phosphorylation by PKC 
has been demonstrated. However the precise cellular functions and regulation of 
MARCKS are still unclear [Salli U et al, 2000]. 
Since the early 1990s, it has become clear that in addition to binding to lipids, 
PKC can also interact with proteins via protein-protein interactions [Ron D et al, 1999]. 
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These interactions play an important role in the localization, translocation and function of 
PKC isozymes. Protein kinase C binding proteins are proteins that bind to PKC directly 
via a non-substrate domain and may or may not be PKC substrates. There are large 
numbers of such PKC binding proteins but here only 2 types of such proteins are 
discussed. Inactive PKC remains attached to the cytoskeletal or membrane via  anchoring 
proteins called receptors for inactive isozymes (RICKS) or A kinase anchoring proteins 
(AKAPS) [Mochly-Rosen D, 1995]. Similarly, there are anchoring proteins for activated 
PKC isozymes known as receptors for activated C-kinases (RACKS). Different types of 
RACKS are PKC isozyme specific. The PKC-RACK interaction is mediated, at least in 
parts by the C2 region in cPKCs and the V region in nPKCs. Two RACKS have been 
identified: RACK1 specifically binds to PKC βII via the V5 domain and to other cPKCs 
via the C2 domain. In contrast, RACK2 (also called β’-COP) specifically interacts with 
PKC ε via the V1 domain that has some homology to the C2 domain of cPKCs. RACKS 
contain WD-40 repeats, a motif known to mediate protein-protein interactions. RACKS 
are known to be involved in translocation of activated PKCs from the cytosol to the 
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Fig 3. Intra-cellular Mechanism of PKC activation [Adopted from, Newton AC, 1997]. 
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VII. Endothelin System 
Endothelin (ET) was first identified as a potent vasoconstrictor in cardiovascular 
homeostasis [Yanagisawa M et al, 1988], embryonic development [Kedzierski RM et al, 
2001] and angiogenesis [Schmitz-Sapanke S et al, 2000]. In recent years, endothelin has 
emerged as a key modulator in reproductive organs involved in the regulation of 
steroidogenesis in follicles [Flores JA et al, 1992; Flores JA, 2000] and CL [Girsh E et al, 
1996a; Hinckley ST et al, 2001, Wright M et al, 2003, Choudhary  et al, 2004, Schams D 
et al, 2004, Meidan R et al, 1999]. Endothelin exists in different isoforms (ET-1, ET-2, 
and ET-3) encoded by three separate genes [Luscher TF et al, 2000]. Endothelin-1 (ET-1) 
is synthesized as a 212-amino acid precursor, prepro ET-1 (ppET-1), which is 
proteolytically cleaved into a 38-amino acid long big ET-1 by furin or furin-like enzymes 
in the trans-golgi network. Big ET-1 is further converted into active ET-1 (21 amino 
acid) by metalloproteinases, specifically endothelin converting enzymes (ECE) [Luscher 
TF et al, 2000; Okuda K et al, 1990]. There are 4 isoforms of ECE [Muller L et al, 2003] 
each of which specifically cleaves its corresponding big ET. Endothelin converting 
enzymes 1 and 2 are transcribed from two separate genes, while ECE-3 and ECE-4 have 
not yet been cloned. ECE-1 is a membrane-bound protein that belongs to the zinc-binding 
metalloendopeptidases [Yanagisawa M, 1995; Opgenorth T et at, 1992]. Endothelin 
converting enzyme -1 has 4 known isoforms formed by transcription initiation at 
alternative promoters [Muller L et al, 2003]. All these isoforms are identical except at 
their N-terminal ends that regulate subcellular localization. Endothelin converting 
enzymes 1a and 1c are expressed on the plasma membrane and are involved in the 
conversion of big ET into active ET-1. In contrast, ECE-1b and ECE-1d are localized to 
endosomes and regulate the availability of ECE-1a on the plasma membrane via 
heterodimerization with the latter [Muller L et al, 2003]. It has been demonstrated that 
endothelial cells in the CL express ECE-1a and ECE-1b, while the luteal steroidogenic 
cells exclusively expresses ECE-1b [Meidan R et al, 2002]. Meidan et al [Meidan R et al, 
2002] proposed a model according to which the endothelial cells expressing ppET-1 
along with the two ECE-1 isoforms are capable of secreting both the big ET-1 as well as 
the mature ET-1. In contrast, the luteal steroidogenic cells expressing only ECE-1b, but 
no ppET-1 are dependent on extracellular big ET-1. 
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Despite the many reports showing that ECE-1 isoforms are able to convert big 
ET-1 to the mature ET-1 peptide, it is still unclear whether ECE-1 plays a physiological 
role in big ET-1 processing. Some studies indicate that ECE might not be the rate limiting 
factor in ET-1 production. In bovine pulmonary smooth muscle cells, ablation of the ECE 
gene by antisense oligonucleotides did not have any effect on either basal or TNFα-
stimulated ET-1 release.The authors proposed that in bovine pulmonary smooth muscle 
cells, an endopeptidase distinct from ECE-1 may be responsible for processing big ET-1 
[Barker S et al, 2001]. In bovine CL, although the ratio of ET-1 / bigET-1 is higher in the 
late than the early-mid luteal stage, ECE-1 is constituitively expressed until the late luteal 
stage, when the gene actually appears to be downregulated [Wright M et al, 2003; 
Choudhary E et al, 2004]. Furthermore, ECE activity remains unchanged throughout the 
estrous cycle [Choudhary E et al, 2004]. These studies indicate that the regulation of ET-
1 production is a complex process that may involve other factors.  
Endothelin acts via the 7-transmembrane-G-protein coupled receptor family [Arai 
H et al, 1990] which exist in two subtypes, ETA (for aorta) and ETB (for bronchus) 
transcribed from two separate genes [Aramori I et al, 1992]. ETA is highly specific for 
ET-1 (about 100 times more than ET-3), while all three (ET-1, ET-2 and ET-3) binds to 
ETB with equipotent affinity [Arai H et al, 1990; Aramori I et al, 1992]. Characterization 
and regulation of ETA [Meidan R et al, 2002; Meidan R et al, 1999; Choudhary E et al, 
2004] in bovine luteal cells have been investigated extensively (discussed in the next 
section), while the role of ETB is still unclear. The intracellular mediators of ET-1 in the 
CL are unknown. However, several studies indicate that ET-1 might act via the PLC-
Ca2+-PKC pathway [Flores JA et al, 1992; Choudhary E et al, 2005], details of which are 
discussed in subsequent chapters. 
 
VIII. Luteolysis 
The life span of the CL varies from species to species and can be altered by 
pregnancy and mating. Regardless of the duration of life span, the CL ultimately loses the 
capacity to produce P4 and undergoes structural involution. The term “luteolysis” used 
extensively in the literature to describe this process is defined as “degradation of the CL” 
(Medical Subject Headings, MeSH, US National Library of Medicine). Rothchild  
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[Rothchild I, 1981] defined luteolysis as “ stopping the secretion of P4 by the CL”. Hoyer 
[Hoyer PB, 1998] referred to the decrease of P4 as “functional regression” while 
described the cell death as “true” regression. In contrast, Niswender et al. [Niswender 
GD, 2000] referred to the structural demise of the CL as luteal regression and the loss of 
P4 synthesis capacity by the CL as a part of the regression process. Thus, it can be 
broadly said that luteal regression (luteolysis) consists of two “components” ; 1) an initial 
loss of steroidogenic and secretory function of the CL called “functional” luteolysis and 
2) a subsequent morphological demise of the nonfunctional CL involving apoptosis and 
termed  “structural” demise.  There is still much controversy in the literature with respect 
to the appropriate terminology describing “luteolysis” or “luteal regression”. This study 
primarily concentrates in the cellular mechanisms involved during functional luteolysis. 
 
1. Anti-steroidogenic effects of PGF2α  
During luteal regression, the initial decrease in P4 concentrations is not due to loss of 
steroidogenic cells, since the numbers of luteal cells remain unchanged until after the 
decrease of P4 concentration [Braden TD et al, 1988]. Functional luteolysis occurs 
primarily due to decreased steroidogenic capacity of individual luteal cells. In luteal 
steroidogenic cells (SLC and LLC), morphological changes that are indicative to 
apoptosis appear 24-36h after PGF2α exposure, in contrast to the steroidogenic capacity 
of the cells that get markedly reduced by this time [Sawyer HR et al, 1990]. There are 
likely multiple mechanisms by which PGF2α decreases P4 synthesis: 1) downregulation 
of receptors for luteotropic hormones, 2) decreased cellular uptake of lipoproteins, 3) 
decreased cholesterol transport and 4) decreased activity of steroidogenic enzymes 
required for P4 biosynthesis.  
PGF2α decreases mRNA of LHR, however the number of LHR does not decrease 
until after the concentration of P4 in the serum has already decreased [Diekman MA et al, 
1978; Spicer LJ et al, 1981].  However, whether these LHR are functional or not is 
unclear.  Prostaglandlin F2α interferes with function of secondary messengers for LH 
[Agudo SPL et al, 198]. Prostaglandin F2α increases phosphodiesterase activity, resulting 
in cAMP degradation and thereby affecting PKA activity [Garverick HA et al, 1985]. 
Inhibiting lipoprotein receptor expression did not have any effect on P4 synthesis 
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[Wiltbank MC et al 1993]. Also, lipoprotein uptake after treatment with PGF2α was not a 
limiting factor for luteal P4 secretion [Grusenmeyer DP et al, 1992]. The mRNA and 
protein of P450scc and 3βHSD decreased after PGF2α treatment but the activity of these 
enzymes did not decrease even after 24h of PGF2α treatment [Juengel JL et al, 1998a; 
Niswender GD et al, 2000]. Given that circulating P4 decreased within 12h of PGF2α 
treatment it has been proposed that inhibition of P450scc and 3βHSD do not play critical 
roles in lowering P4 concentration during luteal regression [Diaz FJ et al, 2002]. 
Treatment with PGF2α, both in vivo and in vitro, reduced StAR mRNA in bovine luteal 
tissue [Diaz FJ et al, 2002]. The orphan nuclear receptor DAX-1, is thought to mediate 
the inhibitory effect on StAR mRNA, possibly by binding to DNA hairpin structures 
present in the StAR promoter [Zazopoulos E et al, 1997]. PGF2α also regulates StAR 
protein directly. There are multiple potential PKC phosphorylation sites that affect StAR 
activity [Arakane F et al, 1997]. Recently it has been reported that PGF2α treatment 
decreased StAR protein in rat CL. Another target of PGF2α action is sterol carrier protein-
2 (SCP-2). In rats, treatment with PGF2α decreased the amount of SCP-2, thus lowering 
of cholesterol transport [McLean AS et al, 1995]. Disruption of the cytoskeleton by 
PGF2α has been reported to play a role in the decrease of P4 synthesis in variety of 
species [Silavin SL et al, 1980; Murdoch WJ, 1996; Williams MT et al, 1979]. However, 
there is contradicting evidence that disruption of cytoskeleton may also stimulate 
steroidogenesis. Smith and Sridaran [Smith CJ et al, 1991] reported that in CL of rats, 
disruption of cytoskeleton for a short time inhibited steroidogenesis while cytoskeleton 
disruption for a longer time stimulated steroidogenesis. However, the exact mechanism 
by which PGF2α inhibits P4 synthesis during luteal regression is still unclear.  
 
2. Regulation of Luteal Regression by the Endothelial (ET) System 
Several authors have proposed that the ET system plays an essential role in PGF2α -
induced luteolysis, and that PGF2α differentially modulates the expression of genes 
encoding ET-1, ECE-1 and ET-A receptor at early and mid-luteal phases [Girsh E et al, 
1996a; Median R et al, 1999; Girsh E et al, 1996b; Ohtani M et al, 1998; Milvae RA, 
2000; Wright MF et al, 2001].   Endothelin converting enzyme 1 expression measured as 
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the mRNA or protein, was reported to be 3-4 fold greater in mid cycle CL than in the 
early luteal phase [Levy N et al, 2001]. Concentrations of ET-A receptor mRNA and ET-
1 mRNA and protein were upregulated rapidly during natural or PGF2α -induced 
luteolysis [Girsh E et al, 1996a; Median R et al, 2002]. In contrast to these observations, 
Wright et al [Wright MF et al, 2001] reported that mRNA encoding ET-A and ECE-1 
expression, although expressed at higher concentrations in the late luteal phase, were 
expressed constitutively in the early and mid CL. Furthermore, the authors proposed that 
ET-1 gene was most likely regulated by PGF2α during the mid-luteal phase. Choudhary et 
al [Choudhary E et al, 2004] reported the same observation, stating that all components of 
the luteal endothelin system (ET-1/ECE-1/ET-A/ET-B) were regulated dynamically 
throughout the bovine luteal phase. The authors reported the existence of a PGF2α-
independent (early CL) and a dependent (late CL) phase for the regulation of the 
endothelin system. Activity of ECE-1 was unaltered throughout the ovarian cycle. Based 
on this observation, the authors proposed that the alteration of ET-1 availability is most 
likely achieved by the modulation of ppET-1 expression and unlikely by ECE-1.  
Girsh et al [Girsh E et al, 1996b] demonstrated that ET-1 via ET-A receptor, in a 
dose dependent manner, inhibited basal and LH/hCG-stimulated biosynthesis of P4 in the 
mid luteal phase. Moreover, in studies using ET-A antagonist, the PGF2α -induced anti-
steroidogenic effect was decreased significantly [Milvae RA, 2000]. This led to the 
hypothesis that ET-1 might mediate the luteolytic actions of PGF2α. In contrast, 
Choudhary et al [Choudhary E et al, 2005] reported that the potency of ET-1 to inhibit 
both basal and LH-stimulated P4 synthesis in the mid luteal stage was greater in the early 
luteal phase. Furthermore, the authors proposed that ET-1 appeared to be more of a tonic 
inhibitor of P4 synthesis than a mediator of PGF2α actions. 
 
3. Other Factors 
The development and physiology of the CL are regulated by number of cytokines 
like tumor necrosis factor (TNF), interleukin-1 (IL-1) and interferon-γ (INF-γ ) that are 
produced locally. Tumor necrosis factor -α and its receptors (TNFR) are present in the 
CL of many species [Sakumoto R et al, 2004]. Tumor necrosis factor -α  plays multiple 
roles in CL throughout the estrous cycle [Okuda K et al, 2003]. Tumor necrosis factor -α  
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has both luteotropic and luteolytic functions in the CL. In contrast, Fas ligand (Fas L), 
another member of the TNF super family, is recognized primarily for its apoptotic actions 
during luteal regression [Okuda K et al, 2003]. 
In the early luteal phase, expression of TNF-α and TNFR are evident in CL from 
cows [Sakumoto R et al, 2000], pigs [Wuttke W et al, 1997; Miyamoto Y et al, 2002] and 
human beings [Vaskivuo TE et al, 2002]. In vitro, TNF-α acts as a potent stimulator of 
luteal PGs like PGF2α, PGE2 and PGI2 in primary luteal cell cultures [Benyo DF et al, 
1992; Schams D et al, 1995b]. During development of the CL, macrophages [Carswell 
EA et al, 1975; Zhao Y et al, 1998] and EC [Hehnke-Vagnoni KE et al, 1995] are the 
major sources of TNF-α [Reynolds LP et al, 1994]. It has been proposed that TNF-α 
contributes to production of PGs in early CL and may have a role in luteal development. 
However, it has been demonstrated that TNF-α inhibits gonadotropin-stimulated steroid 
production in luteal SC of rats [Adashi EY et al, 1990], sheep [Pitzel L et al, 1993] and 
cows [Benyo DF et al, 1992]. Also, secretion of TNF-α  in bovine CL is greater in the 
mid-late phase compared to the early stages [Shaw DW et al, 1995; Sakumoto R et al, 
2000] and TNFR are present in the bovine CL throughout the estrous cycle [Sakumoto R 
et al, 2000]. These authors suggested that TNF-α acts as a luteolytic agent in the mid-late 
CL, but how it switches from a luteotropic to a luteolytic role is unknown.  
It is well recognized that PGF2α is the major luteolytic agent in mammals. It is 
presumed that ET-1 plays an important role in the regulation of luteal regression. Specific 
binding sites for TNF-α have been reported in cultured EC derived from bovine CL 
[Okuda K et al, 1999; Friedman A et al, 2000] and that ET-1 secretion is increased 
significantly after TNF-α treatment [Friedman A et al, 2000]. Moreover, in vivo, PGF2α 
activates inflammatory cells followed by TNF-α and INF-γ secretion in CL of cows 
[Penny LA et al, 1999] and pigs [Hehnke KE et al, 1994]. Benyo et al [Benyo DF et al, 
1992] reported that in primary luteal cell culture TNF-α in combination with INF-γ 
reduced P4 secretion as well as the number of viable cells. In contrast, TNF-α alone had 
no effect on P4 synthesis [Benyo DF et al, 1992]. It has been suggested that TNF acts in 
conjunction with INF-γ or other substances (eg, ET-1, NO) to inhibit P4 synthesis. 
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Although TNF-α exerts pleiotropic responses, the engagement of Fas with the Fas 
L is known primarily for its role in apoptosis. Fas has been demonstrated to be expressed 
through out the luteal phase [Taniguchi H et al, 2002b; Taniguchi H et al, 2002a] 
However, the physiological significance of Fas or its ligand in the developing CL, is not 
yet known. Expression of Fas/Fas L in bovine primary luteal cell culture induced luteal 
cell death [Taniguchi H et al, 2002b; Pru JK et al, 2002]. Similar results have been shown 
in bovine granulosal cells [Quirk SM et al, 2000]. Structural demise of the CL involves 
interaction of the Fas/Fas L system and other cytokines (TNF, INF-γ). Bovine luteal cells 
became sensitive to Fas/Fas L-induced cell death in the presence of INF-γ alone or in 
combination with TNF-α [Taniguchi H et al, 2002a]. The increased sensitivity of bovine 
luteal cells to Fas L has been correlated with cytokine-induced increase of Fas mRNA 
[Taniguchi H et al, 2002a].  
Tumor necreosis factor-R1 mRNA and specific binding sites for TNF-α are 
present in the bovine CL throughout the estrous cycle [Sakumoto R et al, 2000]. In a 
species dependent manner, TNF-α/TNFR1 complex activated different types of signaling 
pathways. For example in rats, TNF-α induced the PLC-PKC pathway [Zachow R et al, 
1993a] and the cAMP-PKA pathway [Zachow R et al, 1993b]. Also in rat GC, TNF-α 
activated cell survival pathways, involving NFκB [Xiao CW et al, 2002]. In the early 
bovine CL, TNF-α via the MAPK pathway, activated the PLA2 pathway to stimulate PG 
synthesis [Benyo DF et al, 1992; Sakumoto R et al, 2000]. In contrast, in primary bovine 
luteal cell cultures, inhibitors of PKA and PKC did not affect the actions of TNF-α 
[Sakumoto R et al, 2000, Sakumoto R et al, 2004]. In vitro, TNF-α and INF-γ, acting via 
TNFR1 activated MAPK-JNK intracellular effectors that in turn activated the apoptotic 
cascade resulting in structural luteal regression [Okuda K et al, 2003].  
It has been proposed that nitric oxide (NO) might be a mediator and / or 
modulator of PGF2α -induced luteolytic actions in the bovine CL [Skarzynski DJ et al, 
2000; Skarzynski DJ et al, 2003; Jaroszewski JJ et al, 2003]. Nitric oxide directly inhibits 
P4 secretion in cultured bovine luteal cells and augments the action of extragonadal 
PGF2α on the CL [Skarzynski DJ et al, 2000]. Moreover, in cattle, inhibition of NO 
production in the female reproductive tract counteracts both spontaneous [Jaroszewski JJ 
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et al, 2000] and PGF2α -induced luteolysis [Skarzynski DJ et al, 2003; Jaroszewski JJ et 
al, 2003]. In bovine CL, NO stimulated secretion of leukotrine C4 (LTC4) that was 
shown to play a role in luteal regression [Jaroszewski JJ et al, 2003]. In heifers, an in vivo 
microdialysis experiment demonstrated that LTC4 concentration in perfusates from the 




























Chapter II: Statement of Problem 
 
The CL of the early estrous cycle (days1-5) is resistant to the luteolytic action of a 
single dose of PGF2α that induces luteal regression in the mid-late (days 8-15) CL. 
Resistance is not due to the lack of PGF2α receptors, as the receptor already exists in 
maximal concentration in the early CL [Wiltbanl MC et al, 1995]. The mechanism(s) 
responsible for the insensitivity of the early CL are poorly understood, however several 
possibilities have been proposed. It has been reported that the early CL has a greater 
ability to catabolize PGF2α to PGFM [Silva PJ et al, 2000]. Catabolism of PGF2α locally 
in the CL might prevent PGF2α, of uterine origin, from reaching its receptors in the CL.  
However, because PGDH is a cytosolic enzyme, it is more likely that PGDH opposes the 
biosynthetic function of COX-2 in the CL, preventing local accumulation of PGF2α. It 
also has been proposed that the early CL lacks PGF2α synthetic capacity. Tsai and 
Wiltbank [Tsai SJ et al, 1997] reported that PGF2α amplifies the luteolytic signal from the 
uterus in a paracrine/autocrine manner only in the mid-late luteal phase. However, Sayre 
et al [Sayre BL et al, 2000] found that repeated treatment with PGF2α upregulated PG/H 
synthase 2 and PGF synthase in day-4 CL. This observation indicated that a difference in 
sensitivity and not lack of PGF2α synthetic capacity in the early CL might be the primary 
cause for the insensitivity of the early CL. Choudhary et al [Choudhary E et al, 2005] 
recently reported that the potency of PGF2α and ET-1 to inhibit basal and LH-stimulated 
P4 accumulation in luteal SC primary cultures from day-4 CL was lower than that of day-
10.   
There is compelling evidence that a threshold dosage of PGF2α is required before 
the CL is committed to luteolysis [Silvia WJ et al, 1986; Juengel JL et al, 2000]. Thus, a 
major biological function of PGDH in the CL has been hypothesized to prevent luteal 
concentrations of PGF2α from reaching threshold amounts to initiate luteal regression at 
an inappropriate time. The fact that increased PGDH enzymatic activity is correlated 
temporally with luteal resistance supports the existence of such a mechanism [Silva, PJ et 
al, 2000].  
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In the early CL of the cow and the ewe, expression of COX-2 does not increase in 
response to exogenous PGF2α [Tsai SJ et al, 1997]. Because there is high catabolism of 
PGF2α in the early CL, the stimulatory effects of PGF2α on luteal expression of COX-2 
are blunted. Based on this observation, it has been proposed that the insensitivity of the 
early CL may be due to a blockage of PGF2α-induced expression of COX-2 [Silva, PJ et 
al, 2000]. In addition, regulation of expression of different PG receptors and PGF 
synthase, PGE synthase and prostacyclin synthase also influence the type of PG produced 
by the CL, and consequently may alter the function of the CL. Arosh et al [Arosh JA et 
al, 2004b] demonstrated selective activation of PGE2 synthase and EP2 signaling during 
luteal maintenance and increased expression of PGF synthase and EP3 during luteal 
regression. Based on their observations, they proposed that selective expression of luteal 
PGE2 and/or PGF2α, their extra-cellular transportation by PGT and the differential 
expression of PGE and/or PGF receptors and their intracellular mediators during distinct 
stages of the CL life may lead to luteal maintenance or demise. These observations may 
help to understand the mechanism of luteal regression, but fail to explain the cause of 
early luteal insensitivity to the luteolytic actions of PGF2α. If PGF2α availability is the 
primary reason for the insensitivity of the early CL, exogenous PGF2α treatment should 
cause luteal regression. However, in the early CL, both in vivo [Rowson LE et al, 1972] 
and in vitro [Choudhary E et al, 2005], treatment with PGF2α failed to induce luteal 
regression. 
Another proposal put forward by many authors as a possible cause for the 
resistance of early CL is the inability of PGF2α to induce ET-1 synthesis at this 
developmental stage [Levy N et al, 2000]. However, in the early CL, the expression of 
ET-1 system was PGF2α-independent [Wright MF et al, 2001; Choudhary E et al, 2004) 
and Choudhary et al (Choudhary E et al, 2005] has demonstrated that ET-1 instead of 
being strictly a mediator of the luteolytic actions of PGF2α, is a tonic inhibitor of P4 
accumulation. Based on this study, the authors proposed that the insensitivity of the early 
CL to the luteolytic actions of PGF2α is related to differences in developmental sensitivity 
to PGF2α rather than to the absence of ET-1 to mediate the luteolytic action of PGF2α. In 
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mid-late luteal phase, it is hypothesized that tonic inhibition of P4 by ET-1 along with 
PGF2α and possibly with other factors mentioned above, may cause luteal regression. 
Juengel and Niswender [Juengel JL et al, 1998b] have proposed that the 
sensitivity of the ovine CL to the luteolytic actions of PGF2α is regulated at the 
postreceptor/intracellular mediator level. In support of this suggestion, it was 
demonstrated [Juengel JL et al, 1998b] that the concentrations of mRNA encoding PKC 
inhibitor protein-1 (KCIP-1) in day-4 CL is greater than in day-10 and 15 CL. The 
authors proposed that increased resistance of the corpus luteum to PGF2α might be 
attributable to greater concentrations of this biological inhibitor of PKC, and as a result, 
PGF2α fails to fully activate its intracellular mediators. Another suggestion regarding 
difference in the intracellular mediators of PGF2α as a function of development is that 
there may exist a threshold of [Ca2+]i that is required to support P4 synthesis, while a 
change in  [Ca2+]i may lead to luteal regression [Martinez-Zaguilan R et al, 1994; Wegner 
JA et al, 1991]. 
It has been known for some time that PKC and calcium are intracellular mediators 
of PGF2α and is well established that individual PKC isoforms have very specific 
functions and may cause antagonistic effects in the same tissue or cell type. However, 
nothing is known about the array of PKC isozymes expressed in the bovine CL or the 
biological functions of individual PKC isoforms. It is likely that among the PKC isoforms 
expressed in the bovine CL, some might be luteotropic while others might have luteolytic 
actions. These studies investigated the array of PKC isozymes expressed in the bovine 
CL, their cellular source and potential roles of specific PKC isozymes involved in the 










Chapter III: Expression and Activation of Protein Kinase C Isozymes by 
Prostaglandin F2α in the Early and Mid-Luteal Phase Bovine Corpus Luteum 
 
Introduction 
The luteolytic actions of prostaglandin F2α (PGF2α) are mediated by the activation 
of its plasma membrane receptor, a G-protein coupled receptor. In the CL, PGF2α binding 
to its cognate receptor activates the membrane-bound phosphoinositide-specific 
phospholipase C (PLC), yielding inositol 1,4,5-trisphosphate (IP3) and diacylglycerol 
[Davis JS et al, 1987]. In bovine luteal cells PGF2α stimulates phosphatydylinositol 4,5-
biphosphate hydrolysis and mobilizes intracellular Ca2+ [Davis JS et al, 1987; Davis JS et 
al, 1988]. Accordingly, calcium and protein kinase C (PKC) have been shown to be the 
intracellular mediators of actions of PGF2α in the CL [Wiltbank MC et al, 1991]. PKC is a 
family of protein kinases that exist in 11 isozymes examined to date [Sakanoue Y et al, 
1992; Selzer E et al, 2002]. There are 4 conventional PKC isozymes, alpha (α), beta I 
(βΙ), beta II (βII), and gamma (γ); 4 novel PKC, delta (δ), epsilon (ε), theta (θ), and eta 
(η); and 3 atypical, lambda (λ), zeta (ζ), and mu (μ). The PKC μ is also known as PKD 
[Selzer E et al, 2002]. Surprisingly, the array of PKC isozymes expressed, their sub-
cellular distribution and their roles in the regulation of luteal function, have received very 
little attention. In the CL of the mid-luteal phase, the α-(in cytosol) and ε-(in plasma 
membrane) isozymes have been reported to be immunonochemically detectable [Orwig 
KE et al, 1994].   
In cows and various other animals in which PGF2α induces luteolysis, the CL of 
the early estrous cycle (days 1-5) is resistant to the luteolytic action of a dose of PGF2α 
that induces luteolysis in mid-late (days 8- 15) CL. Resistance of the early CL to PGF2α is 
not because of the lack of receptors, because those are already maximal at this stage of 
the cycle [Mamluk R et al, 1999; Wiltbank MC et al, 1995]. The mechanism(s) 
responsible for insensitivity of the early CL to PGF2α are not fully understood, however 
several possibilities have been implicated. For instance, a greater ability of the early- than 
late-CL to inactivate PGF2α has been documented [Silva PJ et al, 2000]. There is evidence 
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that the early-CL lacks PGF2α synthetic capacity. Tsai and Wiltbank, 1997 [Tsai SJ et al, 
1997] reported that PGF2α amplifies the luteolytic signal from the uterus in a 
paracrine/autocrine manner only during the mid-and late-cycle ovine and bovine CL. 
However, Sayre et al. 2000 [Sayer BL et al, 2000] found that repeated treatment with 
PGF2α up-regulated prostaglandin G/H synthase 2 and PGF2α synthase in Day-4 CL. This 
observation by Sayre et al. [Sayer BL et al, 2000] stresses a difference in sensitivity 
rather than a lack of PGF2α synthetic capacity in the early CL. Levy et al. [Levy N et al, 
2000] reported another possible cause for resistance of early CL. These investigators 
have proposed that the endothelin (ET) system plays an essential role during PGF2α 
induced luteolysis, and that PGF2α differentially modulates the expression of the genes 
encoding ET-1, the ET receptor type A and the ET converting enzyme-1 (ECE-1) at the 
early and mid luteal phases [Levy N et al, 2000; Meidan R et al, 1999, Girsh E et al, 
1996a; Girsh E et al, 1996b; Ohtani M et al, 1998; Milvae RA et al, 2000]. The work by 
these investigators has led to the hypothesis that the limited ability of PGF2α to stimulate 
ET-1 synthesis during the early luteal phase may be responsible for the insensitivity of 
the early CL to PGF2α. 
Although PGF2α reaches the early corpus luteum (CL), can bind to its cognate 
receptor, and initiate some of the events that lead to luteolysis, the early CL is resistant to 
the luteolytic actions of PGF2α. The possibility that cellular mechanisms acting at the post 
receptor level (i.e. intracellular signal transduction) might contribute to this insensitivity 
or resistance of the early CL has not been explored. For example, there is no information 
available regarding expression of the PKC isozymes as a function of the developmental 
age of the CL, or about the ability of PGF2α to induce their activation in the early- and 
late-luteal phases.  
Here we have examined by, a semi quantitative Western blotting analysis, the 
array of PKC isozymes expressed by the bovine CL at two developmental stages, days 4 
and 10 of the estrous cycle. Furthermore, because a unifying theme in the activation of 
these isozymes is that PKC activation results in rapid redistribution of PKC from the 
cytosol to the membrane, we have examined membrane translocation of PKC after in 




Materials and Methods  
Behavioral estrus was determined in 10 nonlactating beef cows. After three 
consecutive cycles, five Day-4 (d-4) and five Day-10 (d-10) corpora lutea were collected 
via supravaginal incision under epidural anesthesia. Corpora lutea were dissected free of 
any connective tissue and then cut into approximately 1 mm2 fragments immediately 
before the experiments were initiated. About 25 CL fragments were added to a disposable 
culture tube/treatment/time (Fisher Scientific, Pittsburgh, PA) containing MEM-HEPES 
(GIBCO BRL, Life Technologies, Grand Island, N.Y.) alone or MEM-HEPES containing 
0.1, 1.0 and 10 nM PGF2α  (Cayman Chemical, Ann Arbor, Michigan). The PGF2α stock 
solution was prepared in dymethylsulfoxide (DMSO, Pierce, Rockford, IL) and there was 
a 1:10,000 dilution (v/v) of the DMSO in MEM-HEPES to obtain the 10 nM 
concentration of PGF2α. The MEM-HEPES control received the same amount of DMSO 
as the PGF2α treatment. The tissue and media were separated after 0, 2.5, 5, 10 and 20 
min, immediately frozen in liquid nitrogen and stored at - 80o C.  
The tissue was later pulverized and homogenized in buffer containing 20 mM 
Tris-HCl, 0.25-mol sucrose, 1.2 mM EGTA, 0.1 mM Phenylmethylsulfonyl Fluoride 
(PMSF, Eastman Kodak Company, Rochester, NY), 20 μg/ml leupeptin, and 20 mM 2-
mercaptoethanol (GIBCO BRL, Life Technologies, Grand Island, N.Y.). The 
homogenized tissue was centrifuged at 1,000 X g for 2 min at 40 C to remove floating 
large tissue particles. The supernatant was used for sub-cellular fractionation by 
differential and discontinuous sucrose gradient centrifugation. The cytosol fraction was 
obtained by centrifugation at 100,000 X g for 60 min. The pellet of the first 100,000 X g 
centrifugation was homogenized in homogenization buffer containing 1 % triton-X 100. 
The homogenized pellet was re-centrifuged at 100,000 X g for 60 min. The supernatant 
constituted the membrane fraction. Protein concentrations in the cytosolic and membrane 
fractions were determined using a BioRad assay (BioRad, Hercules, CA) with BSA 
(GIBCO BRL, Life Technologies, Grand Island, N.Y.) as standards. Sample proteins 
were analyzed by semi quantitative Western blotting as previously described [Wright Mf 
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et al, 2001]. For semi quantitative analysis of the PKC isozymes, the protein 
concentration in samples was adjusted to 8.0 µg / lane. 
The SDS-PAGE was carried out as previously described [Wright Mf et al, 2001]. 
Briefly, protein samples were loaded onto 8 % polyacrylamide gel. After electrophoresis 
at 150V for 1 hr, the resolved proteins were transferred to polyvinylidene fluoride 
membrane (Biotechnology Systems, Boston, MA). The membranes were blocked in 1% 
BSA with 0.05% Tween-20 in Tris-buffered saline (TBS-T, pH 7.5) for 2 hr at room 
temperature. The membranes were incubated with primary antibody for 2 hr at room 
temperature and washed three times for 10min in TBS-T. Subsequently, the membranes 
were incubated with anti-rabbit (1:5000 [v/v]; Amersham Pharmacia Biotech, 
Piscataway, NJ) or anti-mouse (1:30,000 [v/v]; Gibco, Grand Island, NY) horseradish 
peroxide-conjugated antibodies for 1hr. Visualization of the selected proteins was 
achieved using the WestPico detection system (Pierce, Rockport, IL) and Kodak Biomax 
Light Film (Eastman Kodak Company, Rochester, NY). This system was selected 
because of its versatility in allowing the stripping of primary and secondary antibodies 
from membranes for sequential re-probing of membranes with variety of antibodies. 
Stripping of membranes was performed with Restore Western Blot Stripping 
Buffer (Pierce, Rockport, IL). Stripping conditions were tested to demonstrate complete 
removal of antibodies, and 30 min at room temperature was found to be effective for all 
antibodies used in this study. Images of the detected proteins were captured using the 
Fluor-S MultiImager. Densitometry of the bands of interest was performed using 
Quantity One quantitation software. The intensity of the signal corresponding to the 
protein of interest was standardized by the corresponding intensity of the actin control in 
that sample. This normalization of data allowed us to estimate, in a semi quantitative 
manner, the amount of protein in the samples of interest. This semi quantitative Western 
blot methodology has been described earlier [Wright Mf et al, 2001]. The following 
primary antibodies were used in these studies. A mouse anti-actin monoclonal antibody 
([used at a dilution of 1:3000 (v/v] Chemichon International, Inc., Temecula, CA); nine 
PKC isozyme specific (α, βI, βII, γ, η, ε, θ, λ, and μ) polyclonal antibodies and their 




Statistical analyses were performed using JMP, a statistical software program for 
the Apple Macintosh [Cary NC, 1994]. The analysis was based on the ratio of optical 
density (arbitrary units) for the PKC isozyme divided by the optical density for actin. The 
results were expressed as the mean ± SEM. Two-way ANOVA followed by the Tukey-
Krame Honesty Significant Difference was used to determine statistical significant 
differences between the days of cycle and the effect of the PGF2α treatment. A value of P 




PKC isozymes Expressed in the Bovine CL  
The antibodies specific for the PKC isozymes detected protein bands of 
approximately 80 kDa in some of the luteal samples examined (Figure 1). This molecular 
weight corresponded closely to the published size bands detected for the different PKC 
isozymes [Blumberg PM, 1991]. These 80 kDa bands were detected when the samples 
were used at concentrations of 5 to 50 μg (Figure 1A); at lower protein concentrations no 
bands were detected (data not shown). Based on these findings, sampled proteins were at 
a total protein concentration of at least 8 μg to evaluate the PKC isozymes present in the 
d 4 and d 10 bovine CL. The specificity for each of isozyme-specific antibodies was 
confirmed by incubation of each antibody with excess antigenic peptide; an example for 
specificity of the PKC βI antibody is shown in Figure 1B.  In all samples examined, a 43-
kDa-protein band was detected with the antibody for actin (Figure 1C). This molecular 
weight corresponded closely to the published size band for actin [Otey CA et al, 1987]. 
The specificity of the band detected with the actin antibody has been similarly confirmed 
elsewhere [Otey CA et al, 1987]. 
Specific protein bands corresponding to the conventional PKC isozymes 
α, βΙ, and βΙΙ were detected in the protein samples prepared from both d 4 and d 10 
corpora lutea. In contrast, no protein was detected with the antibody for the conventional 
PKC γ.  With antibodies corresponding to the novel PKC group, only the PKC ε  was 
detected; the antibodies corresponding to PKC η, λ, and θ isozymes failed to detect 
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protein bands in the bovine CL (data not shown). The antibody specific for the PKC μ 
isozyme detected a protein band of the appropriate size in both d 4 and 10 luteal protein 
samples (data not shown). 
The semi-quantitative Western blot analysis allowed us to estimate the amount of 
protein corresponding to each PKC isozyme expressed in the samples prepared from d-4 
and -10 CL (Figure 2). The PKC βII and ε isozymes were differentially expressed at 
these two developmental stages of the bovine CL. For the ε isozyme, this difference was 
dramatic. In the day 4 samples this protein was barely detectable (Figures 1 and 2). In 
contrast, in the d-10 samples, the actin corrected ratio for PKC ε was 1.16 ± 0.13. This 
ratio was higher than that detected for PKC βI and μ at this developmental phase of the 
bovine CL (P<0.01), but it was comparable to the ratio detected for the PKC α, and β II 
(Figure 2). The PKC βII isozyme, was differentially expressed in a less dramatic manner 
than PKC ε . The actin-corrected ratio for this PKC in the d 10-CL was 0.85 ± 0.2, while 
in the d-4 CL, it was only 0.35 ± 0.09  (P< 0.01). The actin-corrected ratios for all other 
PKC isozymes did not differ with day, α (d-4 = 0.93 ± 0.16, d-10 = 0.97 ± 0.09), βΙ  (d-4 
= 0.54 ±. 073, d-10 =0.48 ± 0.74, and μ, (d-4 = 0.21 ±. 042, d-10 = 0.21 ± 0.38, Figure 2).  
The PGF2α treatment at concentrations less than 10 nM (0.1 and 1.0) had no effect 
on the redistribution of PKC isozymes from cytoplasm to membrane (data not shown). 
The time-course for the cellular distribution of the expressed PKC isozymes after 10 nM 
PGF2α stimulation was variable. For instance, for PKC α, 4/5 samples from d 10 showed 
clear translocation from the cytosol to membrane fraction. The two patterns observed for 
PKC translocation is shown in Figure 3A for PKC α. After 5 minutes exposure to PGF2α 
(10 nM), the optical density of the membrane to cytosol ratio corrected by actin was 
elevated over the ratio observed before PGF2α exposure (Time 0). This elevated ratio 
indicated a redistribution of the PKC α from the cytosol to the membrane compartment. 
The increased ratio (Figure 3 A and B) reached a peak after 10 minutes, and by 20 
minutes, it had returned to values observed at time 0. In the second pattern however, the 
ratio was not maximal until time 10 min, and remained elevated through 20 minutes. 
Based on these observations, 10 minutes was chosen as the best time point for examining 
the cellular redistribution of the PKC isozymes after PGF2α stimulation at these two 
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developmental stages of the bovine CL.   
A summary of the cellular redistribution of the expressed PKC isozymes after 10 
min stimulation with PGF2α (10 nM) of the d-4 and d-10 luteal tissue is presented in 
Table 1. The data are presented as mean ± SEM ratio of the optical density (o.d., arbitrary 
units) detected for the PKC isozyme, corrected by the o.d. detected for actin on that 
sample.  
The isozymes PKC α, βI, and βII were detected exclusively in the cytoplasm 
prepared from the d- 4 MEM-Hepes -treated group, the membrane fractions had no 
detectable PKC (Table 1). In contrast, treatment with 10 nM PGF2α induced the 
association of the PKC α, βI, and βII isozymes with the membrane fractions, so that now 
these isozymes were readily detected on the membrane fractions of these d-4 samples 
(see Table 1). The distribution of the PKC μ and ε isozymes could not be assessed due to 
its low expression. 
In the d-10 samples treated with MEM-Hepes, (Table 1) PKC α (see also Figure 
4) and ε were detected only in the cytoplasm while PKC βI and βII were detected in both 
the cytoplasm and membrane fractions. Treatment with 10 nM PGF2α induced the 
appearance of the PKC α and ε in the membrane fractions, and consequently these 
isozymes were detected in both cellular compartments (Table 1). After treatment with 
PGF2α, the PKC βI and βII were still detected in both the cytoplasm and membrane 
fractions, but the actin-corrected ratio for these isozymes were 1.18 ± .06 and 1.45 ± 0.05 
respectively (P<0.05). However, the actin-corrected ratios for the cytoplasmic fractions 
of the PGF2α -treated samples also were greater than those of the MEM-Hepes-treated 
controls. When this was taken into account, only the PKC βI appeared to be translocated 
after the PGF2α -treatment. The observed increase of some isozymes in both cytosolic and 
membrane factions after PGF2α -treatment could be due to concomitant changes in the 
state of the actin, and thus in the amount which finally appears in the fraction. This is 
obviously a drawback of this approach to assess activation PKC. The distribution of the 




In this study we have demonstrated that the array of PKC isozymes expressed by 
the bovine CL is wider than it had been reported previously. Orwig et al., 1994 [Orwig 
KE et al, 1994] reported the expression of the PKC α and ε in the bovine CL of the mid-
luteal phase. These investigators were not able to reveal the PKC βI, βII or μ, which we 
were able to demonstrate in this study. Chen et al., 2001 [Chen D et al, 2001] reported the 
PKC α, βII and ε in bovine luteal tissue isolated from ovaries from early pregnancy. The 
reason for this discrepancy between these two studies and the study by Orwig et al., 1994 
[Orwig KE et al, 1994] could the different detection systems used in these two studies. 
Orwig et al, 1994 [Orwig KE et al, 1994] used a colorimetric detection system, while 
Chen et al., 2001 [Chen D et al, 2001] and the present study used a chemiluminescent 
substrate. These detection systems are respectively at the low and high ends of the 
sensitivity spectrum of the available methodology. Some of the PKC isoforms revealed in 
the present study were difficult to detect even with this high sensitivity detection system, 
so it is not surprising that the colorimetric detection system, did not detect these isozymes 
expressed in low amounts. 
More importantly, in this study it was demonstrated that the PKC ε and β II are 
expressed differently according to the developmental age of the CL. The most dramatic 
difference was that for the PKC ε which was barely detectable in the d-4 CL with this 
assay. In contrast, in the d-10 CL the expression of the PKC ε was unregulated 
considerably. The expression of the PKC β II was higher in the d-10 than in the d 4 CL  
The potential physiological significance for this differential PKC expression 
between these two developmental luteal stages is that it could be a contributing factor, 
not only in the resistance of the early CL to the luteolytic action of PGF2α, but also in the 
reported differential sensitivity to PGF2α to evoke luteal oxytocin secretion and on its 
effects on progesterone secretion [Cluster EE et al, 1995]. It is possible that the 
expression of the full array of PKC isoymes during the mid-luteal phase confers a broader 
network of intracellular mediators, transducing a full range of luteolytic actions of PGF2α 
in the d-10 CL. Partial expression of the array of PKC isozymes at earlier developmental 
stages would render the tissue differentially sensitive to alternative selective effects of 
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PGF2α, without triggering the luteolytic program prematurely.  
The observed differential sensitivity of the corpus luteum to PGF2α is without 
doubts a complex and interesting biological phenomenon. Most likely, multiple cellular 
mechanisms are involved, including existence of multiple receptors, activation of 
different signal transduction/second messenger systems by a single class of receptor, 
differential developmental regulation of the intracellular mediators as well as targeting 
different genes at different developmental stages, with the intracellular network 
transducing the actions of the ligand. Although there are several studies indicating the 
existence of low and high affinity receptors in the CL, a single class of high affinity 
PGF2α binding site has been demonstrated in the bovine CL [Wiltbank MC et al, 1995]. 
However, more recently, two alternative mRNA splicing giving rise to two PGF2α 
receptor isoforms, which differ in their regulation by PKC, have been described 
[Srinivasan D et al, 2002]. 
In addition to the phospholipase C pathway, there is some evidence that PGF2α 
activates the phospholipase D pathway [Liu B et al, 1996] in cells of the Chinese hamster 
ovary transfected with the bovine PGF2αreceptor. These findings have been corroborated 
in functional rat luteal tissue [Yamamoto H et al, 1995].  As far as we know, evidence for 
differential expression of PKC isozymes at developmental stages of the bovine CL 
characterized by resistance and responsiveness to luteolytic actions of PGF2α has not 
been obtained previously.  
PKC ε belongs to the novel PKC isozymes, characterized as calcium independent, 
but diacylglycerol –sensitive serine/threonine kinase. Its activation appears to regulate 
various physiological functions including the endocrine system. For example, PKC ε has 
been implicated as a mediator of both basal and thyrotropin-releasing hormone-
stimulated prolactin secretion [Pickett CA et al, 2002].  Further studies are needed for 
understanding the luteal biological functions for this PKC isozyme. 
Translocation of PKC, detected by Western blotting, although not the best or most 
direct proof for PKC activation, provided strong evidence for PGF2α-stimulated PKC 
activation in both d-4 and d-10 luteal samples. Therefore if the signal transduction 
associated with the luteal PGF2α receptor, PKC, contributes to the mechanism responsible 
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for insensitiveness of the d-4 CL, it is most likely mediated through differences in 
expression of PKC ε  and βII isozymes at this stage. It appears unlikely that the observed 
insensitiveness is due to the inability of the PGF2α receptor to activate the expressed 
isozymes in the early CL. We argue that differences in expression of isozyme 
complement are responsible for differences in response to PGF2a between day 4 and 10 
luteal tissue. 
In summary, the PKC α, βΙ, βΙΙ, ε  and μ isozymes were detected in total protein 
samples prepared from both d-4 and d-10 bovine corpora lutea. The PKC βII and 
ε isozymes were expressed differentially at these two developmental stages of the CL. 
We propose that differential expression of these PKC isozymes is part of the cellular 






Figure 1. Representative validation used in the semi quantitative Western blot analysis of 
the PKC isozyme array expressed in the bovine. Figure 1A demonstrate the amount of 
total sample protein needed to detect the luteal PKC isozymes; a representative Western 
blot corresponding to the PKC β I is shown in panel A. Panel B demonstrate the 
specificity of the Western blot obtained with the PKC βI antibody. In this representative 
Western blot shown, the samples were run in duplicate at a protein concentration of 25 
μg. Lanes c and d correspond to the experimental conditions where the primary antibody 
was pre-incubated with an excess amount of antigenic peptide prior to its use in the 
Western blot.  Panel C demonstrate the differential expression of PKCε isozyme in the 
early- (day 4) and mid- (day 10) phase of the bovine CL. This representative Western blot 
demonstrates the amount of PKCε and actin expressed in protein samples prepare from 
bovine corpora lutea collected at d-4 (n = 5, lanes 1-5) and d-10 (n = 5, lanes 6-10) of the 
estrous cycle. The PKC isozyme specific antibody detected a protein band of 







Figure 2. Semi quantitative analysis of the densitometry derived from the Western blot to 
reveal the array of PKC isozymes expressed in the d-4 and d-10 bovine CL. The y-axis 
shows the ratio of the optical density (o.d.) for each PKC isozyme corrected by the 
detected o.d. for its corresponding actin. The data is shown as mean±SEM, values with 
differing letters denote statistically significant differences by two way ANOVA followed 

























Figure 3. Semi quantitative Western blot analysis of the time course distribution of PKC 
α in the cytosolic and membrane protein fractions isolated from one d-10 CL. Luteal 
tissue fragments were incubated in MEM-Hepes or MEM-Hepes containing 10 nM 
PGF2α for the indicated times.  Panel A depicts the ratio of the optical density (o.d.) 
detected for the PKC isozyme corrected by the o.d. detected for actin. Panel B shows the 


















Figure 4. Representative Western blot demonstrating PKC α in translocation in the d-10 
luteal tissue after stimulation with PGF2α. Panel A reveals the exclusive cytoplasmic 
localization of the PKC α when the tissue was incubated with the control media, MEM-
Hepes. Panel B demonstrates that after 10 minutes incubation of the luteal tissue with 
PGF2α induced the appearance of PKC α in the membrane fraction. Panel C reveals the 








TABLE 1. Summary of the PGF2α-stimulated cellular redistribution of the PKC 
isozymes  





Day   4 
Cytoplasm 
(Ratio  C/A) 
Membrane  
(Ratio  M/A) 
Cytoplasm  
(Ratio  C/A) 
Membrane  
(Ratio M/A) 
PKC α         0.95±0.06              -        0.92±0.0 3         1.11±0.05 
PKC β I         0.59±0.02              -         0.54±0.1        0.30±0.08 
PKC β II         0.35±0.06              -        0.30±0.08        0.37±0.1 
PKC  ε               -              -               -             - 
PKC  μ 
 
Day 10 
              -              -               -             - 
PKC α       0.78±0.09              -        0.79±0.04        1.15±0.1 
PKC β I       0.68±0.03       0.69±0.02        0.81±0.04        1.18±0.06 
PKC β II       0.69±0.02       0.95±0.06        1.15±0.02        1.45±0.05 
PKC  ε       0.61±0.02             -         0.79±0.03         0.71±0.03
PKC   μ 
 









Chapter IV: Effects of Selective Protein Kinase C Isozymes in Prostaglandin F2α -
induced Ca2+ Signaling and Luteinizing Hormone-Induce Progesterone 
Accumulation in the Mid-Phase Bovine Corpus Luteum 
 
Introduction 
Prostaglandin F2α (PGF2α) is generally recognized as the major luteolytic factor in 
domestic ruminants [Niswender GD et al, 1994]. In bovine and ovine corpora lutea, the 
luteolytic action of PGF2α has been shown to be mediated by G-protein-coupled receptors 
that activate the phospholipase C (PLC) effector system [Davis JS et al, 1987]. Indeed, 
stimulation of luteal cells with PGF2α leads to the rapid accumulation of inositol 1,4,5-
trisphosphate (IP3) and 1,2-diacylglycerol (DAG). When it binds to its receptor in the 
endoplasmic reticulum, IP3 stimulates an increase in the concentration of cytoplasmic 
calcium ions ([Ca2+]i) [Davis JS et al, 1987; Putney JW Jr, 1986; Putney JW Jr, 1990]. 
The increases in [Ca2+]i  and DAG result in activation of another intracellular mediator of 
hormone actions, protein kinase C (PKC). Thus, PKC and calcium are two major 
intracellular mediators of the luteolytic actions of PGF2α [Davis JS et al, 1987; Wiltbank 
MC et al, 1991].  
PKC is a family of serine-threonine kinases that exist as at least 11 closely related 
isozymes. They are classified into four categories: conventional (designated as α, ßI, ßII, 
and γ ), novel (δ, ε, ψ, η and υ), atypical ( ζ and λ), and PKCµ. The cofactors required 
for activation of the isozymes differ in each category. Conventional isozymes are 
calcium-dependent, whereas novel isoforms are not. However, both conventional and 
novel isozymes require DAG and phosphatidyl-serine for their activation [Newton AC, 
1995; Mellor H et al, 1998; Mochly-Rosen D et al, 1998]. Moreover, the atypical PKC 
isozymes are calcium- and DAG-independent [Newton AC, 1995; Mellor H et al, 1998; 
Mochly-Rosen D et al, 1998]. A hallmark of PKC activation is its redistribution from one 
cytoplasmic compartment to another [Kraft AS et al, 1983]. Translocation of PKCs is 
mediated by isozyme-specific anchoring proteins termed RACKs [Mochly-Rosen D, 
1995; Mochly-Rosen D et al, 1991]. RACK binding results in anchoring the activated 
PKC isozyme near its substrate. Phosphorylation of the PKC substrate then leads to 
isozyme-specific physiological responses. Thus, the subcellular localization and 
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functional specificity of activated PKC isozymes depend on their binding to their 
corresponding RACK [Newton AC, 1995; Mochly-Rosen D et al, 1998; Pauken CM et al, 
2000; Akita Y, 2002].  
In addition to the Ca2+ requirement for activation of conventional PKC isozymes, 
various isozymes are themselves involved in regulating agonist-induced Ca2+ signaling in 
different cell types [Smeets RL et al, 1998; Song SK et al, 1998; Petersen CCH et al, 
1994; Bissonnette M  et al, 1994; Xu Y et al, 1995; Gronroos E et al, 1996; Crooke ST et 
al, 1989; Vegesna RV et al, 1998]. For example, PKC-epsilon (PKC ε) is necessary for 
initiation of leukotriene D4-induced Ca2+signaling in intestinal epithelial cells [Thodeti 
CK et al, 2001]. And in neurons, PKC ε regulates Ca2+ signaling by modulating N-type 
Ca2+ channels [Maeno-Hikichi Y et al, 2003]. Additional actions of PKC on Ca2+ 
signaling include reducing intracellular calcium storage capacity and augmenting Ca2+ 
entry with submaximal intracellular calcium pool depletion [Carla M et al, 1996], 
mediation of a negative feedback loop involved in inhibition of IP3 production with a 
consequent constant frequency of [Ca2+]i oscillations in mouse lachrymal acinar cells 
[Bird GS et al, 1993], PKC-stimulated modulation of IP3 / Ca2+ signaling in the 
submandibular duct cell line A253 [Sugita K et al, 1999], and PKC activation of 
capacitative calcium entry in an insulin-secreting cell line RINm5F [Bode HP et al, 
1994].  
Sensitivity of the corpus luteum (CL) to luteolytic actions of PGF2α  is affected by 
luteal development. The CL of the early estrous cycle (Days 1–5) is resistant to the 
luteolytic action of a dose of PGF2α  that induces luteolysis in the mid to late CL (Days 8–
15). The mechanisms responsible for this insensitivity are not fully understood but it is 
likely that several mechanisms are integrated in diverse populations of luteal cells. A 
recent study [Sen A et al, 2004] demonstrated that the array of PKC isozymes expressed 
in the bovine CL includes α, ßI, ßII, ε, and µ. Moreover, PKC was differentially 
expressed according to the developmental stage of the CL [Sen A et al, 2004]. Based on 
these observations, we proposed that differential expression of PKC ε could contribute to 
the cellular mechanisms responsible for the relative insensitivity of the early CL to the 
luteolytic actions of PGF2α   [Sen A et al, 2004]. However, specific roles of specific PKC 
isozymes in CL physiology have received little attention to date.  
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In this study, a PKC ε-specific inhibitor peptide (εV1–2) was used to investigate 
the role of this isozyme in previously well-characterized luteolytic actions of PGF2α. This 
inhibitor is 6–8 amino acids long and is derived from the RACK-binding site for PKC ε. 
Binding of the inhibitor peptide to PKC ε-specific RACK blocks binding of the activated 
isozyme to RACK, thereby preventing its translocation and its physiological response 
[Johnson JA et al, 1996; Koponen S et al, 2003; Gray MO et al, 1997]. Effective delivery 
of inhibitor into cells is achieved by means of peptide-delivery technology [Derossi D et 
al, 1994; The'odore L et al, 1995; Vives E et al, 1997]. Once in the cell, the bond linking 
the inhibitor to a carrier peptide is cleaved, releasing the free inhibitory peptide. The use 
of this technology in combination with saponin-mediated cell permeabilization facilitates 
cellular entry of inhibitory peptides [Derossi D et al, 1994; The'odore L et al, 1995; Vives 
E et al, 1997]. The specificity of these isozyme-selective peptides has been fully 
characterized in a variety of cell types, including intestinal epithelial cells [Chang Q et al, 
2003], pancreatic cells [Yedovitzky M et al, 1997], esophageal smooth cells [Sohn UD et 
al, 1997], and vascular smooth muscle cells [Lee YH et al, 1999].  
The aim of this study was to use a PKC ε -specific inhibitor to investigate the role 
of this isozyme in two luteal end points: 1) a PGF2α-induced rise in [Ca2+]i, and 2) a 
PGF2α-induced decline in basal and LH-induced progesterone accumulation. The 
potential role of PKC ε in these aspects of luteal physiology was investigated during the 
early luteal and mid-luteal phases, developmental stages at which PKC ε is known to be 
expressed at low and high concentrations, respectively. Based on the results, it is 
suggested that PKC ε plays an important role in the ability of PGF2α to induce these two 
effects on the midphase bovine CL.  
 
Materials and methods 
 Tissue Collection 
Nonlactating beef cows were observed visually for estrus twice daily at 
approximately 12-h intervals for a minimum of 30 min per observation. The day when 
standing estrus was observed was designated as Day 0 [Casida LE, 1959]. After two 
cycles, four Day-4 and seven Day-10 corpora lutea were collected by ovariectomy (Day 
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4) or blunt dissection (Day 10) via supravaginal incision under epidural anesthesia. For 
the epidural anesthesia, 6–9 ml of 2% lidocaine was administered for cows weighing 
450–700 kg (Butler Company, Columbus, OH). The CL or ovary was collected into ice-
cold PBS pH 7.4 and transported to the laboratory within 15–30 min after collection. The 
West Virginia University Animal Care and Use Committee reviewed and approved the 
protocol for the tissue collection (Animal Care and Use Committee 01-0809).  
 
Luteal Cell Dispersion and Purification 
In the laboratory, the corpora lutea were dissected free of connective tissue, 
weighed, placed in cell-dispersion medium (CDM; M-199 containing 0.1% BSA, 25 mM 
Hepes, and 100 U/ml fungicide), and cut into small (about 1 mm3) fragments. The tissue 
fragments were washed twice with CDM and placed into 5 ml of fresh CDM containing 
collagenase type IV (420 U ml g of tissue; Gibco, Invitrogen Life Technologies, 
Carlsbad, CA). The details of the tissue dissociation protocol have been previously 
published [Choudhary E et al, 2005]. Luteal endothelial cells were separated by a 
procedure previously described [Mamluk R et al, 1998; Levy N et al, 2001]. Briefly, 
magnetic Tosylactivated beads (Dynal Biotech, Lake Success, NY) were coated with BS-
1 lectin (0.15 mg/ml; Vector Laboratories, Burlingame, CA,) for 24 h at room 
temperature. The beads were washed and stored at 4°C until use. Dispersed luteal cells 
were suspended in 1% PBS, mixed with beads at a bead:cell ratio of 1:3, and placed for 
25 min at 4°C on a rocking platform. The bead-adherent cells were washed with 1% PBS 
and concentrated using a magnetic particle concentrator (Dynal Biotech). Both BS-1-
adhering (endothelial cells) and nonadherent cells (steroidogenic-enriched luteal cells) 
were collected by this procedure. In this study, the cell population we designated as 
steroidogenic those cells did not have beads attached, but they represent a heterogeneous 
population of cells that include fibroblasts, pericytes, lymphoid, and any endothelial cells 
not removed by our separation procedure. Cell viability and density were determined 






Single-Cell Calcium Measurements 
The cell density of the enriched populations of luteal cells was adjusted to 1 x 105 
cells/ml by adding bicarbonate-buffered medium 199 (M199) supplemented with 5.0% 
fetal calf serum (FCS). This initial concentration of FCS in M199 allowed luteal cell 
attachment to microscope slides. An 80-µl aliquot of the cell suspension was applied to a 
Cunningham chamber constructed on poly-L-lysine-coated microscope slides [Flores JA 
et al, 1998; Flores JA et al, 1990; Flores JA  et al, 1991]. The Cunningham chambers 
were maintained overnight in a tissue culture incubator (37°C, 95% air-5% CO2). Poly-
L-lysine, M199, FCS, and penicillin-streptomycin were from Life Technologies (Grand 
Island, NY).  
Experiment 1: Potential Role for PKC ε in PGF2α-Initiated Ca2+ Signaling 
In this experiment, we tested the involvement of PKC ε in the PGF2α-induced 
calcium signaling in luteal steroidogenic cells isolated from Day 4 and Day 10 corpora 
lutea. Steroidogenic cells cultured overnight in Cunningham chambers were randomly 
divided into three groups and treated as follows: 1) M199 containing 50 µg/ml saponin 
(Sigma, St. Louis MO); 2) M199 containing 50 µg/ml saponin and 1 µM PKC-specific 
inhibitor, V1–2 (MTA, Stanford, CA); or 3) M199 containing 50 µg/ml saponin and 1 
µM PKC conventional-specific inhibitor, betaC 2, 4 (MTA) for 1 h at 37°C. After 
saponin permeabilization and inhibitory peptide-delivery, the cells were prepared for 
single-cell calcium measurements. The tissue culture medium in this portion of the 
experiment consisted of 127 mM NaCl, 5 mM KCI, 1.8 mM CaCl2, 2 mM MgCl2, 5 mM 
KHPO4, 5 mM NaHCO3, 10 mM Hepes, 10 mM glucose, and 0.1% BSA pH 7.4. Luteal 
cells were loaded with 1 µM fura-2/AM (Calbiochem, San Diego, CA) in experimental 
medium (without hormones) for 20 min at 37°C. The cells were washed with 
experimental medium and incubated for an additional 20 min at 37°C to allow 
cytoplasmic de-esterification of the fura-2/ AM dye.  
After dye loading, the Cunningham chamber was placed on the stage of an 
Olympus PROVIS AX70 microscope (Olympus America Inc., Melville, NY) equipped 
for epifluorescence microscopy. All experiments were performed at room temperature 
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(22–25°C). The details for microscope set up for dual wavelength ratio capture and 
analysis of intracellular calcium concentration have been previously published 
[Choudhary E et al, 2005]. For further analysis, the cell responses were represented as 
changes in the 340:380 nm fluorescence ratios over time. Changes in fluorescence ratio at 
these two wavelengths have been demonstrated to be due to changes in [Ca2+]i. 
Microscopic fields were selected using a bright field image with a 20x objective lens with 
which cell size and morphology could be determined. Both steroidogenic cells were 
round and contained lipid droplets; steroidogenic cells identified as large (LLCs) had a 
diameter of 20 µm or more, while the small steroidogenic cells (SLCs) measured 15 µm 
or less (Fig. 1). This field selection procedure allowed recording two to three cells per 
slide. The identified cells were then challenged with experimental medium alone 
(control) or with experimental medium containing 1000 ng/ml PGF2α. This concentration 
of PGF2α was selected because a previous experiment had demonstrated that in the early 
CL, lower concentrations of PGF2α were not effective in eliciting maximal responses in 
these cells [Choudhary E et al, 2005].  
 
Experiment 2: Potential Role for PKC ε in PGF2α-Induced Inhibition of Basal and LH-
Stimulated Progesterone Accumulation 
This experiment was designed to test the involvement of PKC ε in PGF2α-induced 
inhibition of basal and LH-stimulated progesterone (P4) secretion by Day 4 and Day 10 
steroidogenic cells. After luteal cell dispersion and purification, steroidogenic cells (1 x 
105 cells) were added in small aliquots (100 µl) to wells (Corning 35-mm cell culture 
clusters; Fisher Scientific Company, Blawnox, PA), containing the following: 1) 1 ml 
M199; 2) 1 ml M199 and saponin (50 µg/ml); 3) 1 ml M199, saponin, and PKC ε 
inhibitor (1 µM); 4) 1 ml M199, saponin, and conventional PKC inhibitor (1 µM); 5) 1 
ml M199, saponin, and PGF2α (1000 ng/ml); 6) 1 ml M199, saponin, PGF2α, and PKC ε 
inhibitor; 7) 1 ml M199, saponin, PGF2α, and conventional PKC inhibitor; 8) 1 ml M199, 
saponin, and LH (100 ng/ml); 9) 1 ml M199, saponin, LH, and PKC ε inhibitor; 10) 1 ml 
M199, saponin, LH, and conventional PKC inhibitor; 11) saponin, LH, and PGF2α; 12) 1 
ml M199, saponin, LH, PGF2α, and PKC ε inhibitor; and 13) 1 ml M199, saponin, LH, 
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PGF2α, and conventional PKC inhibitor. Each treatment was applied in duplicate to cells 
from each CL. The cells were incubated for 4 h at 37° C (95% air, 5% CO2). After 
incubation, medium free of cells was removed from each well and stored frozen until 
assayed for measurement of P4. Measurements of P4 in the culture media were 
performed using a radioimmunoassay (RIA) as previously described [Sheffel CE et al, 
1982]. The standard curve for this RIA ranged from 10 pg/ml to 800 pg/ml, and the 
intraassay and interassay coefficients of variation were 9.2% and 12.8%, respectively.  
 
Statistical Analysis 
Statistical analyses were performed using the JMP 3.0, a statistical software 
program from Statistical Analysis Systems [Cary NC, 1994]. Data are presented as means 
± SEM for all experiments. The data for fold increase (340:380 nm ratio) were arcsine 
transformed to meet the assumptions of normality, and for presentation, all the means 
were back-transformed accordingly. Three-way analysis of variance (ANOVA) followed 
by a Tukey-Kramer honestly significant difference test was used to determine statistical 
significance of fold increase in [Ca2+]i between PKC inhibitor-treated cells and untreated 
cells (control). The P4 data were log-transformed to meet the assumptions of normality, 
and for presentation, all the means were back-transformed accordingly. One-way 
ANOVA followed by a Tukey-Kramer honestly significant difference test was used to 
determine statistical significance differences in P4 accumulation. A value of P < 0.05 was 




Morphological characteristics of the LLCs and SLCs identified from 
steroidogenic-enriched cell populations are shown in Figure 1; SLCs had a diameter <20 
µm, LLCs typically had a diameter >20 µm. Using the 20x objective lens typically 
allowed recording two or three cells per slide. For each cell, any increase in fluorescence 
ratio that exceeded basal values before stimulation was considered a response. To 
demonstrate agonist-specificity of the responses, both LLCs and SLCs were stimulated 
with vehicle media alone. Representative traces of Day 10 LLCs stimulated with vehicle 
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media, PGF2α in the absence or presence of a PKC ε inhibitor are shown in Figure 2. In 
Day 10 cells, only 5 of 70 LLCs (7%) and 10 of 80 SLCs (12%) responded to vehicle, 
and the amplitude of this response was only 1.2-fold ± 0.2-fold in LLCs and 0.8-fold ± 
0.5-fold in SLCs over basal values before stimulation. Similarly, in cells from Day 4 
corpora lutea, no responders were observed of 80 LLCs tested, while 12 of 90 SLCs 
(13%) responded with an amplitude of 0.8-fold ± 0.3-fold above the basal level when 
treated with vehicle media alone.  
The concentration of PGF2α used (1000 ng/ml) was effective (P < 0.05) in 
eliciting agonist-specific increases in [Ca2+]i in LLCs and SLCs (Fig. 3). Representative 
traces of these PGF2α -induced Ca2+ responses in LLCs and SLCs collected from Day 4 
and Day 10 corpora lutea are shown in Figures 3 and 4. Most of the elicited responses 
were observed within 45 sec, but there was variability in this aspect of the response. In 
general, CL development (Day 10 vs. Day 4, compare control LLCs in Figures 3 and 4) 
and cell type (LLCs vs. SLCs, compare control LLCs with control SLCs in Figures 3 and 
4) had significant (P < 0.001) effects on the fold increase in the PGF2α-induced rise in 
[Ca2+]i. This is shown clearly in Figure 5, in which the total analysis of the elicited 
responses is presented. 
The fold increase in the PGF2α-induced rise in [Ca2+]i in Day 4 LLCs was 
significantly lower than in Day 10 LLCs (Fig. 5; 4.0 ± 0.6, n = 116 vs. 21.3 ± 2.3, n = 
110). Similarly, the fold increase in the PGF2α-induced rise in [Ca2+]i in Day 4 SLCs was 
lower than in Day 10 SLCs (Fig. 5; 1.6 ± 0.2, n = 198 vs. 2.7 ± 0.1, n = 95). On both 
developmental days examined, the fold increase of the PGF2α -induced rise in [Ca2+]i  
was lower in SLCs than in LLCs (Fig. 5). Although the PGF2α -induced fold increase in 
[Ca2+]i in Day 4 SLCs was small (1.56 ± 0.2), it was specific and greater (P < 0.05) than 
when SLCs were challenged with vehicle alone (0.8 ± 0.3).  
The PKC ε-specific inhibitor had a significant negative effect on the PGF2α -
induced rise in [Ca2+]i in both Day 10 LLCs and SLCs (see lower panels in Fig. 4). The 
presence of the PKC ε inhibitor drastically reduced the PGF2α -elicited responses to 3.5 ± 
0.3 (n = 217) and 1.3 ± 0.1 (n = 205) in Day 10 LLCs and SLCs, respectively (Fig. 5). In 
contrast, treatment with the PKC ε inhibitor had no effect on the PGF2α -induced rise in 
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[Ca2+]i in Day 4 LLCs and SLCs (Fig. 5). In Day 10 cells, a response of great amplitude 
could still be elicited in inhibitor-treated cells by stimulating them with the calcium 
ionophore, A23187 (1 µM; Fig. 1, lower panel). This result provides a strong argument in 
favor of the interpretation that the decrease in the PGF2α -induced response was indeed 
due to the specific effect of the inhibitor on blocking PKC ε activation and function.  
To assess the specificity of PKC ε involvement in affecting the PGF2α -induced 
calcium signaling, we examined the effect of a PKC inhibitor for all conventional PKCs, 
beta C2,4. Conventional PKC inhibitor-treated Day 10 LLCs and SLCs responded 
similarly to control cells without inhibitor (Fig. 5).  
 
Experiment 2 
To further analyze the involvement of PKC ε in the luteolytic actions of PGF2α, 
we measured basal and LH-induced P4 accumulation in the presence and absence of a 
PKC ε-specific inhibitor. Progesterone data from treatments 2, 5, 8, and 11–13 (Materials 
and Methods) from cells isolated from Day 10 corpora lutea are shown in Figure 6. No 
significant differences were observed due to treatment for groups 1, 3, 4, 6, 7, 9, and 10 
described in Materials and Methods; therefore, the data corresponding to those groups 
are not shown.  
In Day 4 isolated cells, the basal amount of P4 accumulated in cultures was 14.7 ± 
4.3 ng ml 4 h, and none of the treatments had an effect.  
Basal P4 accumulation in cultures of Day 10 steroidogenic cells was three times 
higher than in Day 4 isolated cells (45.3 ± 10.8 vs. 14.7 ± 4.3 ng ml 4 h, respectively; P = 
0.03). PGF2α had no effect (P = 0.27) on basal P4 accumulation (Fig. 6). However, LH 
(100 ng/ml) induced a significant (P = 0.01) increase in P4 accumulation (more than a 3-
fold increase) over that observed under basal conditions (Fig. 6). And PGF2α significantly 
(P = 0.01) decreased this effect of LH, reducing it to values below basal conditions (Fig. 
6). Progesterone accumulation in luteal cells incubated with LH, PGF2α, and the 
conventional PKC inhibitor was significantly greater than in cells incubated with PGF2α 
and LH, although not quite as much as incubations with LH, PGF2α, and the PKC ε 




  This study provides evidence for a differential and specific PKC isozyme function 
on well-characterized actions of PGF2α in bovine luteal physiology. The results indicate 
that PKC ε, an isozyme previously shown to be differentially expressed in Day 10 
corpora lutea, has a regulatory role in the PGF2α-induced Ca2+ signaling, and that this in 
turn, has consequences on the ability of PGF2α to inhibit LH-stimulated P4 synthesis at 
this developmental stage. In other tissues, it is well established that PKC isozymes have 
very specific functions [Mischak H et al, 1993; Borner C et al, 1995], but in the CL, the 
biological functions of individual PKC isoforms had not yet been elucidated.  
Our single-cell calcium experiments demonstrate that both LLCs and SLCs from 
Day 10 corpora lutea respond to PGF2α with a rise in [Ca2+]i of greater amplitude than 
cells from Day 4 corpora lutea. A similar observation was recently reported by 
Choudhary et al. [Choudhary E et al, 2005], who studied the full dose-response of LLCs 
and SLCs to PGF2α as a function of luteal development. Based on this observation, it is 
strongly suggested that a developmental difference exists in the ability of PGF2α to 
increase the [Ca 2+]i in both steroidogenic cell types of the bovine CL. That both cell 
types respond to PGF2α with a rise in [Ca 2+]i is consistent with previous reports that both 
steroidogenic cell types in bovine CL express functional PGF2α  receptors [Mamluk R et 
al, 1998; Alila HW et al, 1988c; Davis JS et al, 1988]. Although PGF2α  stimulated a rise 
in [Ca 2+]i in LLCs and SLCs at both developmental stages, the elicited response in SLCs 
was of lower amplitude than the one stimulated in LLCs. This latter observation agrees 
with the responses elicited by PGF2α in LLCs and SLCs in the study by Choudhary et al. 
[Choudhary E et al, 2005]. In earlier studies [Wiltbank MC et al, 1991; Martinez-
Zaguilan R  et al, 1994; Wegner JA  et al, 1991], PGF2α-induced Ca 2+ responses were 
observed only in LLCs. These difference could be due to species differences between 
cows and sheep [Wiltbank MC et al, 1991], or to technical differences; a cell population 
approach was used in one of those studies [54], whereas a single-cell approach was used 
in the present study for the measurement of [Ca2+]i. Differences in regulation of [Ca2+]i 
homeostasis in LLCs and SLCs have been documented previously [Davis JS et al, 1988; 
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Martinez-Zaguilan R  et al, 1994; Wegner JA  et al, 1991; Wegner JA et al, 1990; 
Wiltbank MC et al, 1989a] in ovine and bovine corpora lutea. This difference between 
LLCs and SLCs might explain the differences observed here with regard to the responses 
elicited by PGF2α in LLCs and SLCs. Alila et al. [Alila HW et al, 1990] reported that LH 
induced a rapid increase in [Ca2+]i that differed both in magnitude and profile between 
LLCs and SLCs [Alila HW et al, 1990]. Of interest, in the study by Alila et al., it was the 
SLCs that responded with greater amplitude when stimulated by LH [Alila HW et al, 
1990].  
The PKC ε-specific peptide inhibitor (ε V1–2) used in this study has been 
demonstrated to block the interaction of PKC ε with its specific RACK in an effective 
manner, thereby preventing its translocation and its function [Mochly-Rosen D, 1995; 
Mochly-Rosen D et al, 1991; Johnson JA et al, 1996; Koponen S et al, 2003; Gray MO et 
al, 1997]. The interpretation that this was also true in our study is supported by the 
observation that this inhibitor greatly decreased the amplitude of the PGF2α-induced Ca2+ 
response in cells isolated from Day 10 corpora lutea. As expected, in Day 4 corpora lutea 
in which PKC ε is expressed at very low levels, blocking PKC ε action had no effect on 
the magnitude of the PGF2α-induced Ca2+ signal, which was of low amplitude to begin 
with. Therefore, based on our data it is suggested that PKC ε might have a regulatory role 
in the PGF2α-induced Ca2+ signal in both cell types of the mid-luteal phase corpora lutea. 
Furthermore, we propose that the developmental difference in the ability of PGF2α to 
increase the [Ca2+]i in both steroidogenic cells types of the Day 4 vs. Day 10 bovine CL is 
due to the lower expression of PKC ε at this stage [Sen A et al, 2004].  
Of interest, PGF2α inhibited LH-stimulated P4 accumulation only in Day 10 luteal 
cells. This developmental association of the inhibitory action of PGF2α agrees with the 
report by Choudhary et al. [Choudhary E et al, 2005]; however, in that study, the 
inhibitory actions of PGF2α were observed on basal and LH-stimulated P4 accumulation. 
This discrepancy is most likely due to the permeabilization protocol used in the present 
study. Although saponin did not have any effect on P4 accumulation on medium-treated 
control cells (data not shown), the effects of LH and of PGF2α may have been affected 
due to increased digitonin-mediated permeability. This interpretation is supported by the 
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observation that in the present study, LH-stimulated P4 accumulation occurred only in 
Day 10 luteal cells, whereas Choudhary et al. [Choudhary E et al, 2005] reported an LH-
stimulated P4 accumulation in Day 4 and Day 10 luteal cells. However, more 
importantly, the PKC ε inhibitor greatly reduced the ability of PGF2α to inhibit LH-
stimulated P4 accumulation. Therefore, at the level of P4 accumulation, PKC ε might 
also have some regulatory role in the PGF2α-induced inhibition of P4 accumulation in 
cultures of cells isolated from bovine corpora lutea that had acquired luteolytic 
responsiveness to PGF2α. Our results do not allow us to discern the precise link between 
calcium signal and P4 synthesis, but clearly, Figure 6 illustrates that both conventional as 
well as ε PKC isozymes are involved in mediating the inhibitory actions of PGF2α. 
However, on the basis of calcium and progesterone data presented here, we propose that 
once the CL has acquired the ability to respond to inhibitory actions of PGF2α, PKC ε is 
the isozyme that significantly mediates the PGF2α-induced calcium signal, and that this in 
turn, via conventional PKC isozymes, mediates the inhibition by PGF2α of LH-stimulated 
inhibition of P4 accumulation. This interpretation is supported by the observation in 
experiment 2 in which P4 accumulation in luteal cells incubated with LH, PGF2α, and the 
conventional PKC inhibitor was significantly higher than in cells incubated with LH and 
PGF2α, although not quite as much as with LH, PGF2α, and the inhibitor of PKC ε.  
The role of PKC in luteal physiology is quite controversial; this may be related to 
differences in the mechanism used to activate PKC (PMA or PGF2α); incomplete 
specificity of PKC inhibitors such as H-7, W-7, GF109203X, and staurosporine used in 
previous studies; the time and dose of agonist used; the tissue used (luteinized granulosal 
cells, different developmental stages of CL); species differences; and so on. For example, 
PMA activates all PKC isozymes, whereas hormones such as PGF2α  may activate only a 
subset of the PKC array expressed in the cells. Consequently, a variety of studies indicate 
that PKC stimulates, has no effect, or inhibits P4 synthesis in luteal tissue [Alila HW et 
al, 1989; Yuan W et al, 1997; Hansel W et al, 1987; Wiltbank MC et al, 1990; Baum MS 
et al, 1987]. Nevertheless, it is clear that an involvement of PKC in the negative 
regulation of P4 synthesis in vivo has been demonstrated [McGuire WJ et al, 1994]. 
Furthermore, Wiltbank et al. demonstrated that PGF2α has a direct antisteroidogenic 
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effect on both LLCs and SLCs that is mediated through the PKC second-messenger 
pathway [Wiltbank MC et al, 1989b].  
As expected, neither PGF2α nor PKC ε inhibitor had any effect on P4 
accumulation in Day 4 cultured steroidogenic cells. Earlier studies using the PKC 
antagonist W-7 have shown an inhibition of both basal and hormone-stimulated P4 
synthesis in SLCs and LLCs [Alila HW et al, 1990]. However, we did not observe any 
effect of PGF2α, conventional PKC inhibitor, or PKC ε inhibitor on basal P4 
accumulation in cells from either day, which may be due to differences in experimental 
procedures as discussed above. Also, our study did not identify whether the effect of 
PGF2α or PKC ε inhibitor on the LH-stimulated P4 accumulation occurs in both LLCs 
and SLCs or in LLCs only.  
LLCs are suggested to be the potential target of the inhibitory (luteolytic) effect of 
PGF2α, whereas SLCs are said to be responsible for the (stimulatory) luteotropic effect of 
PGF2α in the bovine CL [Wiltbank MC et al, 1989b]. However, we observed that PGF2α-
induced Ca2+ responses were significantly decreased in both LLCs and SLCs when PKC 
was blocked. The regulatory role of PKC ε in the PGF2α -induced Ca2+ signal might have 
different cellular consequences in LLCs and SLCs. We do not know whether both 
steroidogenic cell types express the same PKC isozymes. Potentially, both PKC activity 
and substrate availability could bring about differences in regulation of steroidogenesis 
by PKC. In ovine steroidogenic cells it has been reported that PKC activity and available 
protein substrates displayed quantitative and qualitative differences between SLCs and 
LLCs, and that differences in the regulation of steroidogenesis between these cells might 
be due to these differences [Hoyer PB et al, 1989]. It has been proposed by Braden et al. 
that the cytotoxic effects of PGF2α  may be due to sustained elevation of [Ca2+]i [Braden 
TD et al, 1988]. In this regard, there is evidence for both extracellular and intracellular 
calcium contributions to the PGF2α -induced Ca2+ response [Wegner JA et al, 1990]. Our 
studies do not allow an assessment of whether PKC ε is modulating the effect of PGF2α  
on intracellular Ca2+ mobilization, Ca2+ influx, or both.  
An interesting suggestion in the literature is that there may be an appropriate 
threshold of [Ca2+]i that is required to support P4 synthesis [Wegner JA et al, 1991]. An 
alteration in the free calcium concentration could be the intracellular second-message that 
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mediates the luteolytic actions of PGF2α  [Martinez-Zaguilan R et al, 1994]. In this 
context, the differential expression of PKC ε as a function of development [Sen A et al, 
2004] and the possibility that PKC ε has an important regulatory role in the PGF2α -
induced Ca2+ signal can be interpreted as being of great physiological significance. The 
expression of PKC ε and its activation by PGF2α  may shift the [Ca2+]i  signal from a 
luteotropic threshold to a luteolytic one in Day 10, thereby playing a role in the 
differential sensitivity of the CL to PGF2α.  
Blocking the action of all conventional PKC isozymes (α, ßI, and ßII) expressed 
in the bovine CL [Sen A et al, 2004] at both development stages had no effect on the 
PGF2α -induced Ca2+ signal. This supports the interpretation that these actions were 
specific for PKC ε. As mentioned earlier, conventional PKC isozymes also appear to be 
involved in mediating the inhibitory actions of PGF2α  on LH-stimulated P4 
accumulation. However, the exact roles of these PKC isozymes are still unknown.  
In summary, PKC ε appears to have a key regulatory role in the calcium signaling 
initiated by PGF2α, and this, at least in part, appeared to antagonize the inhibitory effect 
of PGF2α  on LH-stimulated P4 accumulation in cultures of Day 10 luteal steroidogenic 
cells. Therefore, we propose that the differential ability of both LLCs and SLCs to exhibit 
a PGF2α -induced rise in [Ca2+]i  as a function of development is due to the differential 
expression and activation of this isozyme in Day 10 corpora lutea. The inability of PGF2α  
to decrease P4 secretion in Day 4 corpora lutea may be related to the absence of this PKC 
ε at this developmental stage of the CL. Thus, based on the above observations, we 
propose that expression and activation of PKC ε in the midphase bovine CL, shifts the 
PGF2α -induced [Ca2+]i  response to a threshold that allows activation of conventional 
PKC isozymes, and this in turn, decreases P4 accumulation characteristic of luteal 
regression. However, other mechanisms such as the tonic inhibition of P4 accumulation 
by ET-1 [Choudhary E et al, 2005], and nitric oxide [Friden BE et al, 2000; Tognetti T et 
al, 2003] may act in an additive fashion with PGF2α  to cause luteal regression during the 









FIG. 1. Representative morphological characteristics of the three cell populations 
obtained from the dissociated bovine CL. Luteal steroidogenic (a and b) and endothelial 
cells were separated using magnetic Tosylactivated beads coated with BS-1 lectin as 
described in Materials and Methods. a) A small luteal steroidogenic cell (SLC), which 
typically had a diameter <20 µm. b) A large steroidogenic cell (LLC); these cells 
typically had a diameter >20 µm. c) Two luteal endothelial cells; these cells had one or 
two magnetic beads attached to their surface. All images were obtained using a x20 
objective lens of an Olympus microscope equipped for Nomarsky microscopy. Bar in (a) 
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are the relative 
fluorescence 
ratio (340:380 
nm) over time 
(in seconds). 
LLCs were 
exposed at the indicated time (arrows) to vehicle media (top), to PGF2  alone (1000 
ng/ml; middle), and to PGF2  (1000 ng/ ml) in the continuous presence of a PKC -
specific inhibitor (bottom). At the end of this trace, the cell was exposed to the calcium 
ionophore, A23187 (1 µM) to demonstrate that even though the PKC  inhibitor prevented 
PGF2 from eliciting its typical calcium signal, the ionophore A23178 was able to elicit a 
calcium response in the same cell. 
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FIG. 3. Representative profiles of the Ca2+ responses induced by 1000 ng/ml PGF2  in 
single, large luteal cells (LLC; left) and small luteal cells (SLC) isolated from Day 4 
bovine CL and the effects of PKC isozyme-specific inhibitors on this PGF2 -stimulated 
Ca2+ response. The cells were isolated and prepared for fura-2 AM imaging of [Ca2+]i as 
described in Materials and Methods. Data are the relative fluorescence ratio (340:380 
nm) over time (in seconds). LLCs (left) and SLCs (right) were exposed at the indicated 
time (arrows) to PGF2  alone (top; Control-LLC and Control SLC), to PGF2  in the 
continuous presence of a conventional PKC inhibitor (middle; PKC (c)-LLC and PKC 
(c)-SLC) and PGF2  in the continuous presence of a PKC -specific inhibitor (bottom; 
PKC (e)-LLC and PKC (e)-SLC). In each panel, a line in the graph represents the trace of 
a single cell. The units used for the y-axis in the top left panel are different from all other 
panels in the figure. 
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FIG. 4. Representative profiles of the Ca2+ response induced by 1000 ng/ml PGF2  in 
single, large luteal cells (LLC; left) and small luteal cells (SLC; all others panels) cells 
isolated from Day 10 bovine CL and the effects of PKC isozyme-specific inhibitors on 
this PGF2 -stimulated Ca2+ responses. The cells were isolated and prepared for fura-2 
AM imaging of [Ca2+]i as described in Materials and Methods. Data are the relative 
fluorescence ratio (340:380 nm) over time (in seconds). LLCs (left) and SLCs (right) 
were exposed at the indicated time (arrows) to PGF2  alone (top; Control-LLC and 
Control SLC), to PGF2  in the continuous presence of a conventional PKC inhibitor 
(middle; PKC (c)-LLC and PKC (c)-SLC) and PGF2  in the continuous presence of a 
PKC -specific inhibitor (bottom; PKC (e)-LLC and PKC (e)-SLC. In each panel, a line in 
the graphs represents the trace of a single cell. The scale units used for the y-axis in the 





FIG. 5. Summary of the effects of conventional PKC [PKC (c)] and PKC  inhibitors 
[PKC ( )] on the PGF2 -stimulated rise in [Ca2+]i in Day 4 and Day 10 LLCs and SLCs. 
The cells were isolated and prepared for fura-2 AM imaging of [Ca2+]i as described in 
Materials and Methods. Cells were pretreated with either no inhibitors (control cells) or 
with PKC(c)- or PKC -specific inhibitor. Values are presented as the mean ± SEM of the 
fold increase in [Ca2+]i induced by PGF2  (1000 ng/ml) from basal values observed 
before the stimulation with PGF2 . Statistical comparisons were made within cell type, 
developmental stage, and treatment; different letters on top of bars denote significantly 
different values (P < 0.05 across treatments depicted by the bars; for Day 4, n = 116, 224, 



















FIG. 6. Effects of conventional PKC [PKC (c)] and PKC  inhibitors [PKC ( )] on PGF2 -
actions on the basal and LH-stimulated progesterone accumulation in cultures of 
steroidogenic cells collected from Day 10 bovine CL. Progesterone accumulation was 
determined in culture media after 4 h of incubation in the following treatments: media 
alone (Media); PGF2  (PG; 1000 ng/ml); PGF2  and LH (PG + LH; 1000 ng/ml and 100 
ng/ml, respectively), PGF2 , LH, and inhibitor conventional PKC [PKC (c) PG + LH; 
1000 ng/ml, 100 ng/ml, and 1 µM, respectively]; and PGF2 , LH, and PKC  inhibitor 
[PKC ( ) PG + LH; 1000 ng/ml, 100 ng/ml, and 1 µM, respectively]. As explained for 
experiment 2 in Materials and Methods, all these treatments also contained saponin (50 
µg/ml). Data are presented as the mean ± SEM of four (Day 10) individual replicates 
(cows). Statistical comparisons were made across cell type, developmental stage, and 








Chapter V: Cellular Source of Luteal PKC Isozymes and their Activation by 
Endothelin-1 (ET-1) in the Mid-phase Bovine Corpus Luteum (CL) 
 
Introduction 
Progesterone (P4) produced by the corpus luteum (CL) is necessary for 
establishing and maintaining pregnancy [McCrracken JA et al, 1999]. If pregnancy does 
not ensue, the CL enters a regression or luteolytic process during which it loses the 
capacity to produce P4 and undergoes structural involution [Niswender GD et al, 2000]. 
Regulation of P4 production as well as luteal regression involves interactions between 
luteal endothelial and steroidogenic cells [Meidan R et al, 1999; O’Shea JD et al, 1989]. 
In mammals, prostaglandin F2α (PGF2α) is the most important hormone associated 
with luteal regression [McCrracken JA et al, 1999; Niswender GD et al, 2000] and based 
on this knowledge, it has been widely used for the purpose of estrous synchronization in 
farm animals. However, despite its widespread application, the mechanisms by which 
PGF2α induces luteal regression are not completely understood. For instance, the CL is 
resistant to the luteolytic actions of PGF2α prior to day 6 of the estrous cycle, rendering 
prostaglandin treatment drastically less effective before that time [Inskeep EK, 1973]. 
Two important intracellular mediators of the luteolytic actions of PGF2α in luteal 
steroidogenic cells [Niswender GD et al, 2000] are protein kinase C (PKC) and calcium 
ions ([Ca2+]i). PKC is a family of serine-threonine kinases that exist in at least 11 closely 
related isozymes [Newton AC, 1995]. We demonstrated by Western blot analysis that the 
array of PKC isozymes expressed in whole bovine CL includes α, βI, βII, ε and μ [Sen A 
et al, 2004]; and that the amount of PKC ε expressed in the day-10 CL was greater than 
in the day-4 CL. The latter observation lead us to propose that differential expression of 
PKC ε as a function of development could play a role in the PGF2α -induced luteal 
regression [Sen A et al, 2004; Sen A et al, 2005]. 
Studies in different species and cell types indicate that differences in co-activator 
requirements for each PKC isozymes as well as distinct cellular localization contribute to 
isozyme functional specificity [Lehel C et al, 1994; Borner C et al, 1995; Pauken CM et 
al, 2000]. The cellular source(s) for each PKC isozyme expressed in the CL has not been 
examined and consequently, our ability to approach several strategies to determine a 
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specific role for each PKC isozyme in luteal physiology is limited. For instance, available 
strategies to down- or up-regulate expression of a given PKC isozyme for assessing its 
function require knowledge of the normal temporal and spatial (cellular source) 
expression of that isozyme.  
   Several authors collectively have indicated that endothelin-1 (ET-1), secreted by 
luteal endothelial cells, plays a role in luteal regression [Meidan R et al, 1999; O’Shea JD 
et al, 1989; Girsh E et al, 1996a; Levy N et al, 2000; Girsh E et al, 1996b; Ohtani M et al, 
1998; Milvae RA, 2000; Wright MF et al, 2001; Levy N et al, 2001; Hinckley ST et al, 
2001]. While some investigators have suggested that ET-1 is a mediator of the luteolytic 
actions of PGF2α, [Meidan R et al, 1999; Girsh E et al, 1996a; Girsh E et al, 1996b; 
Milvae RA, 2000] our own data have indicated that ET-1 although a tonic inhibitor of P4 
synthesis, is not necessarily a mediator of PGF2α actions [Choudhary E et al, 2005]. The 
intracellular mediator(s) of ET-1 actions in luteal regression is not yet known, however, 
actions of ET-1 in luteal cells [Choudhary E et al, 2005] as well as in granulosal cells 
[Flores JA et al, 1992] are known to involve, at least in part, the participation of 
phospholipase C (PLC), inositol phosphates and intracellular calcium. Moreover, little is 
known about the intracellular mediators or mechanism(s) involved in the inhibition of P4 
synthesis by ET-1 in the CL. 
Thus, the aims of these studies were: (1) To determine the temporal expression of 
mRNA encoding PKC ε gene as a function of luteal development, (2) to identify the 
cellular source for each luteal PKC isozyme, (3) to investigate the ability of ET-1 to 
activate in vitro, the different luteal PKC isozymes in the day-10 CL and (4) to determine 
the role of luteal PKC isozymes in the ET-1 mediated inhibition of P4 accumulation in 
steroidogenic cell cultures from day-4 and day-10 CL. 
  
 Materials and Methoda 
  Luteal Tissue Collection  
Bovine CL were collected as previously described [Sen A et al, 2004; Choudhary 
E et al, 2005; Sen A et al, 2005]. Briefly, behavioral estrus was determined in non-
lactating beef cows. The day of standing estrus was designated as Day-0 [Casida LE, 
1959] and after two cycles, day-1, day-4, day-10 and day-17 CL were collected by 
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ovariectomy (day-1 and -4) or blunt dissection (day-10 and -17) via supravaginal incision 
under epidural anesthesia [Sen A et al, 2004; Sen A et al, 2005; Choudhary E et al, 2005]. 
For the epidural anesthesia, 6 to 9 ml 2% lidocaine were administered for cows weighing 
450 -700 kg (Butler Company, Columbus, OH). The CL or ovary was collected into ice-
cold phosphate- buffered saline (PBS) pH 7.4 and transported to the laboratory within 15 
to 30 min after collection. The West Virginia University Animal Care and Use 
Committee reviewed and approved the protocol for the tissue collection (ACUC # 01-
0809). 
 
Luteal Cell Dispersion and Purification  
Luteal cell dispersion was performed as previously described [Sen A et al, 2005; 
Choudhary E et al, 2005]. Briefly, the luteal tissue was dissociated in cell dispersion 
medium (CDM, M-199 containing 0.1% BSA, 25 mM Hepes, 100 U/ml fungicide) 
containing collagenase type IV (GIBCO, Invitrogen Life Technologies, Carlsbad, CA, 
420 U/ml/g of tissue). The dispersed luteal cells were then suspended in 1% PBS, mixed 
with magnetic tosylactivated beads (Dynal Biotech, Lake Success, NY) coated with BS-
lectin and placed for 25 min at 4o C on a rocking platform.  The bead-adherent cells were 
washed with 1% PBS and concentrated using a magnetic particle concentrator (Dynal 
Biotech, Lake Success, NY).  Both BS-1-adhering (endothelial cells) and non-adherent 
cells (steroidogenic luteal cells) were then collected by this procedure. Cell viability and 
density were determined using tryptan blue exclusion and a hemacytometer. 
 
 Semi-quantitative reverse transcriptase- PCR  
Total RNA was isolated with Trizol reagent according to the manufacturer’s 
instructions (GIBCO BRL, Gaithersburg, MD). The isolated RNA was quantified 
spectroscopically at 260 nm and used in a one-step semi-quantitative reverse 
transcriptase-PCR (RT-PCR, Qiagen, Valencia, CA) for PKC ε and GAPDH (reference 
gene). The identity of the primers for PKC ε were those published elsewhere [Webb BL 
et al, 1997]; sense 5’-AGCTTGAAGCCCACAGCCTG-3’; antisense 5’-
CTTGTGGCCGTTGACCTGATG -3’. Primers for GAPDH amplification have been 
published [Wright MF et al, 2001; Choudhary E et al, 2004], sense 5’-
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TGTTCCAGTATGATTCCACCC-3’; antisense 5’-TGTTCCAGTATGATTCCACCC-
3’. The specificity for this primer set has been documented [Wright MF et al, 2001; 
Choudhary E et al, 2004], while the primer specificity for amplification of PKC ε mRNA 
was confirmed here by using the nucleotide database of National Center for 
Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?DB=pubmed) with the BLAST software. 
The RT-PCR assay conditions were as follows: 50 °C for 30 mins for reverse 
transcription reaction, 95 °C for 15 min for activation of reverse transcriptase enzyme, 
95°C for 50 sec for PCR cycles, 58°C for 30 sec for denaturing, 72°C for 1 min for 
annealing, extension, followed by 5 min final extension at 72°C. The RT-PCR products 
were electrophoresed on 2% agarose gel stained with ethidium bromide and viewed using 
the Fluro-S MultiImager (BioRad Laboratories, Hercules, CA). Data were collected using 
densitometric analysis of Quantity One quantification software package (Version 4, 
BioRad Laboratories, Hercules, CA). The intensity of the signal corresponding to PKC ε 
was standardized by the corresponding intensity of GAPDH control in that sample.   
 
Semi-quantitative Western Blotting  
Proteins from separated luteal cell populations were isolated by sonication 
followed by centifugation at 100 X g for 10 min to separate cellular debris. Protein 
concentration in the samples was determined by BioRad assay (Hercules, CA) with BSA 
(Gibco BRL, Life Technologies, Grand Island, N.Y.) as standard. Ten μg / lane of sample 
protein was used for semi-quantitative western blot analysis as previously described [Sen 
A et al, 2004]. The following primary antibodies were used in this experiment: mouse 
anti-actin monoclonal antibody (used at a dilution of 1:3000 [v / v]; Chemicon 
International, Inc., Temecula, CA); four PKC isozyme specific (α, βI, βII and ε) 
polyclonal antibodies (used at a dilution 1:1000 [v / v]; Gibco). The following secondary 
antibodies were used in this experiment. Anti-rabbit (1:5000 [v / v]; Amersham 
Pharmacia Biotech, Piscataway, NJ) and anti-mouse (1:30,000 [v / v]; Gibco) horseradish 
peroxide-conjugated antibodies.  Validation of the semi-quantitative western blot analysis 
and stripping conditions have been determined previously [Sen A et al, 2004]. The 
intensity of the signal corresponding to the protein of interest was standardized by the 
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corresponding intensity of the actin control in that sample. Normalization of data allowed 
us to estimate, in a semi-quantitative manner, the amounts of protein in the samples of 
interest. 
 
Immunohistological assay  
Frozen CL were sectioned at 10 μM thickness using a cryostat HM505 E (Microm 
Laborgerate GmbH) and towed-mounted on microscope slides. These sections were used 
for immunohistochemistry. The tissue sections were fixed with ice cold acetone for 15 
min, followed by 3X wash in TBS for 10 min each. Blocking of non-specific binding 
sites was accomplished with 5% normal goat serum (NGS, Sternberger Monoclonals, Inc, 
Baltimore, MD) in TBS for 30 min in a humid chamber at room temperature. Sections 
were then incubated with PKC ε specific primary (1°, Gibco) antibody at a dilution of 
1:500 [v / v] in 1%NGS-TBS at 4°C overnight in humid chambers. The next day the 
slides were washed 3X in TBS for 10 min each followed by incubation with secondary 
(2°) antibody, anti rabbit IgG (Amersham Pharmacia Biotech, Piscataway, NJ) at a 
dilution of 1:200 [v / v] in 1%NGS-TBS at room temperature for 30 min in humid 
chambers. Endogenous peroxidase activity was reduced by incubating the sections in a 
solution of 3% hydrogen peroxide in methanol at room temperature for 30-45 min. Tissue 
sections were then washed 2X in TBS for 10 min each and incubated with rabbit PAP 
(Sternberger Monoclonals Incorporated, Baltimore, MD) complex at a dilution of 1:200 
[v / v] in 1%NGS-TBS at room temperature for 30 min. The PAP solution was removed 
and slides were washed 3X in TBS for 10 min each. The CL sections were incubated with 
the substrate, 3,3’-Diaminobenzidine chromogen solution (DAB, prepared according to 
the manufacturers instructions; Biogenex, San Ramon, CA) at room temperature for 3 
min, 5 min and 10 min. Slides incubated for 5 min showed the best signal to noise ratio 
and that was selected as the incubation time to be used in all sections of the four CL used 
for analysis. Slides were allowed to dry at room temperature and an aqueous mounting 
medium with anti-fading agents (Gel/Mount Biomedia Corp. Foster City, CA) was added 
to completely cover the tissue and cover slips were placed on the slides. These slides 
were later observed under an Olympus PROVIS AX70 microscope (Olympus America 
Inc., Melville, NY). Each treatment was performed in three consecutive sections on 
 83
different slides. Pre-incubation of the primary antibody with excess antigenic peptide has 
previously [Sen A et al, 2004; Graness A et al, 1997] validated the specificity of the 
primary antibody.  In this study specificity of the immunohistological detection was 
further determined by: (1) omission of primary antibody, (2) omission of secondary 
antibody, and (3) omission of PAP antibody. The slides were examined using the 
Olympus PROVIS AX70 microscope for the presence / absence of specific brown color 
accumulation indicating immunoreactivity.  
 
Experiment 1: Temporal expression of mRNA encoding PKC ε during luteal development 
The temporal expression of mRNA encoding PKC ε was examined using a one-
step semi-quantitative reverse transcriptase-PCR assay with RNA samples isolated from 
day-1 (n=3), day-4 (n=3), day-10 (n=4) and day-17 (n=3) CL samples. The amount of 
total RNA in the assay for each developmental day was adjusted to 200 ng per reaction 
and the number of cycles was optimized to 26 and 40 for amplification of GAPDH and 
PKC ε respectively. Subsequently, as under these conditions, the amount of mRNA 
encoding PKC ε was lowest in the day-1 samples, the RT-PCR assay also was performed 
with different amounts of total RNA (100 ng, 300 ng and 500 ng) for samples with lowest 
day-1, and highest day-10 amounts of PKC ε mRNA. The validity of the temporal 
expression of mRNA encoding PKC ε gene found by using the semi-quantitative RT-
PCR was further corroborated by one real-time PCR. 
 
Experiment 2: Cellular source of luteal PKC isozymes 
The cellular source for each luteal PKC isozyme was examined using a semi-
quantitative Western blot analysis of proteins isolated from enriched steroidogenic and 
endothelial cell populations collected from day-10 CL (n = 3) and by an 
immunohistological detection of PKC ε on luteal sections prepared from frozen tissue 





Experiment 3: Ability of ET-1 to activate luteal PKC isozymes 
Day-10 CL were dissected free of any connective tissue and then cut into small 1 
mm3 fragments just before the experiment was initiated. The CL fragments were added to 
disposable culture tubes (Fisher Scientific, Pittsburgh, PA) containing MEM-HEPES 
(GIBCO BRL, Life Technologies) alone or MEM-HEPES containing 100 nmol ET-1. 
The tissue and media were separated by centrifugation after 10 min, snap frozen in liquid 
nitrogen and stored at - 80o C. The tissue was later pulverized and homogenized in buffer 
containing 20 mmol Tris-HCl, 0.25-mol sucrose, 1.2 mmol EGTA, 0.1 PMSF, 20 μg/ml 
leupeptin, and 20 mmol 2-mercaptoethanol. The homogenized tissue was centrifuged at 
1,000 X g for 2 min at 40 C to remove floating tissue particles. This supernatant was used 
for subcellular fractionation by differential and discontinuous sucrose gradient 
centrifugation. The cytosolic fraction was obtained by centrifugation at 100,000-x g for 
60 min. The pellet of the first 100,000 X g centrifugation was homogenized in 
homogenization buffer containing 1 % triton-X 100. The homogenized pellet was 
centrifuged at 100,000 X g for 60 min. This supernatant constituted the membrane 
fraction. Protein concentrations in the cytosolic and membrane fractions were determined 
using a BioRad assay with BSA as standards. 10 μg / lane of sample proteins were 
analyzed by a semi quantitative Western blotting as previously described [Sen A et al, 
2004]. Data are presented as the ratios of actin-corrected optical density (OD) detected 
for the PKC isozyme in the membrane fraction to the corrected OD for the same isozyme 
in the cytosolic fraction (M / C). 
 
Experiment 4: Role of luteal PKC isozymes in the ET-1 mediated inhibition of P4 
synthesis in day-4 and day-10 luteal steroidogenic cells  
The aim of this experiment was to test the involvement of conventional PKC (α, 
βI, βII) and novel PKC isozymes (ε) in ET-1 induced inhibition of P4 synthesis 
[Choudhary E et al, 2005] by day-4 (n = 4) and day-10 (n = 3) luteal steroidogenic cells. 
This experiment was performed as previously described [Sen A et al, 2005]. Briefly, 
enriched population of steroidogenic cells (1 x 10 3 cells) were added in small aliquots 
(100 μl) to wells (Corning 35-mm cell culture clusters; Fisher Scientific Company, 
Blawnox, PA), containing the following: 1) 1 ml M199 and saponin; 2) 1ml M199, 
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saponin and LH (100ng/ml); 3) 1ml M199, saponin and ET-1 (100nM); 4) 1ml M199, 
saponin, LH and ET-1; 5) 1ml M199, saponin, LH, ET-1 and conventional PKC inhibitor 
(1 μM) and 6) 1ml M199, saponin, LH, ET-1 and PKC ε inhibitor (1 μM). Each 
treatment was applied in duplicate to cells from each CL. The cells were incubated for 4h 
at 37°C (95% air, 5% CO2). After incubation, medium free of cells was stored frozen 
until assayed for P4 measurement by radioimmunoassay (RIA) as previously described 
[Sen A et al, 2005; Choudhary E et al, 2005]. The standard curve for this RIA ranged 
from 10 pg / ml to 800 pg / ml, and the intra-assay and inter-assay coefficients of 
variation were 9.2% and 12.8%, respectively. 
Statistical Analysis 
Statistical analyses were performed using JMP, a statistical software program 
from Statistical Analysis Systems [Cary NC, 1994]. The results were expressed as the 
mean ± SEM. Two-way ANOVA followed by Tukey-Kramer Honestly Significant 
Difference test was used to determine statistically significant differences between 
amounts of PKC ε mRNA among different luteal developmental stages or PKC isozymes 
and cell types or PKC isozymes and ET-1 treatment.  One-way ANOVA followed by a 
Tukey-Kramer honestly significant difference test was used to determine statistically 





Figure 1A shows the profiles for the amount of luteal mRNA encoding PKC ε at 
the four luteal developmental stages examined. Abundance of PKC ε mRNA gradually 
increased from day-1 to day-10 CL. There were increases from day-1 to day-4 and from 
day-4 to day 10 (P < 0.05). No further increase in the amount of mRNA encoding PKC ε 
was observed in day-17 CL; the amount of PKC ε mRNA in day-17 was similar to that of 
day-10. 
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A representative picture of the RT-PCR products obtained using primers for PKC 
ε and GAPDH from day-1 and day-10 samples is shown in Figure 1B. Typically, the 
sizes of the amplified PKC ε and GAPDH fragments were 480 and 900 bp, respectively 
[Wright MF et al, 2001; Webb BL et al, 1997; Choudhary E et al, 2004]. 
  When the RT-PCR assay was performed using increasing amounts of RNA / 
reaction (100, 300 and 500 ng / reaction), in the day-1 samples, an amplified fragment 
corresponding to the PKC ε mRNA was obtained only when 300 and 500 ng / reaction 
were used. In contrast, when the RNA from day-10 samples was used, all three amounts 
of RNA were effective for amplifying the cDNA fragment corresponding to PKC ε 
(Figure 1B). This quantitative relationship is shown in Figure 1C. Furthermore, the 
abundance of the amplified fragment in the day-1 samples was always lower than that 
amplified in the day-10 samples (Figure 1C).  This clearly indicates that amplified 
product was a function of the amount of mRNA template and that this in turn, was 
expressed at lower concentrations as a function of luteal development as depicted in the 
summarized data in Figure 1A. The real-time PCR experiment corroborated the 
observation that the abundance of the RNA encoding PKC ε in day-1 samples was lower 
than in day-10 samples (data not shown). 
 
Experiment 2 
Figure 2A shows a representative blot for PKC α, ε and actin obtained from the 
enriched luteal cell populations tested. PKC ε was detected exclusively in the 
steroidogenic cells (Figure 2A) in contrast to PKC α that was detected in both the cell 
populations. Figure 2B shows the summary of the amount of protein corresponding to 
PKC α, βI, βII and ε in separated steroidogenic (LLC and SLC) and endothelial cells 
from day-10 CL. Although, both steroidogenic and endothelial cells expressed PKC α, βI 
and βII, their amounts were significantly lower in endothelial cells than in setroidogenic 
cells (P < 0.05). Furthermore, in steroidogenic cells, all PKC isozymes were expressed in 
equal amounts; whereas in endothelial cells, α and βII isozymes were expressed in higher 
amounts than βI (P < 0.05). 
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The immunohistological assay of day-10 CL sections revealed that PKC ε was 
detectable in what appeared to be LLC and SLC (Figure 3, Panel C). Immuno-reactivity 
in these was specific, because it was abolished in all the controls tested (Figure 3, Panel 
A and B). Immuno-reactivity was not observed in endothelial cells of any of the vascular 
components examined (Figure 3).  
 
Experiment 3 
  Figure 4A shows a representative blot obtained with the protein samples isolated 
from tissue of experiment 3 to examine the cellular redistribution of PKC ε as a function 
of stimulating the luteal tissue with ET-1 (100nM). In luteal tissue samples treated with 
MEM-HEPES (Media), PKC ε was detected only in the cytoplasm (Figure 4A, right 
panel). In contrast, stimulating the luteal tissue with ET-1 resulted in the detection of 
PKC ε in the cell membrane fraction (Figure 4A, left panel). Figure 4B summarizes the 
data for PKC redistribution for all the isozymes tested. In spite of the fact that in MEM-
HEPES-treated luteal samples (Figure 4B) PKC α, βI and βII were detected in both the 
cytoplasmic and cell membrane fractions, ET-1 was able to increase the amount of PKC 
α and βI detected in the cell membrane fraction (P < 0.05). In contrast, no cellular re-
distribution of PKC βII was induced by similar ET-1 stimulation (Figure 4B). In our 
previous study [Sen A et al, 2004] PKC α was not detected in both the cytoplasmic and 
cell membrane fractions of media-treated samples. In this study, in only one out of five 
animals PKC α was detected in both membrane and cytosolic fraction in media-treated 
samples. This discrepancy may be due to variability among animals. 
 
Experiment 4 
 To analyze the involvement of luteal PKC isozymes in the luteolytic actions of 
ET-1, we measured basal and LH-induced P4-induced accumulation in the presence and 
absence of conventional PKC and PKC ε specific inhibitor [Sen A et al, 2005]. 
Moreover, based on Choudhary et al’s work [Choudhary E et al, 2005], 100 nM 
concentration of ET-1 was used in this study. 
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 In day-4 enriched steroidogenic cells ET-1 and LH had no effect on basal P4 
accumulation (Fig 5A). In contrast when cells were incubated with ET-1 and LH the P4 
accumulation values were reduced below basal condition. This inhibitory effect of ET-1 
on P4 accumulation was significantly (P < 0.05) antagonized in cells incubated with 
conventional PKC inhibitor, LH and ET-1. PKC ε inhibitor did not have any affect on P4 
accumulation when incubated with LH and ET-1. 
 P4 accumulation in day-10 enriched population of steroidogenic cells was three 
times higher than in day-4 cells for all the treatments tested (Fig 5B). ET-1 had no effect 
on basal P4 accumulation. However, LH induced a significant (P < 0.05) increase in P4 
accumulation over that observed under basal conditions, while ET-1 significantly (P < 
0.05) decreased this effect of LH. P4 accumulation in cells incubated with either 
conventional or ε specific PKC inhibitor, LH and ET-1 were same as LH-induced values 
(Fig 5B).  
 
Discussion 
The present data demonstrate that the steroidogenic cells constitute the source of 
PKC ε in the bovine CL. This important observation supports our previous suggestion 
that this isozyme may play an important role in regulation of P4 synthesis in the CL of the 
mid-late phase [Sen A et al, 2005].  Furthermore, our immunohistological data strongly 
indicate that PKC ε is found in both large and small steroidogenic luteal cells. This 
observation supports the report that the PGF2α- induced rise in [Ca 2+]i was decreased in 
LLC and SLC when their PKC ε was inhibited [Sen A et al, 2005].  
It could be argued that the detected expression of PKC α, βI and βII in endothelial 
cells could be due to contamination of the enriched EC population with steroidogenic 
cells. However, we have reported that PKC α, βII and ε are expressed in similar amounts 
in day-10 CL [Sen A et al, 2004]. Thus, it is unlikely that only PKC α, and βII but not 
PKC ε would be detected in the contaminated EC population. Based on this argument we 
interpret that the presence of these isoforms in EC is more likely due to their being 
expressed by these cells rather than by SC contamination. Although PKC α, βI and βII 
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were expressed in both steroidogenic and endothelial luteal cells, their amounts were 
significantly less in endothelial than in steroidogenic cells. Whether this difference in 
expression of PKC α, βI and βII between these two luteal cell types has any 
physiological significance is still unclear. Interestingly, Wu et al [Wu YL et al, 2001] 
reported that PKC α and β acting on E-box DNA elements specifically increased Cox-2 
transcription in LLC. As far as we know, the role for these PKC isozymes in luteal 
endothelial cells has not been examined previously.  
The lower expression of mRNA encoding PKC ε in the early luteal stage (day-1 
and day-4) than in the mid-late luteal stage (day-10 and day-17) supports our previous 
observation of differential expression of PKC ε protein as a function of development [Sen 
A et al, 2004]. We reported that the amount of protein corresponding to PKC ε was 
barely detectable in day-4 CL, while it was significantly upregulated in the day-10 CL 
[Sen A et al, 2004]. These observations indicate that the lower amount of PKC ε protein 
in the early CL, at least in part, is due to lesser availability of PKC ε mRNA at this 
developmental stage. This interpretation is supported further by the observation that the 
amount of total mRNA necessary to amplify a cDNA product corresponding to PKC ε in 
the day-10 samples was greater than from day-1. However, the regulatory mechanism(s) 
of PKC ε gene expression during CL development are currently not known. 
  The potential physiological significance of the differential expression of PKC ε 
during the development of the CL is that it could participate in the cellular mechanisms 
rendering the early CL resistant to the antisteroidogenic actions of PGF2α. Importantly, 
the ability of ET-1, like PGF2α [Sen A et al, 2004], to activate PKC α, βI and especially ε 
in day-10 steroidogenic cells underlines the importance of PKC ε in luteal regression. 
Choudhary et al [Choudhary E et al, 2005], demonstrated that ET-1 induced increases in 
[Ca2+]i  in steroidogenic and endothelial luteal cells . The ability of ET-1 to activate the 
metabolism of phosphoinositides, intracellular calcium and PKC also has been reported 
in swine granulosal cells [Flores JA et al, 1992], rat gonadotropes [Stojilkovic SS et al, 
1992] and many other tissues [Badr KF et al, 1989; Simonson MS et al, 1989]. All these 
observations further support the fact that ET-1, like PGF2α utilizes, at least in part, the 
PLC effector system with PKC and calcium as intracellular mediators.  
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We have proposed that ET-1 appears to be a tonic inhibitor of luteal P4 production 
[Choudhary E et al, 2005] rather than a mediator of PGF2α actions as suggested by other 
investigators [Girsh E et al, 1996a; Levy N et al, 2000; Girsh E et al, 1996b]. We 
demonstrated that the early CL is responsive to in vitro stimulation with ET-1 
[Choudhary E et al, 2005] on both basal and LH-stimulated P4 accumulation. However, in 
this study we did not observe any effect of LH nor ET-1 over basal P4 accumulation. This 
discrepancy, as previously described [Sen A et al, 2005] is most likely due to 
permeabilization protocol used in this study. This interpretation further support the 
observations of Sen et al [Sen A et al, 2005] where the same permeabilzation procedure 
was performed and no effect of LH was observed in day-4 luteal steroidogenic cells. 
However, when cells were incubated with ET-1 and LH the P4 accumulation decreased 
below basal conditions. This effect can be due to the interactions of LH and ET-1 
pathway. Several studies have demonstrated that LH [Alila HW et al, 1989; Davis JS et 
al, 1996; Flores JA et al, 1998] and ET-1 [Flores JA et al, 1992; Choudhary et al, 2005] 
activates the PLC -Ca2+ -PKC effector system.  Infact, in a recent study it was 
demonstrated that PLC-inhibitor blocked LH stimulated P4 production in primary culture 
of bovine luteal cells [Nishimura R et al, 2004]. Thus, it is possible that when the luteal 
cells were treated with both LH and ET-1, the synergistic effect of both the treatments 
caused the [Ca2+]i  to shift from a P4 favorable to a P4 inhibitory level as proposed by 
Sen et al [Sen et al, 2005]. In contrast, LH or ET-1 treatment alone was unable to shift the 
[Ca2+]i threshold to P4 inhibitory condition.  This increase in [Ca2+]i  caused by LH and 
ET-1 treatment may in turn activate the cPKC that lowered the P4 accumulation. In fact, 
the observation that conventional PKC inhibitor treatment increased the P4 accumulation 
values back to basal level supports this hypothesis. Less is known about ET-1 availability 
in vivo in its specific luteal target cells in the early CL. If, indeed ET-1 is available in the 
early CL, our studies indicate that regulation of P4 accumulation at this stage is 
independent of PKC ε, but might be via the conventional PKC isozymes.  
 In day-10 luteal cells LH stimulated P4 accumulation over basal value while ET-1 
inhibited this effect. This observation supports previous studies by Sen et al and 
Choudhary et al [Sen A et al, 2005; Choudhary E et al, 2005]. The difference in the effect 
of the treatments among the day- 4 and –10 may also be due the sensitivity of the tissue 
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as a function of development. The inhibitory effect of ET-1 on LH-stimulated P4 
accumulation was antagonized by both conventional and PKC ε specific inhibitors. This 
demonstrates that in contrast to day-4 at this developmental stage PKC ε is equipotent as 
conventional PKC isozymes in mediating the inhibitory actions of ET-1 on LH-
stimulated P4 accumulation. However, whether the actions of PKC ε are synergistic or 
additive to that of conventional PKC isozymes need further investigation. We propose 
that the presence of PKC ε in addition to conventional PKC isozymes at mid luteal stage 
shift the balance towards luteal regression. 
  In summary, the presence of PKC ε exclusively in steroidogenic cells along with 
the higher availability of PKC ε mRNA and protein [Sen A et al, 2004] in the mid-late 
CL, in contrast to early CL and its potential regulatory role in LH-stimulated P4 
accumulation in the mid-late CL [Sen A et al, 2005], underlines the importance of this 
isozyme in luteal regression. The differential expression of PKC ε may be one of the key 
factors responsible for the sensitivity of the CL to luteal regression. Moreover, the tonic 
inhibition of P4 accumulation by ET-1 [Choudhary E et al, 2005] in the early CL may be 














Figure 1A. Semi-quantitative analysis of the amounts of mRNA encoding PKC ε as a 
function of luteal development. Total RNA (200 ng / reaction) isolated from day 1 (n=3), 
day 4 (n=3), day 10 (n=4) and day 17 (n=3) CL were used for the RT-CR assay. Data are 
presented as the ± SEM of densitometric analysis of PKC ε relative to GAPDH mRNA; 
values with different letters denote statistically significant differences (P < 0.05). 
 
Figure 1B. Representative 
RT-PCR products obtained 
by using different amounts 
of RNA / reaction (100 ng, 
300 ng and 500 ng) isolated 
from day 1 (lower panel) 
and day 10 (upper panel) 
CL using GAPDH and 
PKC ε specific primers. The sizes of the amplified products for GAPDH and PKC ε were 









Figure 1C. Semi-quantitative analysis of amplified PKC ε mRNA as a function of 
different amounts (100 ng, 300 ng and 500 ng) of RNA / reaction from day 1 (n=3) and 
day 10  (n=3) CL. Data are presented as the ± SEM of densitometric analysis of PKC ε 
relative to GAPDH mRNA; values with different letters denote statistically significant 
differences (P < 0.05). 
 
 
Figure 2A. Representative 
Western blot of PKC α, PKC ε 
and actin from enriched 
sterroidogenic and endothelial 
cells collected from day 10 CL 
(n=3). The middle panel reveals 
the exclusive localization of PKC 
ε in the steroidogenic cells. 10 μg 
/ lane of protein were used for the 






Figure 2B. Semi-quantiative analysis of Western blots to reveal the cellular source of 
luteal PKC isozymes in day 10 CL (n=3). The y-axis shows the ratio of optical density 
(O.D.) of each luteal PKC isozymes corrected by the detected O.D. for its corresponding 
actin. Data are presented as the ± SEM; values with different letters denote statistically 
significant differences (P < 0.05). 
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Figure 3. Immunohistological detection of PKC ε in frozen sections of day 10 CL. Panel 
A is a lower magnification view of the field shown in panel C. Panel B shows a negative 
control using a consecutive section to that used in panel A but omitting the primary 
antibody in the detection protocol. The arrow with the number 1 in panel C indicates EC 
the in the lumen of blood vessels. The arrow with the number 2 indicates an 
immunopositive SLC, while the arrowhead represents an immunopositive LLC. The 
arrow in number 4 represents a LLC that is not stained. Microphotographs shown in 
panels A and B were taken at the same magnification. The bars in panel A and C 








Figure 4A. Representative Western blot demonstrating ET-1 stimulated PKC ε 
redistribution in day 10 luteal tissue (n=5). Right top panel shows the exclusive 
cytoplasmic localization of PKC ε when the tissue was incubated with control media, 
MEM-Hepes. Left top panel demonstrates that a 10 min incubation of the luteal tissue 
with ET-1 (100 nM) induced the appearance of PKC ε in the membrane fraction. Lower 
left and right panel show the amount of actin associated with each sample. Each lane 































Figure 4B. Semi-quantitative analysis of ET-1 stimulated PKC redistribution. The y-axis 
represents the actin corrected ratio of the optical density (O.D.) detected for each PKC 
isozyme in the membrane and cytosolic fractions (M / C). Data are presented as the ± 
SEM; values with different letters denote statistically significant differences (P < 0.05). 
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Figure 5. Effects of conventional PKC [PKC (c)] and PKC ε inhibitors [PKC (e)] on ET-
1 (100 nM) actions on P4 accumulation in cultures of steroidogenic cells collected from 
(A) Day 4 and (B) Day 10 bovine CL. P4 accumulation was determined in culture media 
after 4 h of incubation. Data are presented as the ± SEM; values with different letters 







Chapter VI: Discussion and Future Studies 
 
These studies were done to investigate the possibility that differences in the 
intracellular mediators with respect to luteal development might contribute to the relative 
insensitivity of the early CL towards the luteolytic actions of PGF2α. The array of PKC 
isoforms expressed in the early (d-4) and mid-luteal (d-10) phase of the bovine CL 
include: α, βI, βII, ε and μ (chapter 3). More importantly, PKC ε was expressed 
differentially expressed and activated as a function of luteal development. Based on these 
observations it is hypothesized that the differential expression of PKC ε  might be one of 
the factors responsible for the insensitivity of the early CL. In chapter 4, it was shown 
that in the mid-late CL, PKC ε has a regulatory role in the PGF2α-induced rise in [Ca2+]i 
and P4 synthesis. This observation somewhat supports the hypothesis that rise in [Ca2+]i 
might be a regulating factor for P4 synthesis [Martinez-Zaguilan R et al, 1994; Wegner 
JA et al, 1991].  In the early CL, a number of studies [Miyamoto A et al, 1993; Hansel W 
et al, 1991; Choudhary E et al, 2005] have demonstrated that PGF2α has luteotropic 
effects. In the study presented in chapter 4, PGF2α-induced rise in [Ca2+]i in the early 
luteal phase was lower than the mid CL. The expression of PKC ε in the mid luteal stage 
might shift the PGF2α-induced rise in [Ca2+]i from a P4-favorable to a P4-inhibitory 
condition. Whether this rise in [Ca2+]i is due to influx or efflux of Ca2+ is unknown and 
needs further investigation. Furthermore, rise in [Ca2+]i  is very compartmentalized in 
cells. Nothing is known about the localization of PGF2α-induced rise in [Ca2+]i within the 
cell with respect to the sub-cellular localization of PKC isozymes at different 
developmental stages of the CL.  
The exclusive expression of PKC ε in the luteal SC, as reported in chapter 5, further 
indicates an important role of this isoform in the regulation of rise in [Ca2+]i. In SC, 
PGF2α [Chapter 4; Choudhary E et al, 2005] and ET-1[Choudhary et al, 2005] induced 
greater rises in [Ca2+]i in the mid-luteal phase than in the early stage. In contrast, in EC, 
PGF2α and ET-1 induced rises in [Ca2+]i were equal in both developmental stages 
[Choudhary E et al, 2005]. This might be due to the absence of PKC ε in the EC. The 
study in chapter 5 demonstrated the ability of ET-1 to activate PKC isoforms in the mid 
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luteal phase. In addition, Choudhary et al [Choudhary E et al, 2005] reported that ET-1 
can elicit rises in [Ca2+]i in both SC and EC. These observations indicate that ET-1, like 
PGF2α utilizes, at least in part, the PLC effector system with PKC and calcium as 
intracellular mediators. Whether ET-1 also activates other intracellular mediators is still 
unclear. In the bovine CL, both ETA and ETB receptors are expressed throughout the 
estrous cycle [Meidan R et al, 2002, Choudhary E et al, 2005]. However, very little is 
known about the ETB receptor. It is possible that these two endothelin receptors are 
linked to different effector systems that induce diverse physiological responses during 
luteal regression. 
Choudhary et al [Choudhary et al, 2005] proposed that ET-1 is a tonic inhibitor of P4 
accumulation rather than a mediator of the luteolytic action of PGF2α. The study in 
chapter 5 further demonstrated that tonic inhibition of ET-1 on P4 accumulation might be 
via the cPKC isozymes. An interesting observation in this study was that when luteal SC 
were incubated with ET-1 and LH, the P4 accumulation decreased below basal 
conditions. In contrast, LH or ET-1 treatment alone had no effect on P4 accumulation. 
This effect can be due to the interactions of LH and ET-1 pathways. Several authors have 
demonstrated that LH [Alila HW et al, 1989; Davis JS et al, 1996; Flores JA et al, 1998] 
and ET-1 [Flores JA et al, 1992; Choudhary et al, 2005] activate the PLC -Ca2+ -PKC 
effector system. Also, it has been demonstrated that PLC-inhibitor blocked LH-
stimulated P4 production in primary cultures of bovine luteal cells [Nishimura R et al, 
2004]. Thus, it is possible that when the luteal cells were treated with both LH and ET-1, 
the synergistic effect caused the rise in [Ca2+]i  to shift from a P4-favorable to a P4- 
inhibitory status as proposed in chapter 4. In contrast, LH or ET-1 treatment alone was 
unable to shift the rise in [Ca2+]i threshold to P4-inhibitory conditions.  The increase in 
[Ca2+]i  caused by LH and ET-1 treatment might in turn, activate the cPKC that lowered 
the P4 accumulation. In the early CL, very little is known about ET-1 availability in its 
specific luteal target cells. Indeed, if ET-1 is available in the early CL, this study 
indicated that regulation of P4 accumulation at this stage is independent of PKC ε, but 
might be via the conventional PKC isozymes. 
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The role of the conventional PKCs in regulation of luteal regression is poorly 
understood. Wu et al [Wu et al, 2001] demonstrated that only in the mid-late LLC, PKC 
α and β acting on E-box DNA elements specifically increased Cox-2 transcription. 
However, they failed to explain possible reasons for differential expression of Cox-2 by 
cPKCs. The cPKCs are expressed and activated in both early and mid luteal phase 
(chapter 3). Thus, the differential expression of Cox-2 by cPKCs is not due to the 
unavailability of cPKCs. PKC activates a large number of different transcription factors 
[Ray A et al, 2000]. It is likely that PKC α and β activate a TF that acts on E-box DNA 
elements present in the Cox-2 promoter region, thereby causing Cox-2 expression. It is 
possible that, expression of such a TF only in the mid-late CL might result in cPKC 
induced differential expression of Cox-2 gene. Further investigation is required to 
identify the physiological roles of cPKCs involved in luteal regression. 
   In EC, presence of FP is controversial. Mamluk et al [Mamluk R et al, 1998] have 
shown the presence of FP mRNA in EC. Moreover, Choudhary et al [Choudhary E et al, 
2005] demonstrated that EC exhibited a rise in [Ca2+]i when treated with PGF2α . Both 
these studies were performed with bovine primary EC culture models. In contrast, other 
studies with EC failed to detect FP or PGF2α -responsive intracellular signaling pathways 
[Cavicchio VA et al, 2002; Chen DB et al, 1998]. These studies used a commercially 
available bovine-CL-derived microvascular EC called CLENDO cells. It is possible that 
these CLENDO cells have morphological differences such that the normal EC or FP 
expression in these cells has been lost during cell preparation. In order to address this 
controversy, better characterization of the CLENDO cells is needed. On the other hand, 
immunohistochemical studies using FP specific antibodies and PGF2α  binding studies on 
EC are required to support the presence of FP. In bovine CL, there might be two types of 
EC; cytokeratin positive and cytokeratin negative [Spanel-Borowski K and Fenyves A, 
1994a; Spanel-Borowski K et al, 1994b; Spanel-Borowski K et al, 1990]. It is possible 
that these two EC cell types differ in their expression of FP [Aust BEG et al, 1999; 
Lehmann I et al, 2000].  
In bovine luteal tissue, the mechanisms by which PKC-calcium pathway regulates 
P4 synthesis are unclear. Studies have shown that calcium and PKC regulate PLA2 and 
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arachidonic acid release [Chang TM et al, 1999; Zor U et al, 1991; Wiltbank MC et al, 
1989b; Wiltbank MC et al, 1989a; Wu XM et al, 1990; Tsai SJ et al, 2001; Wiltbank MC 
et al 2003]. It is possible that Ca2+ and PKC isoforms might regulate gene expression 
or/and activity of PG metabolic enzymes during distinct luteal stages and that this may 
lead to luteal maintenance or demise. In bovine luteal cells [Chen DB et al, 1998; Chen D 
et al, 2001] it has been demonstrated that PKC activates MAPK pathway, in turn 
regulates gene expression. Similarly, calcium is known to regulate gene expression via 
calcium-calmodulin pathway [Wu KK, 2002]. Moreover, calcium [Srivastava AK et al, 
1980] and protein kinases [Jiang G et al, 2003] are known to regulate enzymatic activity. 
In the bovine and ovine CL, StAR activity can be modulated by PKA/PKC 
phosphorylation [Niswender GD et al, 2000]. Studies have shown that expression of 
StAR can be regulated by PKA/PKC via DAX-1/SF-1 nuclear receptors in other species 
[Christenson LK et al, 1998; Hammer GD et al, 1999; Ito M et al, 1998; Zazopoulos E et 
al, 1997]. In bovine luteal cells, the regulation of StAR expression and activity and the 
PKC isoforms involved in this process are poorly understood. Because of the complexity 
involved in regulation of luteal regression, DNA microarray and proteomic techniques 
may provide insight in relation to the different stages of luteal development. Furthermore, 
overexpression and gene ablation studies of PKC ε will help to elucidate the mechanism 
of early luteal insensitivity. 
In summary, these studies depict the complexity involved in the process of luteal 
regression. The regulation of luteal regression involves interactions among different 
factors, intracellular mediators and signaling pathways resulting in differential expression 
and activation and/or inactivation of a number of proteins. It is proposed that the 
differential expression and activation of PKC ε as a function of development may be one 
of the several factors responsible for the insensitivity of the early CL. Expression of PKC 
ε in the mid-luteal phase shifts the PGF2α -induced rise in [Ca2+]i from a P4-favorable to a 
P4-inhibitory condition. Based on these observations, it is hypothesized that the 
insensitivity of the early CL towards the luteolytic actions of PGF2α might be due to 
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